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I 
Abstract 
A vital factor for foetal development is the nutrient transport at placental level. This is 
because any disturbances in the maternal compartments, for example due to maternal stress or 
nutritional status, which will affect foetal development, will involve the foetal-placental 
barrier. Moreover, numerous studies have linked other factors such as preterm labour as the 
leading cause of perinatal morbidity and mortality in the developed world. To this date, 
despite a numerous epidemiological and clinical studies that identify potential risk factors for 
the mother as well as the foetus, there is no comprehensive analysis at all these levels taken 
from the same cohort of patients. Our working hypothesis is that for a successful pregnancy 
certain events at nutritional, biochemical, genetic and molecular level could be tightly linked. 
Therefore, in this study we followed a “holistic” approach investigating how maternal stress, 
nutrition, placental mTOR and glucocorticoid receptor (GR) signalling can influence 
pregnancy outcome. We have decided to map in detail the components of these two 
signalling pathways as they appear to cross-talk as well as been implicated in stress 
responses.  
The largest part of the questionnaire was focused on the nutritional status with questions 
targeting the maternal dietary habits before, as well as during, pregnancy. The collection of 
data took place at the Department of Obstetrics and Gynecology, University of Crete Medical 
School. With regards to this profile, key findings included the significant reduction in the 
intake of alcohol, caffeine-containing and sugar-containing refreshments, whereas passive 
smoking during pregnancy stayed the same.  Another major finding of this part of the study 
was the effects of maternal stress on foetal weight and how pregnancy planning was 
implicated in this complex relation. In our cohort, women with negative attitudes during 
pregnancy gave birth to infants with significantly lower birth weights (2.5Kg) than those 
women showing positive or neutral attitudes towards their pregnancy (2.9Kg). We then 
assessed how maternal stress might affect this signalling cascade using two placental models 
(BeWo and JEG-3 cell lines) mimicking a stress milieu in vitro. Treatment of these cell lines 
with cortisol (100nM and 1000nM) significantly downregulated Deptor and upregulated 
GAS5 at mRNA level.  
In an attempt to dissect further a potential gene-environment interaction, we have assessed 
how 4 well-characterised polymorphisms (ThtIII 1, Bcl I, ER22/23EK, N363S) of the GR 
gene might affect foetal and placental weight. We have demonstrated that only the maternal 
ThtIII 1 polymorphism was suggestive of a nature-nurture interaction since only in ThtIII 1 
  
II 
(CC), maternal stress attitude predicts foetal weight-reduction, but not in ThtIII 1 (GC) 
independent of confounders such as BMI, pregnancy planning or fast food eating during 
pregnancy. This is the first time that a gene-environment interaction between a common GR 
polymorphism and foetal weight was noted. Finally, one of the most important findings of 
our study came from the preclinical studies using placental tissues. Quantitative PCR 
revealed that the major transcripts in the human placenta are GRα, GAS5 (decoy for GR 
DNA binding) and Deptor. We have shown for first time that there are marked differences in 
the relative mRNA abundance of these components between term and preterm labour as well 
as colocalisation of GRα with GAS5.  
With regards to placental regulation these data conclusively demonstrate that: a) there is 
evidence of gene-environment interaction between maternal stress, pregnancy planning, 
glucocorticoid receptor polymorphisms and foetal weight and b) potential cross-talk of 
mTOR and glucocorticoid signalling. We propose that measuring maternal stress levels in 
addition to circulating cortisol and mapping for known GR polymorphisms could become a 
useful non-invasive tool of diagnostic and prognostic value, with implications for preterm 
labour. 
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1.1. Nutrition and Mediterranean Diet 
Up to very recent years in the history of human nutrition, people were heavily relying on the 
food produced in the local environment for their nutrition. The biological and cultural 
resilience of humans is demonstrated by the fact that populations have survived and 
developed in highly different climates and ecological backgrounds with respectively 
changeable dietary patterns. Even though the survival through the reproductive age was 
achieved by the different populations living in very wide range of environments, the dietary 
patterns adhered to in these environments were not always in support of the populations’ 
long-term health and well-being. The options of the human population in selecting their foods 
to eat have dramatically increased by the transplantation of numerous plant species across the 
continents and by the modern developments of transportation and food preservation 
technologies. Consequently, the implications of these revised options on health outcomes 
have become of a great interest (Willett, 2006). 
According to the Seven Countries Study that started in the late 1950s led by Ancel Keys and 
his colleagues (Keys, 1980), the first evidence were presented to the scientific community 
showing the several important health benefits of the Mediterranean diet in a number of 
diseases compared with other dietary models examined (Keys, 1980). In this study seven 
countries in four regions of the world (United States, Northern Europe, Southern Europe, and 
Japan) were included. Specifically, one cohort was in the United States, two cohorts were in 
Finland, one in the Netherlands, three in Italy, five in the former country of Yugoslavia, two 
in Greece (Crete and Corfu), and two in Japan (Keys, 1980).  
The Mediterranean diet (MedDiet) could be defined as a dietary pattern originally found in 
the Mediterranean area where the prominent regional characteristic was the high olive 
cultivation, in late 1950 and early 1960's, when the consequences of the Second World War 
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had been overcome, but the culture of fast-food had not yet reach the area (Fung et al., 2009; 
Kushi et al., 1995
A
; Kushi et al., 1995
B
). A large body of evidence has shown that the 
traditional MedDiet meets several important criteria for a healthy diet (Trichopoulou, 2004). 
The main characteristics of the MedDiet as seen in pyramid Fig. 1.1 are the high ratio of 
monounsaturated to saturated dietary lipids (mainly olive oil), the moderate consumption of 
alcohol, the  high consumption of  legumes, the high consumption of  non-refined cereals 
including bread, the high consumption of fruits, the high consumption of vegetables, the low 
consumption of meat and meat products and the moderate consumption of milk and dairy 
products (Trichopoulou, 2009; Trichopoulou, 2004). 
 
 
Figure: 1.1: Food Pyramid (Adapted from: Supreme Scientific Health Council, Hellenic Ministry of 
Health). 
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The beneficial effects of the MedDiet have been corroborated by a number of studies 
performed in large cohorts in different parts of the world. For example, a large study of 
74.607 participants where the main objective was to examine if the adherence to a modified 
MedDiet, in which unsaturated fats were substituted for monounsaturated lipids, was 
associated with a longer life expectancy among older people showed that indeed an 
adherence to a modification of this diet was related with an increased survival among older 
people (Trichopoulou et al., 2005). In another study by Martínez-González where 13.380 
Spanish university graduates without diabetes were followed up for a median of 4.4 years, it 
was shown that adhering to a MedDiet reduced the risk of developing type II diabetes among 
healthy individuals (Martínez-González et al., 2008). 
The effects of the MedDiet on the status of metabolic syndrome have also been examined 
(Salas-Salvadó et al., 2008). Metabolic syndrome or “Syndrome X” is the combination of 
abdominal obesity, hypercholesterolemia, hypertension and hyperglycemia linked by an 
underlying resistance to insulin (Reaven, 1998). The National Health Nutritional Survey 
conducted from 1988-1994 showed that 47 million people in the U.S.A had metabolic 
syndrome, and in the last decade it was anticipated that the prevalence would be one in four 
adults in the U.S.A. The pernicious health impact of metabolic syndrome qualifies it the 
foremost public health problem that the Western societies are experiencing (Ford et al., 
2002). In a study of 1224 participants were that were recruited from the PREDIMED 
(Prevención con Dieta Mediterránea), the authors concluded that the metabolic syndrome 
could be managed by adhering to a traditional MedDiet enriched with nuts (Salas-Salvadó et 
al., 2008). 
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1.2. Nutrition and Pregnancy 
Pregnancy is associated with major physiological and psychological changes, and adaptations 
to these changes are crucial for normal foetal development (Lazinksi et al., 2008; Lobel et al., 
2008). Maternal nutrition during pregnancy is an important factor which influences the health 
of both, mother and foetus (Mouratidou et al., 2006). A healthy balanced diet should supply 
the quantity and quality of nutrients to ensure the optimal health of the mother and the 
offspring. Pregnant women are in need of more energy and nutrients to help meet the 
increasing demands of the developing foetus (Scholl, 2008).  
The nutritional needs of pregnant women have long been addressed (Laraia et al., 2004). The 
growth of the foetus is affected by the nutritional status of the woman before, as well as 
during, pregnancy; this also affects the course of the pregnancy and enhances the risk of 
obesity for both mother and infant (Scholl, 2008; Siega-Riz et al., 2001; Shaw et al., 1995). 
In addition, the risk of developing gestational diabetes mellitus (GDM) is increased by an 
unbalanced nutrient supply where the carbohydrates of the diet are substitute with fats 
(Saldana et al., 2004). If a diet of low glycaemic index is followed this can lead to low birth 
weight, where a diet with a high-fat and low-carbohydrate content can double the risk of a 
small-for-gestational-age baby (Scholl et al., 2004). Macronutrient components of the diet 
such as, proteins, fats and carbohydrates, have been associated to lower birth weight and 
lower placental weight which include high intakes of carbohydrates and low intakes of 
protein in the diet (Godfrey et al., 1996). In contrast, where a very high protein to 
carbohydrate diet is followed, blood pressure has been found to be raised later on in adult life 
(Shiell et al., 2001). A higher placental size and birth weight has been associated with high 
maternal intakes of iron and folate late in pregnancy (Godfrey et al., 1996).  As a result, a 
suitable eating pattern is important not only throughout the childbearing years but also during 
pregnancy in order to ensure a healthy pregnancy and offspring development (Pick et al., 
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2005; Siega-Riz et al., 2001). Recent studies focusing on healthy diet during pregnancy have 
compared Northern European diets with the Mediterranean-type diet, which has been shown 
to have possible benefits, including the prevention of premature birth (Mikkelsen et al., 
2008). The results obtained from the Danish National Birth Cohort showed that pregnant 
women adhering to a diet rich in red and processed meat and high-fat dairy products, were 
associated with an increased risk of small-for-gestational-age infants (Knudsen et al., 2008). 
A recent study, in which the participants adhered to the highest quality diet in the first 
trimester of pregnancy, had a significantly lower risk of delivering a growth restricted baby 
(Rodriguez-Bernal et al., 2010). A poor in utero environment triggered by either maternal 
dietary or placental insufficiency may result in “programming” foetal susceptibility for the 
development of cardiovascular metabolic diseases later in adult life. This is also known as the 
thrifty phenotype or Barker’s hypothesis (Prentice, 2005; Godfrey, 2002; Barker, 1997). 
Inadequacy of the maternal nutrient supply to meet the foetal demands can obstruct the 
normal foetal growth leading to severe consequences on the health in adult life (Constancia et 
al., 2005).  On the other hand, an abundance of maternal nutrients being available exceeding 
the requirements of the foetus can lead to a superimposition of the deviation of the normal 
growth pattern thus leading to disease outcomes later in life (Godfrey & Barker, 2001). Foetal 
programming depicts in utero events “whereby a stimulus or insult at a critical, sensitive 
period of early life has permanent effects on structure, physiology and metabolism” (Godfrey 
& Barker, 2001).  
Two key studies have investigated the relationship between decreased maternal food intake 
and the long-term consequences of prenatal exposure to famine conditions. These studies 
were the Dutch famine (Rooij et al., 2010; Schulz, 2010) and the study of the Siege of 
Leningrad (Stanner & Yudkin, 2001). The main evidence from the Dutch Hunger Winter 
study was that exposures in utero resulting in long lasting consequences for adult health do 
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not always shows an altered weight at birth. Even though a reduced infant weight at birth is 
easily accepted as a proxy for intrauterine deprivation, it is not the sole cause of the 
development of later in life diseases. The adverse foetal environment which is followed by an 
abundance of food in adulthood may result in the development of adult chronic disease 
(Schulz, 2010). This is in support with the Siege of Leningrad study where no associations 
were detected between intrauterine starvation and a number of pathologies such as glucose 
intolerance, dyslipidaemia, hypertension or cardiovascular disease in adult life. These studies 
add to the understanding of the mechanisms of the 'thrifty phenotype' and also sustain the 
importance of the catch-up growth during early childhood which was the result of the famine 
in the Netherlands but not in Leningrad (Stanner & Yudkin, 2001). The evidence from the 
studies of the Dutch Hunger Winter (Rooij et al., 2010) and the Leningrad Siege (Stanner & 
Yudkin, 2001) emphasize the importance of the pre- and early postnatal environment on the 
growth and development, and also the timing of the insult or deviation from the normal 
nutrition, as important as the insult itself in determining (a) the affected organ system(s) and 
(b) the onset and the severity of disease outcome (Godfrey & Barker, 2001).  
Strong associations between low weight at birth and the increased risk of developing any 
metabolic disorders are well studied. Cardiovascular disease (Godfrey & Barker, 2001), type 
2 diabetes (Hales et al., 1991), central adiposity (Laitinen et al., 2004), abnormal lipid 
metabolism and hypertension (Phillips, 1998) and increased risk of death from ischemic heart 
disease  (Eriksson et al., 1999; Forsen et al., 1999), have all been constantly linked to birth 
weight. Adverse consequences in the offspring have also been observed by maternal 
overnutrition before and during pregnancy. This has been suggested to lead to long-term 
effects on offspring’s adiposity (Gale et al., 2007). Maternal diet can exert differential effects 
depending on the gestational trimester and development stage. Undernutrition early in 
development results in decreased demands for nutrients to avoid the adverse consequences of 
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growth restriction in late gestation. This may also result in the ‘brain-sparing’ reflex observed 
later in gestation, when nutrients fuel brain development at the expense of other organs and 
body segments. For example, offspring’s thinness at birth, can be due to early influences 
during pregnancy when placental development still takes place (Godfrey, 2002; Barker, 
1997). A careful distinction should be drawn between maternal and foetal nutrition, which 
describes the net supply of metabolic substrates delivered to the foetus. A “supply line” at the 
end of which the foetus grows, links the maternal diet at one end with the uptake from the 
foetal tissue at the other end (Bloomfield & Harding, 1998). This “supply line” includes the 
maternal nutrient uptake, the maternal metabolism and endocrine milieu, the uterine and 
umbilical blood flows as well as the placental transfer and metabolism. Fairly large changes 
in the maternal diet may have only a small impact on the foetal nutrition if the capacity of the 
foetal supply line is such to allow a large boundary of safety for optimum foetal growth. On 
the contrary, some of the common clinical causes of impaired foetal growth such as maternal 
hypertension being associated with reduced uterine blood flow or placental infarctions that 
comprise the placental transfer capacity, may severely limit the nutrient supply reaching the 
foetus but without a corresponding change in maternal nutrition (Harding, 2001). 
 
 
 
 
Figure 1.2: The foetal “supply line” along with the factors which mediate the differences between the 
maternal and foetal nutrition (Harding, 2001). 
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An important component of the foetal supply line is the placenta having multiple roles 
(Jansson & Powell, 2007). The capacity of the placenta to transport nutrients from the 
maternal to the foetal circulation is the most important placental influence on the nutrition of 
the foetus. Placental surface area and availability of specific nutrient transporters on the 
membranes are key factors that influence the transfer capacity of the placenta where these 
factors may be influenced in turn by the maternal nutritional environment (Das et al., 2004; 
Bassett et al., 1996). The foetal nutrition is also influenced by the placenta’s metabolic 
demands for nutrients. As shown in sheep, the placenta consumes 60% of the glucose and 
oxygen that is taken up from the uterine circulation in the late gestation (Owens et al., 1989). 
In a scenario where the uterine glucose levels decrease, the placenta consumes an increasing 
amount of foetal glucose in order to maintain its own metabolic needs (Gu et al., 1987). 
Equally, it has been shown that the foetus exports amino acids back to the placenta when the 
maternal supply is limited (Owens et al., 1989). Furthermore, the placenta influences foetal 
nutrition by producing hormones which in turn influence the foetal and maternal nutritional 
supply. For example, placental lactogen and growth hormone are produced and contribute to 
the maternal insulin resistance thus increasing the availability of glucose and other nutrients 
in the maternal circulation being available for transfer to the foetus (Bauer et al., 1998). 
 
1.3. The physiology of the human placenta 
The human placenta is a unique transient organ that separates foetal and maternal blood. Two 
cell types are the main cellular components of the chorionic villi: the trophoblast and the 
mesenchymal cells. The trophoblast is evident approximately 4 days after fertilisation as the 
outermost layer of the blastocyst. From the early stage of gestation, it differentiates into two 
cell layers: the outer differentiated syncytiotrophoblast and the inner proliferative 
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cytotrophoblast (Benirschke, 1998). Syncytiotrophoblast and cytotrophoblast form the 
primary villi which become secondary villi. This transformation occurs when the 
mesenchymal cells, derived from the extraembryonic mesenchyma, begin to invade the villi 
and tertiary villi during the formation of the foetal blood vessels. In the tertiary villi, the 
villous trophoblast consists of the highly differentiated syncytiotrophoblast (surface layer) 
and the cytotrophoblast (basal layer) (Petraglia et al., 1996). The cytotrophoblasts are the 
germinal cells and the syncytia, the secretory cells, are derived from the cytotrophoblasts. 
Each cytotrophoblast is characterised as a single cell with well-demarcated borders and a 
single distinct nucleus. Among the cytotrophoblasts there are frequent mitoses (Ramsey, 
1982). However, these characteristics are lacking in the syncytium, in which the cytoplasm is 
amorphous, lacking cell borders and the nuclei are multiple and diverse in shape and size 
(Cunningham et al., 1993). The remaining trophoblasts are used for the development of other 
parts of the placenta such as the: chorion laeve, marginal zone, chorionic plate, basal plate 
including cell columns, septa, and cell islands. They are named extravillous trophoblast 
(Petraglia,1996). 
 
Figure 1.3: Panel (A): Diagrammatic representation of the anatomy of human placenta 
(www.theodora.com/anatomy/images39.gif), Panel (B): Proposed placental functions (The Mc Graw-
Hill Companies, Inc.) 
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A large number of studies show that syncytiotrophoblasts express the majority of pituitary-
like hormones such as human chorionic gonadotropin (hCG), human placental lactogen (hPL) 
(Kato & Braunstein, 1989), corticotropin-releasing hormone (CRH) (Frim et al., 1988), 
adrenocorticotropic hormone (ACTH) (Petraglia et al., 1987), as well as neurohormones/ 
neuropeptides, cytokines, and growth factors which have been preferentially localised in the 
cytotrophoblast (Wood, 1980; Hunt, 1989). In addition, near term, the human placenta is 
involved in steroidogenesis, and vast amounts of estrogens are produced almost exclusively 
by syncytiotrophoblast cells (Cunningham et al., 1993). 
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1.4. Maternal exercise during pregnancy 
Physical activity is highly recommended during pregnancy by physicians and the American 
College of Obstetricians and Gynaecologists (ACOG): in the absence of any medical or 
obstetric complications, moderate exercise on a daily basis of 30 minutes or more is 
recommended for most pregnant women (ACOG Committee Obstetric Practice, 2002). 
Although the common sense as well as a small number of observational studies and 
controlled trials are in support of this recommendation, a recent review by Kramer has 
concluded that the available evidence of the possible benefit or harm to mother or foetus 
regarding the recommendations  of aerobic exercise during pregnancy are highly insufficient. 
The authors concluded that the available studies are very small, the experimental design is 
possibly flawed, and an inconsistence in methodology is observed which renders these 
studies unable to support this recommendation (Kramer, 2004). The benefits of regular 
aerobic exercise during pregnancy have become of an interest to the American College of 
Obstetricians and Gynaecologists and an attempt has been made to redirect the focus on the 
variety of theoretical risks that exercise poses to the mother and the foetus (Snyder & 
Pendergraph, 2004). The positive benefits of regular exercise during pregnancy on women as 
reported by Kramer, include improvement of overall body image and steady maintenance of 
their physical fitness (Kramer, 2004). In the currently available studies where the parameters 
studied included mode of delivery, length of labour, growth parameters, preterm birth, and 
Apgar scores, no other benefits or risks on the health of the mother or the foetus were 
supported (Kramer, 2004). However, despite the many limitations of the current studies, 
some evidence has emerged suggesting that smaller babies were born to women who 
exercised vigorously during their pregnancy, resulting in neonatal fat mass restriction. Also, 
it has been suggested that these leaner babies could have a lower risk of becoming obese as 
children and as adults (Magann et al., 2002).  
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Excess weight gain during pregnancy and the postpartum inability to return to a healthy 
weight have been shown to be associated with increased rates of maternal obesity eight to ten 
years later (Rooney & Schauberger, 2002). Many women find appealing enough the 
enhanced body image resulting from exercise and along with the perceived benefits of 
physical fitness continue to exercise during pregnancy. Yet, very little has been published 
regarding the acceptability of exercise during pregnancy in women of diverse cultural 
backgrounds. Given that in some population subgroups there is a high prevalence of obesity 
and overweight (U.S Department of Health and Human Services: office of the surgeon 
general, 2001) an extra encouragement to exercise during pregnancy may be desirable. 
Therefore, for the successful implementation of the ACOG guidelines a cultural acceptance 
of the idea of exercising during pregnancy will be a necessity, thus an understanding of the 
attitude of women from diverse backgrounds towards exercise during pregnancy is crucial 
(Snyder & Pendergraph, 2004). Moderate aerobic exercise is a safe, affordable way for 
women to improve their sense of well-being during pregnancy and this is further enhanced by 
the ACOG’s  statement that potential risks are rare in properly screened pregnant women who 
avoid extreme environmental conditions and activities that can lead to abdominal trauma 
(Snyder & Pendergraph, 2004). However the specific benefits of regular exercise for the 
mother and the foetus have yet to be confirmed by further studies but shifting away from the 
view that aerobic exercise poses potential hazard for the health of  pregnant women is still of 
major benefit  (Snyder & Pendergraph, 2004). Given the current epidemic of obesity and the 
associated increasing incidence rates of metabolic syndrome and type II diabetes, it would 
therefore appear that well-designed, large-scale prospective clinical trials examining the 
effects of exercise during pregnancy as well as long-term follow-up of the exercising women 
and their infants would help to elucidate the real benefits versus the risks of exercise during 
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pregnancy and allow future recommendations to be based on evidence rather than expert 
opinion (Snyder & Pendergraph, 2004). 
 
1.5. Maternal Stress and Foetal Outcome 
Stress is defined as “a state of physiological or psychological strain caused by adverse stimuli 
physical, mental, or emotional, internal or external, that tend to disturb the functioning of an 
organism and which the organism naturally desires to avoid” (Dorland, 2007). Widely 
accepted as being a complex construct, stress, is divided into several stages: 1) the stressors 
which are the event leading to the clinical features associated with stress, 2) the mediators 
which can involve the appraisal, of as well as coping with, the stressor, 3) the moderators 
where this  can include the social support being available as well as the personality of the 
individual  and finally, 4) the stress response itself which includes innervations of the 
hypothalamic-pituitary-adrenal (HPA) axis and the sympathetic nervous system (Gidron & 
Ronson, 2008; Thanker & Sood, 2008; Smith & Vale, 2006; Weinman & Kaptein, 2004). The 
physiological response to stress is usually where the HPA axis is activated above the basal 
level, as well as stimulation of the sympathetic nervous system to induce the synthesis and 
secretion of glucocorticoids (GC) (such as cortisol) and catecholamines (such as adrenalin) 
(Ogden, 2007). A stressor can include a stimulus received from the individual, a situation or a 
circumstance experienced by an individual and could potentially induce a stress response 
(Weinman & Kaptein, 2004). Perceived stressors are subjected to appraisal which is 
connected to the personality of the individual, to their past experiences as well as to the 
physical and psychological state of one being in (Weinman & Kaptein, 2004). Stressors can 
vary from being acute (short termed) to chronic (constant) and also to chronic intermittent 
(long lasting but not constant). Mediators will determine and moderate the level of the stress 
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response by acting as “buffers” against the negative health consequences induced by the 
stressor. Psycho-social factors, for example the ability of coping and the social support being 
available can have a great effect on the outcome (Weinman & Kaptein, 2004; Olstad et al, 
2001). A stress reaction elicits responses on more than one level and more than one (i.e. 
emotional, cognitive or behavioural) of the responses can be felt at any one time (Weinman & 
Kaptein, 2004).  
Pregnancy is associated with major physiological changes and maternal adaptation to these 
changes is crucial for a normal development of the foetus (Lazinksi et al., 2008; Lobel et al., 
2008). Emotional stress is considered to be a response to the stressor, therefore during 
pregnancy; the developed emotional stress may interfere with the necessary adaptation and 
lead to a dysregulation of the two major stress response systems: the HPA axis and the 
sympathetic nervous system (Lazinski et al, 2008). Perceived life-event stress including 
depression and anxiety predicted lower birth weight, decreased Apgar scores, smaller head 
circumference, and small for gestational age babies (Marcus & Heringhausen, 2009). It has 
been widely documented, that stress during pregnancy correlates with pre-term birth as well 
as lower birth weight (Bolten et al., 2010; Dole et al., 2003). Also in association with 
smoking, it has been shown that pregnancy-specific stress aid directly to pre-term delivery 
and indirectly to low birth weight (Lobel et al, 2008). By examining these effects it is evident 
that pregnancy-specific stress may be a more powerful contributor to problematic birth 
outcomes than general stress (Lobel et al, 2008). Despite the origin of the stressor, the 
physiological responses to it are the innervations of the HPA axis and that of the sympathetic 
nervous system (Gidron & Ronson, 2008). The responses following the perception of a 
stressor can be seen in Fig. 1.4.  
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Figure 1.4: Diagram illustrating the parts of the adrenals (blue lines) including what they secrete and 
how stress is perceived and the following responses (Barot et al., 2005). 
 
It is of great importance to note that with an exogenous stimuli like chronic and repeated 
stress, dysregulation of the HPA axis is seen leading to an altered cortisol secretion, thereby 
affecting the end-organ function (Guilliams & Edwards, 2010;  Nussey & Whitehead, 2001). 
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1.6. Hypothalamic-Pituitary-Adrenal (HPA) Axis  
Neurosecretory cells that are present in the periventricular nucleus of the hypothalamus 
secrete  corticotropin-releasing hormone (CRH). This peptide moves to the anterior pituitary 
where it initiates a signal transduction cascade stimulating the synthesis and the secretion of 
the adrenocorticotropic hormone (ACTH) via arginine vasopressin which is also being 
released in the hypothalamus (Nussey & Whitehead, 2001). ACTH acts on the adrenal glands 
and specifically the adrenal cortex, where it increases the transport of cholesterol to the inner 
mitochondria membranes and consequently increases the rate of synthesis of cortisol (Nussey 
& Whitehead, 2001). The synthesis and secretion of cortisol is highly regulated by the 
presence/absence of ACTH. In the adrenal cortex, ACTH acts to stimulate GC synthesis via a 
G protein-coupled receptor (GPCR) (Nussey & Whitehead, 2001) and cortisol is then 
released in a pulsatile fashion (Nussey & Whitehead, 2001; Sapolsky et al, 2000). The 
bioavailability of cortisol and glucocorticoids are regulated by a negative feedback loop (Fig. 
1.5) which controls the circulating concentrations of cortisol and the other adrenal 
glucocorticoids. Neurons in the hypothalamus are able to detect these concentrations and 
therefore glucocorticoids act back on the hypothalamus and pituitary by suppressing CRH  
and ACTH production in a negative feedback cycle thus modulating/co-ordinating the 
synthesis and secretion of ACTH, and subsequently cortisol  (Miller et al., 2007; Nussey & 
Whitehead, 2001).  This feedback mechanism can be temporarily interrupted when stress is 
introduced. The exogenous stress stimulus encourages increases in CRH and therefore 
ACTH, consequently increasing cortisol concentrations. The level of cortisol, can be restored 
via the feedback mechanism (Nussey & Whitehead, 2001; Laudat et al, 1988).  
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Figure 1.5: The hypothalamic-pituitary-adrenal (HPA) axis and its regulation. Stress as well as 
sleep/wake cycles can induce the secretion of corticotrophin releasing hormone (CRH) in the 
hypothalamus.  CRH is perceived by the pituitary gland which secretes adrenocorticotropic hormone 
(ACTH).  ACTH is perceived by the adrenal cortices which secrete cortisol.  Cortisol reacts in the 
body in a number of different ways and also provides a negative feedback loop to the hypothalamus 
which adjusts its secretion of CRH accordingly (Nussey & Whitehead, 2001, Porterfield, 2001). 
 
 
The light/dark or sleep/wake cycles affect the levels of ACTH that are being released and 
consequently the levels of circulating cortisol, which can be described to follows a circadian 
rhythm (Weerth et al, 2003; de Bosscher et al, 2003). Fig.1.6 below shows the levels of 
(nmol/l) that are being secreted per hours of the day. Cortisol’s secretions peaks in the 
morning, at around the awaking hour (8 am) after which a gradually decline through the 
waking hours is noticed, achieving a daily minimum during the half of the sleep cycle 
(Czeisler et al., 1976). When the body is stressed or when specific foods are eaten this can 
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lead to episodic spikes of cortisol to occur. On the other hand, cortisol levels are at the lowest 
after midnight and up to 4:00 am. The cortisol levels in the morning are indicative of the peak 
of the output of this hormone whereas the levels of cortisol at noon show the adaptability of 
the body to this hormone as well as its usage. The levels in the afternoon are mainly 
associated with the regulation of sugar than with the function of the adrenal glands. The 
baseline function of the adrenals is indicated by the levels of this hormone in the evening 
hours (Lam & Lam, 2010). 
 
 
 
Figure 1.6: Secretory pattern of cortisol over a 24-hour period (Nussey & Whitehead, 2001) 
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1.7. Biological effect of Glucocorticoids / Cortisol 
An uncontrollable biological response to a stressor can exert harmful effects to the body. 
Glucocorticoids are able to protect the body against disruption induced by stress by 
regulating and sustaining gluconeogenesis, metabolism and blood pressure (de Bosscher et al, 
2003; Fujiwara et al, 1996). Cortisol and indeed all glucocorticoids are able to affect lipid 
metabolism (de Bosscher et al, 2003; Christiansen et al, 2007). Steroid hormones including 
cortisol readily cross the blood/brain barrier affecting the neural pathways (Reichardt & 
Schutz, 1998) where in response to various stimuli, including stress, they are able to 
coordinate metabolic, endocrine, immune and nervous system responses (Tronche et al, 
1999). Glucocorticoids are also considered to have an effect on brain function by modulating 
emotional behaviour, cognitive functions and addictive states (Flanagan-Cato & Fluharty, 
1997; Tronche et al, 1999). More specifically as it can be seen from Table 1.1, 
glucocorticoids can also exert effects on the cardiovascular system controlling the fluid 
volume, elevating blood pressure, heart rate and cardiac output with blood being diverted to 
muscles via a series of constrictions and dilation of blood vessels. It has also been shown to 
affect immunity and inflammation, as cortisol influences cells participating in the body’s 
immune reaction and particularly white blood cells (Lam & Lam, 2010). In addition, cortisol 
is reported to be a powerful anti-inflammatory agent. Cortisol increases the blood sugar levels 
in the body thus providing it with the needed energy to physically escape a potential threat or 
injury. Moreover, cortisol can affect metabolic events, neurobiological processes as well as 
reproductive physiology (Scott, 2008; Sapolsky et al, 2000). 
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Effects  of  Cortisol 
 Decrease the effects of insulin on blood glucose 
 Increases block glucose 
 Increases fat and cholesterol in the blood 
 Increases breakdown of proteins into amino acids. 
 Decreases inflammation, immune system function, and healing. 
 Decreases memory due to inhibition and /or death of brain cells. Therefore, 
overtime and problem solving skills are reduced. 
 Increases the number of receptors for epinephrine and norepinephrine, leading to 
blood pressure and heart rate rises. 
 
 
Table 1.1: Summary of the effects of cortisol on human physiology 
 
Glucocorticoids are administered in humans during the late stages of pregnancy in order to 
treat maternal asthma and decrease neonatal respiratory morbidity. However, growth 
retardation and reduced birth weight are reported as side effects of this treatment (Reinisch et 
al., 1978). The programming of the hypothalamo–pituitary–adrenal (HPA) axis has been 
hypothesized to be regulated by prenatal glucocorticoids or stress mediators as the excess of 
glucocorticoids may be associated with hypertension and glucose intolerance (Clark, 1998). 
Animal studies have shown (Vallee et al., 1996) that offspring of prenatally stressed rats had 
increased basal blood glucose levels, were eating less and weighed less in comparison to the 
control group. Another study (Lesage et al., 2004) reproduced these findings; that increase in 
maternal stress resulted in reduced body, adrenal and pancreas weights as well as decreased 
plasma corticosterone and glucose levels in foetuses at term. Male rats of age (24 months old) 
exhibited hyperglycaemia, glucose intolerance and decreased basal levels of leptin. In 
addition, the intake of food following fasting was increased (Lesage et al., 2004). Therefore, 
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an in utero environment with excess glucocorticoids provoked a long-lasting disturbance in 
the feeding behaviour and led to metabolic dysfunction, in the offspring (Lesage et al., 2004). 
 
1.8. The Nuclear Receptor superfamily 
1.8.1. Glucocorticoid Receptor 
Cortisol exerts its actions by binding and activating glucocorticoid receptors (Rhen & 
Cidlowski, 2005; De Bosscher et al., 2003). The glucocorticoid receptor (GR) is a 
phosphoprotein and a transcription factor, which is able to positively and negatively regulate 
the expression of different genes. The GR is a member of the steroid hormone receptors 
subgroup that belongs to the super-family of nuclear receptors. The nuclear receptors are 
members of a large superfamily of DNA-binding transcription factors which are believed to 
be evolutionary maintained and derived from a common ancestor (Owen & Zelent, 2000; 
Escriva et al., 1997). Nuclear receptors regulate a range of programs involved in growth, 
differentiation, metabolism, reproduction and morhogenesis (Lu et al., 2006; Germain et al, 
2006; Aranda & Pascual, 2001). The nuclear receptors are of major importance for 
intercellular signalling as they converge intracellular and extracellular signals on the 
regulation of genetic programs (Chambon, 2005). As they are transcription factors they 
respond through association with a variety of hormonal and metabolic signals. They integrate 
diverse signalling pathways as they relate to targets of post-translational modifications and 
also are able to regulate the activities of other signalling cascades (Chambon et al, 2005).  
The steroid hormone receptors subgroup of the nuclear receptor superfamily includes the 
estrogen receptor (ER), the cortisol binding glucocorticoid receptor (GR), the aldosterone 
binding mineralocorticoid receptor (MR), the progesterone receptor (PR) and the androgen 
receptor (AR). In addition, the steroid hormone receptors subgroup contains three orphan 
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receptors closely related to ER (Kallen et al., 2004; De Bosscher et al, 2003; Escriva et al., 
2000; Thornton & DeSalle, 2000; McKay & Cidlowski, 1999; Nuclear Receptor 
Nomenclature Committee, 1999; Stein & Yang, 1995). All steroid hormone receptors consist 
of a variable N-terminal domain (A/B domain), a conserved domain that binds DNA (DBD or 
C domain), a hinge domain (D domain), a ligand –binding domain (LBD) also known as E 
domain which is conserved among the nuclear receptors (Fig. 1.7) (Bain et al., 2007; 
Germain et al., 2006; Hirata et al, 2003; Aranda & Pascual, 2003). 
 
Figure 1.7:  Illustration of the distinct domains that are common in nuclear receptors. 
 
The amino terminus contains an autonomus transcriptional activation function known as 
activation- function-1 (AF-1) which contributes to the integral ligand- independent activation 
by the receptor. It can also function in synergy with activation function-2 (AF-2). The N-
terminal amino acid domain is unique to each steroid hormone receptor and is of variable 
sequence and length. The DNA binding domain (DBD) which is highly conserved among the 
group binds to DNA and confers sequence-specific DNA recognition. The D domain, is 
situated between the DBD and ligand binding domain (LBD), functions as a flexible hinge 
and contains the nuclear localization signal (NLS). The LBD is key to receptor-ligand 
interactions. All ligand-binding domains fold into a highly homologous three-layered 
structure with a small ligand-binding pocket in the centre. Upon ligand binding, the NLS is 
exposed and assists the translocation of the receptor to the nucleus. This domain also contains 
AF-2 which is a ligand-dependent transcriptional activation function necessary for the 
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recruitment of transcriptional co-activators. The function of the carboxy terminus (F domain) 
remains unknown and it has been shown to have an extremely variable sequence (Nagpal et 
al., 1993; Aranda & Pascual, 2001). 
 
1.9. Activation of the Glucocorticoid Receptor by Cortisol  
As mentioned, cortisol exerts its biological effects via binding to its receptor (Rhen & 
Cidlowski, 2005; De Bosscher et al, 2003). In the absence of hormone, the glucocorticoid 
receptor (GR) is in the cytosol and it is complexed with a variety of proteins including heat 
shock protein 90 (hsp90), the heat shock protein 70 (hsp70) and the protein FKBP52 (FK506-
binding protein 52) which retain it in an inactive state (Pratt et al., 2006; De Bosscher et al, 
2003). Cortisol diffuses through the cell membrane into the cytoplasm and binds to the 
glucocorticoid receptor resulting in the release of the heat shock proteins by changing the 
stereochemical configuration of the receptor (Buckingham, 2006). 
 
Figure 1.8: Activation of GR by cortisol (panomics.com) 
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As can be seen in Fig. 1.8, ligand binding activates and changes the conformation of the GR 
which undergoes phosphorylation (Davies et al., 2002; Dittmar et al., 1997). The 
phosphorylation of the receptor facilitates translocation of the ligand-receptor complex from 
the cytoplasm into the nucleus. Once in the nucleus it forms a homo- or heterodimer with 
another ligand – receptor complex (Nussey & Whitehead, 2001). The zinc fingers that are 
present in the DNA-binding domain (DBD) of the dimerized receptors are able to interact 
with specific grooves in the DNA helix that contain a consensus sequence, known as the 
glucocorticoid response element (GRE) (Nussey & Whitehead, 2001). The GRE (5’- 
GGTACAnnnTGTTCT-3’, where  n  is any nucleotide) is found in the promoter regions of 
the glucocorticoid  responsive genes (Beato, 1989). The GR activates transcription of target 
genes by interaction with the basal transcription machinery (Newton, 2000; McKay & 
Cidlowski, 1999).  
 
1.10. Glucocorticoid  Receptor splice variants 
Govindan and co-workers in 1985 were the first to isolate the human glucocorticoid receptor 
from the breast cancer  cell line MCF-7 (Govindan et al, 1985). Following the cloning of the 
human GR another group determined the structure of the hGR gene (Encio & Detera-
Wadleigh, 1991). It was shown that the gene is of a minimum size of 80kilobases (kb) within 
chromosome 5 and it contains eight coding exons (Zong et al, 1990, Encio & Detera-
Wadleigh, 1991). The first report regarding the transcripts resulting from alternative splicing 
of the GR gene came from Hollenberg and his colleagues (Hollenberg et al, 1985). These 
were the highly conserved GRα and GRβ isoforms that differ only at the carboxy-terminus 
(Dahia et al., 1997).  More specifically, GRα isoform is encoded by exons 2, 3, 4, 5, 6, 7, 8 
and 9α of the GR gene (Hollenberg et al, 1985; Tissing et al, 2003) whereas GRβ isoform is 
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encoded by the same exons but there is alternative splicing of exon 9β instead of 9α and this 
gives rise to 15 unique C-terminal amino acids (Tissing et al, 2003). From the two isoforms 
only GRα shows to be the functional receptor in terms of ligand binding (Encio & Detera-
Wadleigh, 1991; Rivers et al, 1999) whereas GRβ is unable to bind GC and is 
transcriptionally inactive (Rivers et al, 1999). GRβ forms heterodimers with ligand-bound 
GRα either in the cytoplasm with subsequent translocation into the nucleaus or in the nucleus 
to exhibit the dominant negative effect over the GRα isoform (Dahia et al, 1997). In the past 
years it was shown that expression of GRβ  at mRNA or protein level was low in almost 
every human tissue and it was found to be complexed with heat shock proteins, leading to the 
assumption that GRβ has an active role in determining the sensitivity of target tissues to GC 
(Bamberger et al, 1995). Rivers et al, described a new splice variant of the GR gene termed 
GRγ where exon 4 is alternatively spliced to exon 3 and has three basepairs of the intron 
region (Rivers et al, 1999). This results to an addition of another amino acid -arginine- in the 
DNA binding domain of the receptor (Rivers et al, 1999). The insertion of this amino acid at 
this site has been shown to decrease the transcriptional activation of GRγ  to 48% that of GRα 
(Ray et al, 1996). The cloning of another variant was reported by Moalli and his team 
members. This splice variant, GR-P, is encoded by exons 2-7 and a part of intron 7 whereas 
exons 8 and 9 are missing (de Lange et al., 2010; Μoalli et al, 1993). As a result, GR-P lacks 
the ligand binding domain and is unable to bind to glucocorticoid (GC) (Tissing et al, 2003).  
A recent study has demonstrated the presence of GR-P mRNA in tumour cells isolated from 
patients with haematological malignancies, further the activity of GRα was increased upon 
transfection of cells with GR-P. This effect though was found to be cell type specific 
suggesting that specific cell factors and even the ratio of the receptors mRNA influences the 
responsiveness of the tissues to glucocorticoids (de Lange et al., 2010). 
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Up to now, the cloning of four splice variants of the GR gene have been reported formed by 
alternative splicing, these being GRα, GRβ, GRγ and GR-P. The diagram (Fig.1.9) illustrates 
the GR gene as well as the four splice variants (Tissing et al., 2003). A number of studies 
have reported the expression of different GR splice variants in different cell and tissue types 
(Pujols et al., 2002; Honda et al., 2000; Oakley et al., 1999; de Castro et al., 1996). 
Specifically the expression of GRα mRNA was found to be expressed in cells of the brain, 
skeletal, muscle, lung, kidney, liver, heart, nasal mucosa and in the colon. Also in 
inflammatory cells such as macrophages, eosinophils, neutrophils. GRβ  mRNA was detected 
in cells of the liver, skeletal muscle, kidney, lung, brain, nasal mucosa, heart and in the 
inflammatory cells  eosinophils, macrophages, neutrophils , although in concentrations at 
least 400 times lower than GRα mRNA (Pujols et al., 2002). Regarding the expression of GR 
in reproductive tissues, the expression of GR has been reported in the ovary (Alsop et al., 
2009; Rae et al., 2005) and studies have confirmed the expression of GR in the rat testis 
(Weber et al., 2000) and in the testis of the amphibian Bufo arenarum (Denari & Ceballos, 
2006). 
 
 
 
Figure 1.9: A schematic representation of the GR gene and the GR splice variants (Tissing et al, 
2003). 
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1.11. Glucocorticoid Receptor Polymorphisms 
A number of polymorphisms have been described in the gene coding for the GR although it is 
still unclear whether the variability in the glucocorticoid responses observed are due to the 
polymorphisms or to other factors (van Rossum & Lamberts, 2004). Only few of these 
polymorphisms are functionally relevant and these are: the ThtIII 1, the ER22/23EK, the 
N363S, the BclI and the GR-9β  polymorphisms (Fig.1.10). Studies have shown that at least 
three polymorphisms are associated with altered glucocorticoid sensitivity and also changes 
in body composition and metabolic parameters (Manenschijn et al, 2009; van Rossum & 
Lamberts, 2004). Apart from the increased sensitivity to gluocorticoids, a tendency towards a 
lower bone mineral density along with increased body mass index and increased abdominal 
obesity has been observed and associated with the GR polymorphisms (Ukkola et al., 2001; 
Rosmond et al., 2000; Buemann et al., 1997;). A study has reported the relative resistance of 
a polymorphism (ER22/23EK) to glucocorticoids and in addition to this, lower total 
cholesterol and low-density lipoprotein cholesterol levels as well as lower fasting insulin 
concentrations and a better insulin sensitivity was observed (van Rossum & Lamberts, 2004).  
GR polymorphisms have also been associated with lower risk of dementia and white matter 
lesions in elderly (van Rossum & Lamberts, 2004). These polymorphisms have been 
associated with altered sensitivity to glucocorticoids and also altered cortisol levels and with 
certain other diseases including autoimmune, cardiovascular as well as differences in body 
composition and metabolic parameters and may contribute considerably to the observed 
variability in gluococorticoid sensitivity (Manenschijn et al, 2009). 
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Figure 1.10: A presentation of the GR gene and the polymorphisms associated with it (Manenschijn 
et al, 2009). 
 
The ThtIII 1 polymorphism has been described as a restriction fragment length polymorphism 
(RFLP) that is caused by a C T substitution 3807bp upstream the mRNA start site on the 
GR gene (van Rossum et al, 2003). By RFLP we refer to the type of polymorphism which 
results from a variation in the DNA sequence that is recognized by restriction enzymes.  The 
functionality of this polymorphism has been questioned as the linkage between it, and the 
ER22/23EK polymorphism shows that carriers of the ER22/23EK carry  a ThtIII 1 minor 
allele and the sensitivity of those individuals to GCs is decreased. Whereas, carriers of the 
ThtIII 1 allele without  been carriers of the ER22/23EK polymorphism showed no 
alternations in sensitivity to GCs (Manenschijn et al, 2009; Van Rossum et al, 2003). The 
ER22/23EK polymorphism of the GR gene has been located in the transactivation domain of 
the gene. A single nucleotide polymorphism in codons 22 and 23 alters the sequence at DNA 
level resulting in the protein glutamic acid – lysine to be translated instead of glutamic acid- 
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arginine. The N363S polymorphism has been reported in codon 363 of exon 2 resulting in an 
AAT AGT nucleotide change. The result of this substitution is a change of the amino acid 
serine to asparagine. The Bcl I polymorphism has a nucleotide alteration between a C and a 
G, is found 646 nucleotides downstream from exon 2 resulting in fragments of 2.2kb and 
3.9kb. Most frequently occurring is the C allele and thus considered to be the wild-type allele 
(Manenschijn et al, 2009; Van Rossum et al, 2003). The 9β polymorphism has an A to G 
substitution which has been reported in an “ATTTA motif” in the 3’UTR of exon 9β. This 
substitution alters the stability of the mRNA, and subsequently translational events 
(Manenschijn et al, 2009).  The table 1.2 summarizes the sensitivity of the carriers to GC’s 
and the main phenotypes that accompany these polymorphisms. 
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Polymorphisms Sensitivity to 
GC’s 
Phenotypes Substitution 
ThtIII 1 
Not linked 
Associated with depression 
/ carriers at reduced risk of 
bipolar disorder, lower 
volume of hippocampus. 
C  T 
ER22/23EK Resistance 
(minor) 
Increased risk of 
depression, decreased risk 
of dementia, healthy 
metabolic profile, and 
balanced body composition. 
Arg  Lys 
N363S 
Hypersensitivity 
Association with increased 
BMI (controversy in field), 
elevated cholesterol levels. 
Asn  Ser 
Bcl I 
Hypersensitivity 
Deposition of fat in 
abdominal area, less lean 
mass, increased risk of 
depression. 
C  G 
9β 
Not known? 
Balanced body composition, 
increased risk of 
autoimmune diseases, 
increases risk of myocardial 
infarction. 
AG 
 
Table 1.2: Association of all polymorphisms with sensitivity to GC’s and phenotypes (Manenschijn 
et al., 2009). 
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1.12. Signalling of the mammalian Target of Rapamycin (mTOR) 
mTOR is a highly conserved member of the phosphatidylinositol 3-kinase (PI3K)-related 
superfamily in which a lipid kinase homology sector functions as a 289kDa  Ser/Thr  kinase 
(Wen et al, 2005).  mTOR consists of 2549 amino acids (Sabatini et al., 1994) which are 
organized in several structural domains as can be seen in Figure 1.11. The mTOR pathway is 
responsible for basic cellular functions such as cell metabolism and proliferation, growth as 
well as cell cycle progression, checks for DNA damage, and telomere length maintenance 
(Laplante & Sabatini, 2009; Petroulakis et al, 2006). This signal transduction cascade has 
also been under intense investigation for its participation in apoptosis and cell survival 
(Petroulakis et al, 2006), as it also contributes to pathologies including immunodeficiency 
and cancer (Bjornsti & Houghton, 2004). 
 
 
 
 
Figure 1.11: The basic structure of mTOR (Kristof, 2010) 
 
The N- terminus of mTOR consists of 20 sequential HEAT [Huntington, Elongation factor 3 
(eEF3), A subunit of type 2A protein phosphatase (PP2A) and TOR] repeated areas (Kristof, 
2010; Petroulakis et al, 2006). These HEAT repeats are associated with protein-protein 
interactions and consist of two  helices, with both hydrophobic and hydrophilic residues. 
The C- terminus consists of a kinase domain with sequence similarity to that of the catalytic 
domain of PI3K. In addition there is an FKPB12-rapamycin binding (FRB) domain, a 
negative regulatory domain (NRD) and a relatively large FAT [(FRAP, Ataxia telangiectasia 
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mutated (ATM), Transformation/transcription domain associated protein (TRAP)] as well as 
a FAT c- terminal (FATc) domain (Jacinto & Lorberg, 2008; Bosotti et al, 2000). The two 
latter domains are essential for mTOR activity whereas a deletion of an amino acid can 
potentially diminish the activity of mTOR (Peterson et al, 2000; Takahaski et al, 2000). 
Additionally, the interaction of  FAT and FATc domains are also thought to eventually 
expose the catalytic domain (Takahashi et al, 2000). 
 
 
 
Figure 1.12: Summary of the mTOR signalling pathway ( Adapted from Qiagen) 
 
Growth factors acting as stimuli result in the PI3K phosphorylation of the lipid 
phosphatidylinositol-4, 5-biphosphate at the 3’-OH site producing phosphatidylinositol-3, 4, 
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5-triphosphate, which is the second lipid messenger as can be seen from Fig.1.12 (Petroulakis 
et al, 2006). The newly produced triphosphate recruits its downstream effector  Akt, at the 
plasma membrane which becomes phosphorylated at two sites respectively, at Ser473 and 
Thr308 resulting in its activation. This leads to the phosphorylation of the product of the 
tuberous sclerosis complex- 2 gene (TSC-2) and inhibits the tuberous sclerosis complex 
(TSC) which comprises of the heterodimer TSC-1 and TSC-2 (Laplante & Sabatini, 2009; 
Petroulakis et al, 2006). The TSC-1 product which is known as hamartin and TSC-2 product 
which is known as tuberin, act as negative regulators of mTORC-1 which is prevented via 
phosphorylation (Gao et al, 2002). Phosphorylation of  tuberin through Akt/PKB leads to its 
dissociation from hamartin and the subsequent loss of GTPase activating protein action (Tee 
et al, 2005). Tuberin and hamartin  heterodimers function as GTPase activating proteins 
inactivating Ras homolog enriched in brain (Rheb), which has a key role in the activation of 
mTORC-1. Therefore, the regulation of mTOR as a growth factor, involves the activation of 
PI3 kinase signalling which results in the phosphorylation of tuberin (Laplante & Sabatini, 
2009).  The signalling pathway of mTOR with its associated components is illustrated in 
Fig.1.12 whereas the rest of the main molecules that are included in the signalling cascade 
will be further explained below. 
In mammals there are two separate TOR complexes present: mTORC-1 and mTORC-2. The 
first complex consists of: mTOR which is the catalytic subunit of the complex; regulatory-
associated protein of mTOR (Raptor); mammalian lethal with Sec13 protein 8 (mLST8);        
[also known as GβL (G-protein β-like)]; proline rich AKT substrate 40 kDa (PRAS40); and 
DEP-domain-containing mTOR-interacting protein (Deptor) (Peterson et al., 2009; Abraham, 
2002). The precise function of most of the mTOR-interacting proteins participating in 
mTORC-1 is not fully elucidated. Recently it has been proposed that Raptor may affect the 
activity of mTORC-1 by regulating the assembly of the complex and also by recruiting 
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substrates for mTOR (Hara et al., 2002; Kim et al., 2002). The mLST8’s role in mTORC-1 
function remains elusive, as a deletion of this protein has not been shown to affect the activity 
of mTORC-1 in vivo (Guertin et al., 2006). PRAS40, as well as Deptor, has been 
characterized by several studies as distinct negative regulators of mTORC-1 (Peterson et al., 
2009; Sancak et al., 2007; Vander Haar et al., 2007). PRAS40 and Deptor are recruited to the 
complex when the activity of mTORC-1 is reduced, and promote the inhibition of mTORC-1. 
It has been suggested that PRAS40 regulates the kinase activity of mTORC-1 by functioning 
as a direct inhibitor of substrate binding (Wang et al., 2007). Upon activation, mTORC-1 
directly phosphorylates PRAS40 and Deptor and as a result, their physical interaction with 
mTORC-1 is reduced and this activates mTORC-1 signalling (Peterson et al., 2009; Wang et 
al., 2007). 
The mTORC-2 comprises of six different proteins, which some of them are common to 
mTORC-1: mTOR, rapamycin-insensitive companion of mTOR (Rictor), mammalian stress-
activated protein kinase interacting protein (mSIN1), protein observed with Rictor-1 (Protor-
1), mLST8, and Deptor. Evidence has shown that Rictor and mSIN1 function in order to 
stabilize each other, thus establishing the structural foundation of mTORC-2 (Frias et al., 
2006; Jacinto et al., 2006). Rictor has also been shown to interact with Protor-1, but the 
physiological function of this interaction is under investigation (Thedieck et al., 2007; Woo 
et al., 2007). mLST8 has been shown to be essential for the orderly functioning of mTORC-
2, as deletion of this protein severely impairs the stability as well as the activity of the 
complex (Guertin et al., 2006). Deptor has a similar role as in mTORC-2 to its role in 
mTORC-1 and negatively regulates mTORC-2 activity (Peterson et al., 2009). So far, Deptor 
is the only endogenous inhibitor of mTORC-2 that has been characterised (Laplante & 
Sabatini, 2009). The use of the bacterial microlide rapamycin has significantly enhanced the 
knowledge of mTORC-1 function. When rapamycin enters the cell binds to FK506-binding 
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protein of 12 kDa (FKBP12) and then it interacts with the FKBP12-rapamycin binding 
domain (FRB) of mTOR, thereby inhibiting the functions mTORC-1 (Guertin & Sabatini, 
2007).  FKBP12-rapamycin does not physically interact with or inhibit mTORC-2 (Jacinto et 
al., 2004; Sarbassov et al., 2004). Following these observations, mTORC-1 and mTORC-2 
have been characterized as rapamycin-sensitive and rapamycin-insensitive complexes 
respectively. However, Sabrassov and his colleagues have shown this may not be entirely 
accurate, as chronic treatment with rapamycin can, in some cases, inhibit the activity of 
mTORC-2 by blocking its assembly (Sarbassov et al., 2006). 
 
1.13. Key components of  mTOR Complexes 
1.13.1. Raptor (Regulatory-associated protein of mTOR) 
Raptor is an essential subunit of mTORC-1. Is a conserved 150-kDa protein able to bind the 
downstream effectors of mTOR, ribosomal protein S6 kinase 1(S6K1) and eukaryotic 
translation initiation factor 4E-binding protein 1 (4E-BP1). Raptor homologs contain a unique 
as well as conserved region in the amino- terminal followed by three HEAT repeats and 
seven WD-40 repeats in the C-terminal. The HEAT repeats present in the mTOR which are 
situated in the N-terminal are responsible for the efficient interaction with Raptor (Hara et al., 
2002; Kim et al, 2002). Mutations that occur in the conserved N-terminal of Raptor or within 
the HEAT repeats interfere with the ability of Raptor to bind to mTOR suggesting the 
presence of multiple contact points between the two molecules (Kim et al, 2002). 
Knockdown experiments of Raptor in mammalian cells underpinned the importance of this 
gene for mTOR activity (Kim et al, 2002). Opposing the positive regulation of mTOR by 
Raptor, one report indicates that, upon nutrient deprivation the association of Raptor–mTOR 
becomes stabilized in a manner that inhibits the activity of mTOR kinase (Kim et al, 2002). 
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Raptor appears to be an adaptor protein, recruiting mTOR substrates by binding the 
downstream effectors of mTOR, S6K1 and 4E-BP1. Moreover, Raptor is necessary for the in 
vitro phosphorylation of 4E-BP1 by mTOR as well as for the efficient phosphorylation of 
S6K1 (Beugnet et al, 2003; Choi et al, 2003; Nojima et al, 2003; Schalm et al, 2003). The 
interaction of Raptor with S6K1 and 4E-BP1 is facilitated by a 5 amino acid motif termed 
TOR signaling (TOS) which is present in the N-terminus of both S6K1 and 4E-BP1 (Schalm 
& Blenis, 2002). Mutations that are present in the TOS motif distinctly inhibit mTOR-
mediated phosphorylation of 4E-BP1 (Beugnet et al, 2003; Choi et al, 2003; Nojima et al, 
2003; Schalm et al, 2003). It has been reported that rapamycin is able to disrupt the mTOR–
Raptor interaction (Kim et al, 2002; Oshiro et al, 2004) thereby preventing the 
phosphorylation of S6K and 4E-BP by mTOR. Taken together, these data support a model 
whereby a change in the configuration of the mTOR-Raptor complex, which is sustained by 
nutrient conditions such as amino acid availability, affects the ability of mTOR to interact 
with and phosphorylate its substrates. In a state where amino acids are absent, the mTOR–
mLST8–Raptor complex prevents mTOR from binding to its substrates and prevents the 
access of mTOR (or mTOR-associated kinases) to its substrates. On the other hand, in the 
presence of amino acids, a conformational change promotes the efficient interaction between 
Raptor and mTOR substrates and increased accessibility of the substrates to mTOR and its 
associated kinases (Oshiro et al., 2004; Kim et al., 2002). 
 
1.13.2. Rictor (Rapamycin-insensitive companion of mTOR) 
Rictor has a predicted molecular weight of 190 kDa and it was the first subunit identified that 
is unique to mTORC-2 (Jacinto et al., 2004; Sarbassov et al., 2004).  It shares homology with 
AVO3 in yeast and is the defining member of the rapamycin-insensitive complex. The amino 
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terminal region has some domain structures that are relatively conserved among species, but 
the functions of these domains are still unknown. It has been suggested that these domains 
may mediate substrate binding and play an important role for the assembly of mTORC-2. 
Rapamycin does not block the interaction between Rictor and mTOR nor does the level of 
nutrients, where these are conditions known to regulate the activity of mTORC-1. Therefore, 
it is not a surprise that knocking down Rictor by RNA based interference (RNAi) in cultured 
cells does not change the phosphorylation status of S6K1 and 4EBP1. This therefore suggests 
that mTORC-2 has different physiological functions from mTORC-1. The  physiological 
importance of Rictor is evident in knockout studies, where mice die due to defects in their 
vascular development (Guertin et al., 2006; Shiota et al., 2006; Yang et al., 2006). 
 
1.13.3. Deptor (DEPDC6, DEP-containing protein 6) 
Another key modulator of the mTOR pathway, termed Deptor has been recently described. 
Deptor binds to both mTORC-1 and mTORC-2 complexes and this was evident from co-
immunoprecipitation experiments (Peterson et al, 2009). Its precise function is not fully 
elucidated, but Peterson et al. have shown in a series of elegant experiments that knocking 
down Deptor leads to activation of signalling through mTORC-1 and mTORC-2. This is 
demonstrated both by the observation that there is a change in the phosphorylation status of 
S6K1 and Akt/PKB when Deptor levels are decreased RNAi and by the increased in vitro 
activity against these substrates of mTOR complexes from cells with decreased levels of 
Deptor (Proud et al, 2009). Loss-of-function data presented by Peterson shows that Deptor is 
able to inhibit both mTOR complexes pathways (Peterson et al., 2009). Conversely, with 
mTORC-1 inhibition, the overexpression of Deptor eases mTORC-1 mediated inhibition of 
PI3K, thus causing the activation of PI3K and also the mTORC-2-dependent outputs, such as 
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Akt. Also when Deptor is greatly overexpressed following the inhibition of mTORC-1, and 
the unexpected activation of the PI3K/mTORC-2/Akt pathway it has been shown that this 
indirect mode of PI3K activation is important for the viability of a subset of myeloma cells 
which normally lack PI3K-activating mutations. Therefore Deptor functions as an 
endogenous inhibitor of mTOR where its deregulated overexpression is able to promote the 
survival of myeloma cancer cells (Peterson et al., 2009). Deptor interacts with mTOR via its 
PDZ domain, but so far there is no information regarding the function of the tandem DEP 
domains that the Deptor protein also contains. In other proteins though, the DEP domains 
mediate protein-protein interactions (Ballon et al, 2006; Yu et al, 2007). Based on the current 
evidence, Deptor protein shows preference for mTOR regulation and it has been proposed 
that in vertebrates it is likely to be involved in regulating other outputs of the mTOR 
signalling network besides the growth and survival pathways that have been already 
examined. The mTOR complexes and Deptor have the potential to negatively regulate each 
other, therefore suggesting the existence of a loop where loss of Deptor leads to an increase 
in the activity of mTOR activity, which in turn reduces further the expression of Deptor. 
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1.14. Mammalian Target of Rapamycin (mTOR) and the human placenta 
A vital factor for foetal development is nutrient transport at the placental level. This is 
because any disturbances in the maternal compartments, for example due to maternal stress or 
nutritional status, which will affect foetal development, will involve the feto-placental barrier. 
Interestingly, mTOR is a highly conserved Serine/Threonine protein kinase that functions as 
an ATP and amino acid sensor to balance nutrient availability and cell growth (Dennis et al., 
2001, Brown et al., 1994). Since foetal growth is critically dependent on placental nutrient 
transport, placental mTOR signalling plays an important role in the regulation of foetal 
growth (Roos et al., 2009). Recent data suggest that mTOR functions as an important 
placental growth signalling sensor, linking maternal nutrient and growth factor concentrations 
to amino acid transport (Roos  et al., 2007; Wen et al., 2005). As mTOR acts as a nutrient 
sensor, several studies have investigated the role of mTOR in the placenta where it was 
shown to be critical for early growth and proliferation as a potential deletion of this gene has 
led to lethal phenotype (Gangloff et al., 2004; Murakami et al., 2004). Moreover, in placentas 
from intrauterine growth restriction (IUGR) pregnancies, the protein expression of placental 
phospho-S6K1 (Thr 389), a measure of the activity of the mTORC-1 complex, was 
significantly reduced (Roos et al., 2007). In a hyperthermia (HT)-induced stress model in 
sheep, a range of changes were apparent regarding the mTOR pathway: there was 
upregulation of the phosphorylation status of placental mTOR and Akt and decrease of 
P70S6K (Arroyo et al., 2009). Collectively these data indicate that there is an intact mTOR 
signalling pathway at placental level that can act as a molecular switch depending on nutrient 
availability and stress conditions (Arroyo et al., 2009). 
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1.15. Growth Arrest Specific 5 (GAS5)  
1.15.1. A convergent of mTOR and GR signalling 
The numbers of noncoding RNAs (ncRNAs) posing regulatory functions are rapidly 
increasing (Mattick, 2005). NcRNAs are shown to affect mRNA transcription, degradation, 
and translation thus influencing the abundance of proteins and also can influence the nuclear 
translocation of proteins thus influencing not only protein abundance but localization as well 
(Barrandon et al., 2008; Mattick, 2005). The growth arrest specific-5 (GAS5), a single-
stranded ncRNA is such a molecule, named so as it accumulates in growth-arrested cells 
(Schneider et al., 1988). The gene encoding for this ncRNA, GAS5 is a member of the 5′-
terminal oligopyrimidine (5′TOP) class genes which are characterized by the presence of an 
oligopyrimidine upstream its tract sequence (Smith & Steitz, 1998; Coccia et al., 1992). This 
gene is composed of 12 exons, from which two alternatively spliced transcripts originate, that 
differ by the presence or absence of exon 7 (Coccia et al., 1992). GAS5’s introns encode 
small nucleolar RNAs (snoRNAs) where its exons contain a small open reading frame that 
has been shown unable to encode a functional protein (Raho et al., 2000; Muller et al., 1998). 
Cell growth arrest caused by serum starvation or by treating with protein translation 
inhibitors results to the translation of 5′TOP RNAs and to the inhibition of their degradation 
(Amaldi & Pierandrei-Amaldi, 1997), thus resulting in the accumulation of spliced GAS5 
RNA in the cell (Smith & Steitz, 1998). The functions of GAS5 non coding cRNA are still 
unknown; though, the multiple small noncoding nucleolar RNAs (snoRNAs) that are 
expressed from its intronic sequences are involved in the biosynthesis of ribosomal RNA 
(Smith & Steitz, 1998). As previously mentioned inhibition of mTOR results in inhibition of 
protein synthesis, partly by reduced the phosphorylation of 4E-BP1 (Fingar et al., 2004; 
Brunn et al., 1997) and S6 kinase1 (Tee & Blenis, 2005; Fingar et al., 2004). Additionaly, 
Chapter 1  Introduction  
42 
inhibition of mTOR results in the disproportionate reduction of the translation of several 
groups of RNAs, including the 5’TOP transcripts, as well as mRNAs that encode for several 
key regulators of the cell-cycle (Rosenwald et al., 1993). The 5’ oligopyrimidine tract of the 
5’TOP RNAs is mainly shown to be  on mRNAs that encode for ribosomal and other proteins  
involved in translation, thus the inhibition of  mTOR  specifically inhibits the protein 
synthesis by directly blocking the production of the protein synthesis machinery per se  
(Meyuhas, 2000). Since GAS5 is a 5’TOP RNA its translation might be controlled by the 
mTOR pathway. Even though GAS5 does not appear to encode a functional protein (Raho et 
al., 2000; Muller et al., 1998) it may still have some functional effects by interactions with 
steroid receptors that inhibit the receptors action (Kino et al., 2010). The cellular behaviour is 
regulated among others by the availability of nutrients, which control the cell growth.  The 
nutrient status dictates the activity as well as the abundance of several transcription factors, 
thus  altering the transcriptional profile of certain set of genes, including those that encode for 
proteins involved in the energy metabolism and the stress responses at cell level as well as 
those that encode proteins that are involved in the immune responses (Lopez-Maury et al., 
2008; Sellick & Reece, 2005). The glucocorticoids regulate the body’s metabolic activities; 
modulate the body’s immune function as well as influencing the cell survival by altering the 
cell’s sensitivity to apoptosis in response to either external, internal stress or both (Chrousos 
& Kino, 2005; Frankfurt & Rosen, 2004; Chrousos, 2001; Wen et al., 1997). It has been 
shown that GAS5 non coding RNA interacts with the DBD of the ligand-activated 
glucocorticoid receptor (GR) through a decoy RNA “glucocorticoid response element”  
(GRE) and in this manner suppresses GR-induced transcriptional activity of endogenous 
glucocorticoid-responsive genes by inhibiting binding of GRs to target genes’ GREs (Kino et 
al., 2010). 
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1.16. Aims and objectives 
Our working hypothesis is that for a successful pregnancy certain events at nutritional, 
biochemical, genetic and molecular could be tightly linked. Despite a plethora of studies that 
identify potential risk factors for the mother as well as the foetus, there is no comprehensive 
analysis at all these levels taken from the same cohort of patients. Therefore, in this study we 
followed a “holistic” approach investigating how maternal stress, nutrition, placental mTOR 
and glucocorticoid receptor (GR) signalling can influence pregnancy outcome.  
More specifically we have decided to study in a cohort of Mediterranean patients, their 
exercise, immune, nutritional and stress profiles before and during pregnancy in an attempt to 
assess how these might influence foetal outcome. 
We have then decided to map key mTOR components (mTOR, Deptor, Rictor and Raptor) 
and all known GR splice variants (including GAS5) at placental level and assessed how 
maternal stress might affect this signalling cascade using clinical data and two distinct 
placental models (BeWo and JEG-3 cell lines) mimicking a stress milieu in vitro. In an 
attempt to dissect further a potential gene-environment interaction, we have assessed (in a 
matched cohort of mothers and babies) how 4 well-characterised polymorphisms of the GR 
gene might affect foetal and placental weight. 
Finally, we have used the fusigenic BeWo cells to mimic fully syncytialised cells in an 
attempt to study how an inducer of syncytialisation (i.e. forskolin) may affect the expression 
of mTOR/GR signalling components. 
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2.1. Solutions 
2.1.1. General solutions and Buffers 
 Elution buffer: Molecular grade H2O. 
 Wash buffer 1: 1 M Tris (pH 7). 
 DNase I containing buffer: Amplification Grade DNase I - 10mM Tris-HCl (pH 7.5), 
10mM CaCl2, 10mM MgCl2 and 10X Reaction Buffer- 200mM Tris-HCl (pH 8.3), 
20mM MgCl2 per 1ml. 
 Stop buffer: 50mM EDTA per 1ml. 
 1x TBE buffer: 90mM Tris, 90mM Boric acid, 2 mM EDTA. 
 10x loading buffer : 20% Ficoll 400 (Fisher Scientific, Cat.No 26873-85-8), 0.1 M 
Na2EDTA (pH 8), 1% SDS, 0.25% Bromophenol blue,  0.25% xylene cyanol. 
 5X first-strand buffer : 250mM Tris-HCl (pH 8.3), 375mM KCl, 15mM MgCl2. 
 2x SSC : 300mM Sodium Chloride, 30mM Sodium Citrate (pH 7). 
 DEPC treated H2O: 0.1% Diethylpyrocarbonate (DEPC) per 1000ml distilled water 
 Hybridization Mix: 50% Formamide, 2x SSC, 200ng/μl sheared, denatured, salmon 
sperm DNA, 5x Denhardt, 50mM NaH2PO4/Na2HPO4 (pH 7), 1mM EDTA. 
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2.2. Cell culture 
The cell lines (BeWo & JEG-3) were obtained from the European Collection of Cell Cultures 
(ECACC, Salisbury, UK), (Appendix  I). BeWo cells were cultured using Ham F12 (Gibco) 
media containing 10% heat-inactivated fetal bovine serum (FBS) (Gibco), and 0.5% 
penicillin-streptomycin (Gibco). Following the supplier’s instructions in order to prevent 
glucose exhaustion in the BeWo cell culture fresh medium was supplied at maximum every 
48 hours. The medium used for culturing JEG-3 cells was Minimum Essential Medium 
(MEM) (Sigma Aldrich) supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
(Gibco), and 0.5% penicillin-streptomycin (Gibco), 0.5% L-glutamine (Gibco), 0.5% sodium 
pyruvate (Gibco) and 1% (v/v) Non Essential Amino Acids (Gibco). JEG-3 cell cultures were 
supplied with fresh medium approximately every 72 hours. Both cell lines were maintained in 
75cm
2
 non treated culture flasks (Nunc) under standard tissue culture conditions of 5% CO2 
in air at 37˚C. When reaching a confluent level the cells were sub-cultured by splitting in a 
1:3 ratio into 19ml per culture flask of specific media for each cell line. Firstly, the cells were 
rinsed with 2.5ml of 1x Phosphate-Buffered Saline (PBS) (Gibco). To detach the cells, 2.5ml 
of 0.25% Trypsin (Gibco) was used for a few minutes at 37˚C and the culture flask was 
gently tapped to ensure full detachment of the cells. The activity of trypsin was neutralised by 
the addition of tissue culture media. The cells were centrifuged for 5 minutes at 1200 rpm. 
The supernatant was removed and the cells were gently resuspended in fresh medium and 
added to new culture flasks to a total volume of 20ml and the flasks were returned to the 
incubator. 
 
2.2.1. Syncytialisation 
The syncytialisation process was performed using the cAMP inducer, Forskolin (Sigma, Cat. 
No. F3917). Forskolin was dissolved in Dimethyl Sulfoxide (DMSO) (Sigma, Cat. No. 
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D8418) at a stock concentration of 0.1M. The syncytialisation process was achieved by 
treating BeWo cells with 50μM and 100μM of forskolin over a period of 72 hours. Forskolin 
treatment was renewed every 24 hours. During the time-dependent treatments, the cells were 
maintained in 75cm
2
 non treated culture flasks (Nunc) under standard culture conditions of 
5% CO2 at 37˚C. 
 
2.3. Cell treatments  
For treatment purposes BeWo and JEG-3 cells were grown in 6-well multi dishes and were 
maintained in cell culture as previously described. Once a satisfactory confluence (~70%) 
level was achieved the media was aseptically removed and the cells were rinsed with 1x PBS. 
A known volume of phenol red free media containing only 100μg/ml of Penicillin and 
100μg/ml of Streptomycin (Gibco) was added to the cells 24 hours before start of the 
treatments. BeWo and JEG-3 cells were treated with three different concentrations (10nM, 
100nM and 1000nM)  of  cortisol (Sigma, Cat. No. H0888) for 24 hours. 
 
2.4. Placental Tissue Collection 
Tissue from human placentae were obtained from women at term (>37 weeks) and pre-term 
(<37 weeks) undergoing either normal vaginal delivery or elective caesarean section. All 
samples were collected from pregnancies without any known pathological problems. 
Immediately after delivery, the maternal and foetal surfaces were dissected off and the foetal 
membranes were peeled gently away from the placenta. Placental tissues were obtained from 
the maternal side of the placentas at maximum of 30 minutes after delivery. The tissue 
samples taken were approximately 0.2-0.5cm
3
 in size and were taken from the centre of the 
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cotyledons evenly across the placenta. The tissues were dissected to remove any visible 
connective tissue and calcium deposits. Depending on the experimental analysis, some of the 
tissues were transferred to 10 volumes of RNAlater solution (Invitrogen). Placental tissue 
sections were also embedded in paraffin by the histology services of the University Hospital 
of Crete were. Ethical approval was obtained from the local ethical committees and also 
informed consent was obtained from all the patients.  
 
2.5. RNA Extraction 
GenElute
TM
 Mammalian Total RNA miniprep kit (Sigma-Aldrich, Cat. No. RTN70) was used 
to extract total RNA from mammalian cells and tissues. The procedures are explained below: 
 
2.5.1. RNA Extraction from cells 
Before adding the Lysis Solution/2-ME (2-mercaptoethanol) mixture to the 6-well plates or 
T-75 flasks, the lysis solution was prepared accordingly; for each 1ml of lysis solution 10μl 
of 2-ME were added. Since BeWo and JEG-3 are adherent cells, they could be lysed directly 
in the culture vessel. The medium was removed and the cells were washed once with PBS 
prior to adding 1ml of  Lysis/2-ME solution in every 75cm
2
 culture flask or 500μl in each 
well of a 6-well multidish. The vessels were then rocked and tapped for a few seconds to 
completely cover the cells. The culture vessels were allowed to sit for 1 to 2 minutes with the 
Lysis Solution/2-ME mixture covering the cells. The rocking and tapping was repeated and 
the culture vessels were tilted to collect the lysates. The lysed cells were then pipetted into a 
filtration column and centrifuged at 16.000 rpm for 2 minutes. This step removes cellular 
debris and shears DNA. Equal volume (500μl) of 70% ehtnanol solution was added to each 
column containing the filtered lysate. The mixture was vortexed to ensure a thorough mix. 
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Since the total volume of the lysate/ethanol mixture per tube was 1ml, the RNA was bound to 
the column in two steps. 700μl of the lysate/ethanol mixture was pipetted into a binding 
column and centrifuged at 16.000 rpm for 15 seconds. The flow-through liquid was discarded 
and the remaining lysate/ethanol mixture was added to the column and centrifuged at 16.000 
rpm for 15 seconds.  500μl of Wash Solution 1 were pipetted into the columns and 
centrifuged at 16.000 rpm for 15 seconds. The binding columns were transferred into a fresh 
collection tub. The flow-through liquid was discarded. 500μl of the ethanol containing Wash 
Solution 2 was added into each column and centrifuged at 16.000 rpm for 15 seconds. The 
flow-through liquid was again discarded but the collection tube was retained. A second 500μl 
volume of the ethanol containing Wash Solution 2 was added into each column and 
centrifuged at 16.000 rpm for 2 minutes to dry the binding columns. Since the binding 
column must be free of ethanol before eluting the RNA, the columns were centrifuged for an 
additional  1 minute at 16.000 rpm. After the additional drying step, the binding columns 
were transferred to fresh collection tubes and 40μl of the elution solution were added into 
each binding column and centrifuged at 16.000 rpm for 1 minute. The purified RNA was 
ready to be stored at -80°C until use. Prior to transferring the RNA samples to -80°C, the 
samples were DNase treated to ensure removal of any DNA from the RNA preparations. 
Deoxyribonuclease I Amplification Grade (AMP-D1, Sigma, USA) was used by adding 4μl 
of 10x Reaction Buffer and 4μl of Amplification Grade DNase I per sample tube and 
incubated at room temperature for 15 minutes. DNase was inactivated by adding 4μl of Stop 
solution to each tube and heating at 70˚C for 10 minutes using a pre-warmed water bath. 
RNA samples were then transferred to -80˚C where they were stored until further usage. 
2.5.2. RNA Extraction from placental tissue 
After collecting our placental tissue samples as previously described, TissueLyser II (Qiagen) 
was used to homogenise the tissue before extracting RNA form our samples. The frozen 
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samples were left to thaw on ice. Once thawed, the placental tissues were transferred into 
sterile 2ml eppendorf tubes containing the lysis mixture. A sterile stainless steel bead was 
added to each tube to facilitate cell disruption as samples were vigorously vortexed for 2 
minutes. Proteinase K (Sigma-Aldrich, Cat. No. P4850) was added directly to each sample 
after homogenization to ensure efficient cell disruption and incubated at 55°C for 10 minutes. 
Next, the lysate was filtered and the same steps as above (section 2.3.1) were followed. The 
quantity and quality of the extracted RNA was measured by analyzing 1μl of RNA sample on 
a Nanodrop-1000 Spectrophotometer (Fisher Scientific). As a blank reading, 1μl of elution 
solution was used. Further, to ensure no RNA degradation, 2μl of 10x loading buffer [(20% 
Ficoll 400/ FisherScientific, Cat.No 26873-85-8) – (0.1 M Na2EDTA pH.8, 1% SDS, 0.25% 
Bromophenol blue, 0.25% xylene cyanol / Sigma, Cat.No 220-167-5 )] were added to 5μl of 
RNA sample and each sample was electrophoresed on a 1% agarose gel (see below section 
2.11 for explanation of the technique) at 80V for 45 minutes and subsequently visuallised 
under UV . Purified RNA was stored at -80 ºC until further use. 
 
2.6. Complimentary DNA (cDNA) synthesis 
Prior to constructing the complimentary DNA the quantity and quality of the previously 
extracted RNA was measured. This was performed by analyzing 1μl of RNA sample on a 
Nanodrop-1000 Spectrophotometer (Fisher Scientific). As a blank reading, 1μl of elution 
solution was used. The concentration of RNA used for cDNA synthesis was standardized at 
500ng/μl for each sample and the corresponding volume of molecular grade H2O was added 
to make it up to 10μl. In a nuclease-free microcentrifuge tube 1μl of random primers, 1μl of 
dNTP Mix (10mM each) and 5μl of molecular grade H2O were added and mixed thoroughly. 
In a clearly labelled nuclease-free microcentrifuge tubes the corresponding volumes of 
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molecular grade H2O and RNA were added for each sample. 7μl of the previously prepared 
mixture were added in each tube and heated using a heat block at 65°C for 5 minutes. The 
samples were briefly centrifuged and 4μl of 5x First-strand Buffer (250mM Tris-HCL, pH 
8.3 at room temperature; 375mM KCL; 15mM MgCl2), and 2μl of 0.1M DTT, 1μl of 
molecular grade H2O were added in each sample tube. The contents were gently mixed and 
incubated for 2 minutes at 25°C. 1μl of SuperScript™ II RT (Invitrogen) was added to each 
tube and mixed up and down using a pipette. The samples were then incubated for 50 minutes 
at 42°C and then at 70°C for a further 15 minutes to inactivate the reaction. The newly 
synthesised cDNA was used as a template for the polymerase chain reaction (PCR). 
 
2.7. Primer design  
The primers design began at: www.ncbi.nlm.nih.gov where gene sequences were searched for 
the genes of interest (listed below) sequences by reference number available from publishing. 
This target sequence was then inserted into Invitrogens own primer design tool, 
OligoPerfect
TM
 Designer at: www.invitrogen.com/content.cfm?pageid=9716 was used for the 
primer design, synthesizing a primer set of sense and antisense primer . The maximum primer 
size required was 25bp, the minimum product should be 200-500bp, and as extremes were 
preferably avoided, the percentage of GC (around 50%) content and temperature of the 
primer (around 60 
o
C) was required to be the same for each one in the pair to prevented 
problems with annealing during PCR. Preparation of the primers to be used from the main 
stock (1μg/μl) was performed prior to commencing the RT-PCR. A 1:10 dilution of each 
primer was carried out by adding 10μl of the primer stock solution and 90μl of molecular 
grade H2O in 1.5ml eppendorf tubes yielding a 100ng/μl working concentration per primer. 
The primers used in this study are listed in Table 2.1 below: 
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Primer Sequence Size (bp) 
mTOR 
sense 5’- TGCCAACTATCTTCGGAACC –3’ 
135 
anti-sense 5’- GCTCGCTTCACCTCAAATTC–3’ 
Deptor 
sense 5’-CACCATGTGTGTGATGAGCA-3’ 
202 
anti-sense 5’-TGAAGGTGCGCTCATACTTG-3’ 
Rictor 
sense 5’-GGAAGCCTGTTGATGGTGAT-3’ 
117 
anti-sense 5’-GGCAGCCTGTTTTATGGTGt-3’ 
Raptor 
sense 5’-ACTGATGGAGTCCGAAATGC-3’ 
170 
anti-sense 5’-TCATCCGATCCTTCATCCTC-3’ 
GRα 
sense 5’- CTATGCATGAAGTGGTTGAAAA-3’ 
96 
anti-sense 5’-TTTCAGCTAACATCTCGGG-3’ 
GRβ 
sense 5’-GAAGGAAACTCCAGCCAGAA-3’ 
81 
anti-sense 5’-CCACATAACATTTTCATGCATAGA-3’ 
GRγ 
sense 5’-TTCAAAAGAGCAGTGGAAGGTA-3’ 
264 
anti-sense 5’-GGTAGGGGTGAGTTGTGGTAACG-3’ 
GR-P 
sense 5’-GCTGTGTTTTGCTCCTGATCTGA-3’ 
194 
anti-sense 5’-TGACATAAGGTGAAAAGGTGTTCTACC-3’ 
GAS5 
sense 5’-CAGTGTGGCTCTGGATAGCA-3’ 
168 
anti-sense 5’-TTAAGCTGGTCCAGGCAAGT-3’ 
PCNA 
sense 5’-GCCGAGATCTCAGCCATATT-3’ 
452 
anti-sense 5’-ATGTACTTAGAGGTACAAAT-3’ 
-Actin 
sense 5’- AAGAGAGGCATCCTCACCCT –3’ 
216 
anti-sense 5’- TACATGGCTGGGGTGTTGAA –3’ 
 
Table 2.1: Primer Sequences with adjacent base pair (bp) 
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2.8. Reverse – Trancriptase Polymerase Chain Reaction (RT-PCR) 
Polymerase chain reaction (PCR) is a technique by which the amplification of a specific 
DNA sequence is achieved where the ends of the sequence are known. The primers, which 
are designed to complement the DNA region of interest, bind to the DNA and the enzyme 
DNA polymerase extends them in the presence of dNTPs. Under optimised conditions the 
reaction synthesises a new complementary DNA strand. By the end of the number of cycles 
performed, the quantity of new DNA synthesised increases exponentially (Fig 2.1). The 
following table (Table 2.2.) shows the reagents along with the volumes and the 
concentrations used for each sample.  
 
Reagent Concentration Quantity 
10 X PCR Buffer 200mM Tris-HCL [pH 8.4], 500mM KCL 5μl 
dNTP Mix 10mM 1μl 
MgCl2 50mM 1.5μl 
Forward Primer 10μM 1μl 
Reverse Primer 10μM 1μl 
cDNA  1μl 
Taq DNA polymerase 5 U/μl 0.5μl 
Sterile, distilled water  39μl 
 
Table 2.2: Quantities and concentrations required of the reagents used for each gene for PCR. 
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In each clearly labelled tube, the corresponding volume of each reagent was added. 49μl of 
the master mix were pipetted into 100μl eppendorf tubes; this step was repeated for each 
master mix.  One μl of either the cDNA of interest or distilled water (used as a negative 
control) was added to make the final volume up 50μl in each 100μl tube. The samples were 
then placed into the thermal cycler (GeneAmp PCR system 2400, Perkin Elmer). The 
components were mixed thoroughly before starting the PCR amplification procedure. The 
samples were initially denatured at 94ºC for 4 minutes followed by 30 cycles at 94ºC for 30 
seconds, primer specific annealing temperature (58˚C - 60˚C) for 30 seconds and 72ºC for 1 
minute, the final cycle was followed by 72ºC extension for 1 minute.  
 
 
Figure 2.1: Overview of gene amplification using PCR technology. Insert table depicts the number of 
specific amplicons generated over 30 cycles of amplification 
  
Chapter 2  Materials  & Methods  
55 
2.9. Quantitative-PCR (Q-PCR) 
Expression of the genes of interest were assessed by quantitative PCR (Q-PCR) on an ABI 
7400 instrument (Applied Biosystems). The 7900HT instrument features a Peltier-based, 
interchangeable sample block module based on the technology established in the GeneAmp® 
PCR System 9700 thermal cycler. The sample block module houses an internal Peltier 
heating/cooling unit. The sample block module is made of aluminum to provide an optimal 
thermal transfer rate between the block and the reaction plate. SYBR
®
 Green-PCR reaction 
mixture (Sigma-Aldrich, UK) was used following the manufacturer's instructions and the 
primers described in Table 2.1. A final reaction volume of 25μl included 2x JumpStartTaq 
ReadyMix that contained 1.25 units Taq DNA polymerase, 10mM Tris-HCl, 50mM KCl, 
3.5mM MgCl2, 0.2mM dNTP, and stabilizers were used along with 1μl of each specific 
forward and reverse primers (0.1μg/μl; Table 2.1), 1x reference dye and cDNA. The reaction 
mixture was thoroughly mixed and 24μl were aliquoted in each of the 96 wells of the plate 
(MicroAmp™ Fast Optical 96-Wells Reaction Plate, Applied Biosystems, Cat.No. 4314320). 
1μl of cDNA was added and the plate was sealed using an optical adhesive film (MicroAmp® 
Optical Adhesive Film, Applied Biosystems, Cat.No. 4314320). The plate was centrifuged 
for 1 minute at 1000 rpm to collect the reactions to the bottom of the wells and then loaded 
onto the Sequence Detection System. All reactions were performed in triplicates and control 
reactions (i.e. no cDNA input) were also added in each 96-well plate. The conditions used for 
Q-PCR reaction were the following: 
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Figure 2.2: Real time PCR cycle conditions. 
 
The DNA levels were expressed as a “relative quantification” (RQ) value, using the “Delta Ct 
method” for comparing relative expression results between treatments in Q-PCR. The 
following equations (User Bulletin #2, ABI PRISM 7700 Sequence Detection System) were 
used to analyse the results obtained from the Q-PCR: 
For cell samples:   ΔCt = Ct (gene of interest) – Ct (housekeeping gene)  
 ΔΔCt = ΔCt (samples) – ΔCt ( calibrator)  
 Relative Quantity (RQ) = 2
- ΔΔCt
 ± ( 2
-ΔΔSD
 (+) - 2
-ΔΔSD
 (-) )  
 
For placental samples: ΔCt= Ct (gene of interest) – Ct (housekeeping gene)  
Arbitrary Value : 2
- ΔCt 
 
 
2.10. Genetic Studies 
Our genetic studies were performed on a cohort of matched mothers (No. 81) and infants 
(No. 87) of which 6 were twins, from whom blood and serum samples were obtained. 
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Medical records of the mothers were evaluated and the subjects had no known pathologies or 
receiving any medications. The subjects were genotyped for the Bcl I,  N363S,  ER22/EK23  
and  Tth111 1  polymorphisms using the Restriction Fragment Length Polymorphism (RFLP) 
method. 
2.10.1. Bcl I Polymorphism  
Genomic DNA was used to amplify the Bcl I RFLP C to G mutation which is 646 bp 
downstream of exon 2 by designing specific intron 2 primers.  Phusion
®
 Blood Direct PCR 
Kit (New England Biolabs) was used according to the manufacturer's instructions. The 
following primers were used: 5'-AAGCTTAACAATGGCCAT-3' and 5'-
TGCTGCCTTATTTGTAAATTCGT-3'. The PCR conditions used where as following: forty 
cycles were performed consisting of an initial denaturing step at 98°C for 5 sec, annealing at 
50°C for 5 sec and elongation at 72°C for 15 sec. To confirm the presence of the Bcl I 
polymorphism, 17μl of the PCR product were digested with 2μl of 10x Restriction 
Endonuclease Buffer and 15 U of the restriction enzyme Bcl I (New England Biolabs, UK, 
Cat. No. R0160S)  for 1.5 hours at 50°C. The resulted digested fragments were separated on a 
2% agarose gel to determine the genotypes. From the digestion of the PCR products, the 
following fragment sizes were obtained: 117 and 222 bp in the case of CC homozygotes, an 
additional band of 335 bp for CG heterozygous individuals, and a single band of 335 bp for 
GG larger allele homozygotes. 
2.10.2. N363S Polymorphism 
The genotyping was performed on genomic DNA using Phusion
®
 Blood Direct PCR Kit 
(New England Biolabs) according to the manufacturer's instructions along with specific PCR 
primers, 5’-AGTACCTCTGGAGGACAGAT-3’ and 5’-GTCCATTCTTAAGAAACAGG-3’ 
The samples were amplified for an initial 5 minutes at 94°C  followed by 35 cycles of 94°C 
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for 30 sec, annealing at 50°C for 30 sec and elongation at 72°C for 30 sec. The restriction 
enzyme Tsp509I (10 U) and 2μl of buffer (New England Biolabs, UK, Cat. No. R0576S) were 
used to digest the PCR products (17μl) at 65°C for 4 hours. The resulted digested fragments 
were separated on a 2.5% agarose gel to determine the genotypes. From the digestion of the 
PCR products, the following fragment  sizes were obtained: 113 bp, 95 bp and 9 bp in the 
case of the wild type and 122 bp and 95 bp in the case of homozygotes mutants. 
2.10.3. ER22/23EK Polymorphism 
The subjects were genotyped for the ER22/23EK polymorphism by PCR with restriction 
fragment length polymorphism (RFLP) analysis. Genomic DNA was used to amplify with the 
use of Phusion
®
 Blood Direct PCR Kit (New England Biolabs) the region of the 
polymorphism by using specific PCR primers : 5’- GATTCGGAGTTAACTAAAAG-3’ and 
5’-CTACCCTTTACTGGACCCTA-3’. The samples were amplified for an initial 5 minutes 
at 95°C followed by 35 cycles of 95°C for 30 sec, annealing at 58°C for 30 sec and 
elongation at 72°C for 30 sec 16.8μl of the PCR product were incubated with 2μl of 1x 
NEBuffer 4 and 0.2μl of 100x BSA and 5U of the restriction endonuclease MnI I (New 
England Biolabs, UK, Cat. No. R0163S) was used to digest the PCR products at 37°C for 4 
hours. The resulted digested fragments were separated on a 2,5% agarose gel to determine the 
genotypes. From the digestion of the PCR products, the following fragment sizes were 
obtained: 163 and 149 bp in the case of the wild type, and 163 bp and 184 bp for the 
heterozygotes. 
2.10.4. TthIII 1  Polymorphism 
The last polymorphism which the subjects were genotyped for was the TthIII 1 
polymorphism. PCR with restriction fragment length polymorphism (RFLP) analysis was 
performed where genomic DNA was used as the template to amplify with the use of 
Chapter 2  Materials  & Methods  
59 
Phusion
®
 Blood Direct PCR Kit (New England Biolabs, UK) the region of the polymorphism 
by using specific PCR primers: 5’-GGCCACAACAATAACCCAGT-3’ and 5’-
CCTATGACACGTATTTTGTGAAAGT-3’. The samples were amplified for an initial 5 
minutes at 95°C   followed by 35 cycles of 95°C for 30 sec, annealing at 61°C for 30 sec and 
elongation at 72°C for 30 sec. The restriction endonuclease TthIII 1 (4 U) (New England 
Biolabs, UK, Cat. No. R0185S) was used to digest the PCR products at 65°C for 4 hours. The 
resulted digested fragments were separated on a 2.5% agarose gel to determine the genotypes. 
From the digestion of the PCR products, the following fragment sizes were obtained: 167 (C 
allele) the T allele consisted of 337 bp and the CT allele of 337 bp and 167 bp.  
 
2.11. Agarose gel electrophoresis 
The gels were prepared by dissolving 2g of agarose (Fisher, Cat.No. BP1356) in 100ml of 1 x 
TBE buffer in an autoclaved conical flask and boiled until clear. Once agarose had cooled, 
5μl of ethidium bromide (Sigma, Cat. No. E1510) were added in order to stain the DNA. 
Swirled gently ensuring that the ethidium bromide has dissolved then the gel was allowed to 
set for approximately 20 minutes. In each PCR product, 5μl of 10x loading dye were added 
and vortexed well. 20μl of the PCR products were loaded per well. 1Kb DNA ladder 
(Invitrogen, Cat.No. 10787-018) or low molecular weight DNA Ladder (New England 
Biolabs, Cat. No. N3233S) was loaded once all of the samples had been loaded into the gel. 
Then, the gel was electrophoresed for a suitable length of time at 80 volts. To visualise the 
DNA, the gels were placed on a short wave, ultra-violet transilluminator, and photographed 
with an Alpha Imager 2200 (Alpha Innotech MultiImage
™
 Light Cabinet). 
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2.12. Indirect Immunofluorescene Analysis 
Immunofluorescence technique allows the visualisation of the antigens of interest by using 
specific antibodies that are tagged to a fluoresent dye. The distribution of the antigen is then 
visualised with the use of a fluorescent microscope. In our study, indirect 
immunofluorescence was used to determine the presence/distribution of mTOR, Deptor, 
Rictor, Raptor, and GRα in placental cell lines (JEG-3 and BeWo) as well as in placental 
tissues. 
2.12.1. Indirect Immunofluorescene on cells  
The cells (BeWo and JEG-3) were grown on sterile 0.13mm - 0.17mm glass coverslips in 6-
well multidishes to a sufficient confluence. Cells were firstly rinsed with 1x PBS three times 
before fixing by using 4% Paraformalhehyde (pfa) and by incubating for 10 minutes at room 
temperature. After the 10 minute incubation three washes with 1x PBS followed. The cells 
were then permeabilised using 0.2% PBS Tween 20 solution, incubated at room temperature 
for 20 minutes and followed by three washes in 1x PBS solution containing 100mM Glycine. 
Following, cells were incubated with 10% specific species serum (Jackson ImmunoResearch) 
in 1x PBS for 1 hour at room temperature in order to minimize any non-specific binding of 
IgG. The blocking serum used for each primary antibody was chosen based on the species in 
which the secondary antibody was raised in. Antibodies were diluted in 1.5% of specific 
species serum dilute in 1x PBS. Primary antibodies used in this study are listed in Table 2.3 
along with their dilutions. The coverslips with the primary antibody were incubated at 4°C 
overnight. Next, the coverslips were washed three times with 1x PBS and incubated with a 
respective secondary antibody (Table 2.3) for 1 hour at room temperature. Cells were then 
washed with 1x PBS and rinsed in distilled water before mounting in Vectashield
®
 Mounting 
Medium containing 4',6-diamidino-2-phenylindole (DAPI). Negative controls were prepared 
by omitting the primary antibody. The slides were viewed and images were captured  using a 
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Plan Apo Neofluor 63X NA 1.25 oil objective (Zeiss) on a Zeiss Axiovert 200M microscope 
and AxioVision software was used to view the images. The data was derived after examining 
three independent coverslips for each sample along with the negative control.  
 
 
Table 2.3: List of primary and secondary antibodies used with their respective dilutions. 
 
2.12.2. Indirect Immunofluorescence on paraffin-embedded placental tissues.  
The paraffin embedded placental tissue samples that were used were heated in an oven at 
65
o
C for 1 hour. Then the slides were dewaxed using Histo-Clear (Fisher Scientific, Cat.No. 
HIS-010-010S) a non-hazardous substitute of xylene. The sections were then dehydrated in 
100% ethanol, twice for 5 minutes each time. The sections were rehydrated through a graded 
series of ethanol in dH2O over 20 minutes (95%, 70%, 50%, and 30%). The slides were 
rinsed in dH2O once, and then in 1x TBS tween 20. The endogenous peroxidise activity was 
blocked by incubating the sections with 3% hydrogen peroxide for 10 minutes at room 
Primary Antibodies Secondary Antibodies 
Antibody Dilution Species Antibody Dilution 
mTOR 1:50 Rabbit Donkey  anti-rabbit 1:400 
Deptor 1:50 Rabbit Donkey  anti-rabbit 1:250 
Rictor 1:50 Rabbit Donkey  anti-rabbit 1:400 
Raptor 1:50 Rabbit Donkey  anti-rabbit 1:75 
GRα 1:50 Rabbit Donkey  anti-rabbit 1:400 
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temperature. After these steps the previously stated methodology in section 2.12.1 was 
followed starting from the blocking step and onwards. The primary and secondary antibodies 
used are listed in table 2.3. The slides were viewed and imaged  using a Plan Apo Neofluor 
63X NA 1.25 oil objective (Zeiss) on a Zeiss Axiovert 200M microscope and viewed using 
AxioVision software. The data was derived after examining three independent coverslips for 
each sample along with the negative control. 
 
2.13. Construction of Questionnaire  
A questionnaire was constructed (Appendix II), comprising of 59 questions which were 
related to the following specific subject areas and variables: a) BMI, b) immune problems, c) 
exercise, d) nutrition, e) stress, and f) medical history. Specific questions were used to 
acquire anthropometrical data which included gestational age, weight of the mother before 
conception as well as the weight of the mother at the time and self-reported height. The 
sources from where the questions were adapted are included in (Appendix III). Behavioural 
data that was collected included smoking, drinking habits, physical activity and was based on 
the Paffenbarger et al. (1978) measure, also multi-mineral/multivitamin supplement usage 
before and during pregnancy was assessed. 
There were specific questions related to the stress profile, which included: whether the 
pregnancy was planned or not planned; how stressed was each woman during the pregnancy, 
with responses ranging from 1 to 4 (1= low, 2= medium, 3= high, 4= very high). This stress 
questionnaire was based on a study by Wang et al. (2004) where women with dysmenorrhoea 
were asked to describe their stress in preceding cycles as ‘low’, ‘medium’ or ‘high’. 
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2.14. RNA Fluorescent in situ hybridization (FISH) 
The slides of the paraffin embedded placental tissue samples were placed in a coplin jar and 
deparaffinised for 30 minutes at 37
o
C using histo-clear (Fisher Scientific, Cat.No. HIS-010-
010S). Following, the tissue sections were rehydrated by placing the slides in ethanol solution 
of different concentrations (100%, 90%, 80%, 70%, 50%, 30%) for 3 minutes. A brief wash 
in 1x PBS solution was performed after this. Pepsin (0.01% in 0.01M HCl) was used to treat 
the tissue for 5 minutes at 37
o
C, and a brief rinse in DEPC treated H2O followed. Then the 
tissue samples were dehydrated by placing them in ethanol solutions (70%, 90%, 100%) for 
3.minutes. A specific Alexa 488-conjugated GAS5 hybridization probe 
(GTGCTATCCAGAGCCACACTGCATCTGCACCCAGCACCATACCTCACAG) was 
utilised as previously described (Kino et al., 2010) and followed by an overnight incubation 
at 37
o
C in a humidified chamber. After this incubation, three 10 minute washes were 
followed in 2xSSC at 37
o
C. The slides were then briefly rinsed in DEPC treated H2O and 
mounted in Vectashield
®
 Mounting Medium containing DAPI prior to examining the emitted 
fluorescent signal under a Zeiss axiovert 200 M microscope viewed using AxioVision 
software.  
 
2.15. Enzyme-linked immunosorbent assay (ELISA)  
A cortisol enzyme immunoassay kit (Enzo Life Sciences, Cat.No. 900-071) was used for the 
quantitative determination of plasma cortisol levels collected from the patients participating 
in the study. Maternal nonfasting blood samples were collected into EDTA tubes between 
09.00 and 10.00 hr and centrifuged immediately at 2500 rpm for 10 min. The resulted plasma 
was separated and snap frozen in dry ice and stored at −20oC until further use. The maternal 
bloods were collected on the same day that the questionnaire has been administered. Foetal 
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blood samples were obtained from the umbilical artery at the time of delivery. Identical 
preparations to maternal samples took place regarding plasma isolation. The assay’s 
sensitivity is 56.72 pg/ml with a range between 156-10.000 pg/ml  (Appendix IV). The inter-
assay coefficient of variation for cortisol was 7.8% at 969 pg/ml and the intra-assay 
coefficient of variation for cortisol was 6.6 % at 1.088 pg/ml. These results were expressed as 
% B/B0 i.e. (B/Bo)* ‘x’100 where B equals A405nm at ‘x’ pg/ml standard concentration and 
B0 equals A405nm at 0pg/ml standard concentration. The principle of this assay lies in the 
use of a monoclonal antibody directed to cortisol that binds to cortisol present in samples. 
Following incubation, a substrate is then added which produces a colorimetric reaction 
resulting in a yellow colour being generated that is read on a microplate reader.Prior to 
commencing the reagents were brought to room temperature for at least 30 minutes. 
Following the manufacturer’s instructions all standards and samples were run in duplicate. 
100μl of standard diluents (assay buffer) were pipetted into the non-specific binding (NSB) 
and the maximum binding (Bo) wells. In the appropriate wells 100μl of the standards were 
added and 100μl of the samples was added.  Into the NSB wells 50μl of the assay buffer was 
added. 50μl of the conjugate were added in each well except the wells indicated to measure 
total activity and the blank wells. 50μl of antibody were then added to the wells except the 
total activity, the blank wells and the NSB wells. The plate was incubated at room 
temperature on a plate shaker for 2 hours at 500 rpm. The wells were emptied from their 
contents and washed by adding 400μl of wash solution in every well. The washes were 
repeated twice so that a total of three washes were performed. After the final wash, the 
content of the wells was aspirated, and the plate was firmly tapped on a lint free paper towel 
thus removing any remaining wash buffer. Following, 5μl of conjugated was added to the 
total activity wells. 200μl of the p-nitrophenyl phosphate (pNpp) substrate in buffer was 
added to each well and incubated at room temperature for 1hour without any shaking. 
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Following, 50μl of stop solution was added to every well, in order to stop the reaction and the 
plate was immediately read. The plate reader was blanked against the blank wells and the 
optical density was read at 405 nm. 
 
2.16. Statistical Analysis 
Data were expressed as mean± SEM. For the quantitative PCR, the following equations were 
used: ΔCt= Ct (gene of interest)-Ct (house keeping gene), ΔΔCt= ΔCt (sample) - ΔCt 
(calibrator), Relative Quantity (RQ) =2–ΔΔCt. RQ value was set up as 1 for the untreated (no 
supplement) BeWo and JEG-3 cells. We have also calculated the gene expression levels as 
RQ values, using the untreated control for each cell line as a calibrator. We did so, since RQ 
values provide a more accurate comparison between the initial amounts of template in each 
sample, without requiring an exact copy number for analysis. Statistical analysis of the ΔCt 
and RQ value was performed using student‘s t-test. For the correlation studies, a two-tailed 
test using SPSS (Version 18) was used. A P value of  ≤0.05 was regarded as significant. The 
ΔCt values from clinical samples were log transformed in order to acquire a normal 
distribution.  
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3.1. Introduction 
A considerable part of this research is dependent on the analysis of a questionnaire (Appendix 
II) which was constructed to help obtain information in specific subject areas that would 
further help understanding the experimental part of the project. The questionnaire had five 
main parts giving us the ability to extract information on the general profile of the subjects 
such as age and BMI [weight (kg)/height (m) ²], exercise and the immune profile, as well as 
their nutritional habits, their stress levels and some information about their medical history. 
Anthropometrical data which included the gestational age, the weight of the mother before 
the time of conception as well as the weight and height of the mother at the time of the survey 
were acquired through a series of specific questions. Also behavioural data was collected that 
included the maternal attitudes towards pregnancy, smoking and drinking habits as well as 
the consumption of multi-mineral/multivitamin supplements before and during pregnancy. 
The largest part of the questionnaire was focused on the nutritional status with questions 
targeting the maternal dietary habits before, as well as during, pregnancy. The collection of 
data took place at the Department of Obstetrics and Gynecology of the Medical School at the 
University Hospital of Crete. Questionnaires were handed out to the female patients at the 
labour ward of the hospital. A face-to-face interview was conducted with each woman, with 
each interview lasting at least 30min.  
 
3.2. Results 
3.2.1. General profile of the participants of the study 
A summary of the general profile is presented in Table 3.1 and the analysis of the 
questionnaire data is presented as percentage for each question. These include the age of the 
prospective mother, which was sub-grouped per decade and as it can be seen, a high 
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percentage of perspective mothers was found in the 3
rd
 decade (21-30 years old), where as the 
lowest percentage was observed in the 2
nd
 decade (below 20). The self-reported information 
on the weight and height of the subjects was used to calculate their Body Mass Index [BMI; 
weight (kg)/height (m)²] before conception. This information was further sub-grouped 
according to the BMI weight status categories. The majority of the participants were appeared 
to be of normal BMI. Information of the weight of the mother as a newborn, as well as if she 
was born at term or pre-term, was also collected and the majority of the participants were 
born in the normal for gestational age range and after the 37
th
 week of gestation which is 
considered to be at term. The maternal body shape was also recorded to help us understand 
the type of the participants adiposity, for example if a participant reported have an apple 
shape the fat is stored around the abdominal region, where the pear shape women tend to 
store the majority of the fat in the lower body, hips and buttocks and lastly the proportionate 
shape shows an equal fat distribution. As seen in the table 3.1 the majority of the participants 
reported to have a pear shape body type. Information on the duration of the pregnancy as well 
as the weight of the foetus was also recorded. Surprisingly, a slightly higher percentage of the 
infants were born prematurely. Lastly, the participants were asked if they had any iron 
deficiency induced anaemia and the majority reported not to have. This question was asked in 
this cohort of patients due to higher prevelance of β-Thalassaemia in the Eastern 
Medittareanean region. 
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GENERAL PROFILE 
 
Age (years) 
 
% 
• < 20 7.7 
• 21 - 30 56.7 
• 31 - 40 35.6 
 
BMI 
 
% 
• Underweight (< 18.5) 13.6 
• Normal (18.5 - 24.9) 64.1 
• Overweight (25 - 29.9) 12.6 
• Obese (> 30) 9.7 
 
Weight of mother as newborn (gr) 
 
% 
• Small (< 2500) 5.1 
• Normal (2500 – 3800) 85.6 
• Large (> 3800) 9.3 
 
Born  prematurely 
 
%  
• Yes 7.1 
• No 92.9 
 
Body shape (B.P) mostly matches yours 
 
% 
• Apple shape 8.7 
• Pear shape 56.3 
• Proportionate shape 35.0 
 
Duration of pregnancy (weeks) 
 
%  
• Term (<  37)  43.2 
• Pre- term ( > 37)  56.8 
 
Foetal weight (gr) 
 
% 
• Small (< 2500) 25.3 
• Normal (2500 – 3800) 72.8 
• Large ( > 3800) 1.9 
 
β-thalassaemia 
 
% 
• Yes 18.3 
• No 74.5 
 
Table 3.1: Details of the general profile of the participants in our study 
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3.2.2. Immune Profile of the participants of the study 
The second profile that was analysed was related to the immune status of the participants, and 
consisted of seven questions in total as it is described in Table 3.2. The participants were 
asked of the number of colds and infections they contracted during their pregnancy and 
according to the replies obtained, certain  subgroups were set. The majority of the participants 
did not contract any colds or infections during their pregnancy. As to the difficulty the 
participants had to recover from an infection the majority responded that they did not find it 
hard to “fight” an infection. Regarding the proneness to thrush or cystitis, the majority of the 
participating subjects reported not to be prone to these gynaecological conditions. Further, the 
majority had reported not to have taken any antibiotics during the last month  prior to the 
interview. In addition the majority of the women reported not to have any inflammatory 
diseases or allergies. A significant inverse correlation has been noted between difficulty to 
“fight” an infection and number of colds (r = -0.289, P = 0.003) as well as number of 
infections (r = -0.446, P < 0.0001) during pregnancy.  An inverse correlation was also 
observed between pregnancy days and number of infections during pregnancy (r = -0.212,    
P = 0.004). Interestingly, the use of antibiotics also inversely correlated with difficulty to get 
rid of a cold (r = -0.422,  P < 0.0001) and how prone these women were to cystitis infections 
(r = -0.389, P < 0.0001). 
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IMMUNE PROFILE 
 
How many colds did you get during pregnancy?  
 
% 
• 0 68.9 
• 1 6.8 
• 2 21.4 
• 3 1.9 
• 4 1.0 
 
How many infections did you get during pregnancy?  
 
% 
• 0 77.9 
• 1 10.6 
• 2 9.6 
• 3 1.9 
 
Do you find it hard to shift an infection (e.g cold)? 
 
% 
• Yes 36.5 
• No 63.5 
 
Are you prone to thrush or cystitis?  
 
%  
• Yes 16.3 
• No 83.7 
 
How often did you take antibiotics in the last month?  
 
% 
• None 71.1 
• Once 21.2 
• Twice 4.8  
• More than 3 times 2.9  
 
Do you have an inflammatory disease (e.g arthritis)?  
 
%   
• Yes 6.8  
• No 93.2 
 
Do you suffer from hay fever, allergies?  
 
%   
• Yes 2.9  
• No 97.1 
 
Table 3.2: Details of the immune profile of the participants in our study 
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3.2.3. Exercise Profile of the participants of the study 
The third profile that was incorporated and analysed in our questionnaire was the exercise 
profile of the women that were taking part in our research (Table 3.3). This profile aimed to 
estimate the level of activity of the women before and during their pregnancy.  The majority 
of the women reported to embark on light activity; this consisted of 2-4 flights of stairs that 
they climbed on a daily basis. This pattern was consistent before as well as during pregnancy. 
As far as their walking habits were concerned, an almost even percentage of women reported 
to light as well as moderate walking activity before pregnancy whereas this the moderate 
activity was lower during pregnancy and the light walking activity (consisting of the 
equivalent of 2-4 city blocks) was the highest category.  With regards to the participation to 
light sports (e.g. dancing, gardening or walking) a good proportion of women appeared to be 
inactive before pregnancy. The inactivity was increased to 60% during pregnancy, with a 
simultaneous drop of the high activity to only 2%. When the participants were asked the 
number of hours per week they would participate in any strenuous sports such as running or 
cycling or tennis, again the majority reported to be inactive both before and during their 
pregnancy. 
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EXERCISE PROFILE 
  
B. P. D. P. 
How many flights of stairs do you climb every day (10 steps 
one flight)? 
 
% 
 
 
% 
 
 
• Inactive (0-1 flight of stairs) 23.1 31.7 
• Light (2-4 flights of stairs) 47.1 47.1 
• Moderate (5-7 flights of stairs) 29.8 21.2 
• Active (8+ flights of stairs) 0.0 0.0 
 
How many city blocks do you walk each day (1 block=130 
metres)? 
 
%  %  
• Inactive (0-1 city blocks) 12.5 23.1 
• Light (2-4 city blocks) 34.6 42.3 
• Moderate (5-7 city blocks) 31.7 22.1 
• Active (8+ city blocks) 21.2 12.5 
 
How many hours/week do you participate in any light sports 
(e.g. dancing, gardening, walking)? 
 
% % 
• Inactive (0 - 1,5) hours/week 41.3 59.6 
• Light (1,6 - 2,5) hours/week 22.1 28.8 
• Moderate (2,6 - 3,5) hours/week 28.8 8.7 
• Active (3,6 +) hours/week 7.7 1.9 
 
How many hours/week do you participate in any strenuous 
sports (e.g. running, cycling, swimming, tennis)? 
 
% % 
• Inactive (0 - 1,5) hours/week 76.9 93.3 
• Light (1,6 - 2,5) hours/week 8.7 6.7 
• Moderate (2,6 - 3,5) hours/week 12.5 0.0 
• Active (3,6 +) hours/week 1.9 0.0 
 
Table 3.3: Details of the exercise profile of the participants in our study. (B.P : before pregnancy; DP: 
during pregnancy).  
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3.2.4. Nutrition Profile of the participants of the study  
The fourth profile (Table 3.4) that was assessed in this study was the nutritional profile which 
was also the most important profile of the study and hence the numbers of questions were 
more in comparison to the previous profiles. As the aim of the analysis of this profile was to 
understand the nutritional habits and detect any changes in them, the questions were asked on 
two levels, before and during pregnancy. The vast majority of the participants were not 
vegetarian and the percentage that reported this remained the same as during pregnancy. A 
higher percentage of women reported to consume full-fat dairy products more often 
compared to those that reported to rarely use full-fat dairy products before pregnancy. When 
women were asked how many of their weekly meals included foods that are high in lipids and 
more specifically in saturated lipids (pies, pastries, fried foods) the majority reported to 
excessively (5 times a week or more) consume these kind of rich in lipids foods before 
pregnancy whereas percentage was lowered significantly during pregnancy where the 
majority reported light consumption of these foods.  A high percentage of women reported to 
moderately consume vegetables on a daily basis before pregnancy and this was maintained 
during pregnancy as well. This was also consistent with the responses obtained regarding the 
daily consumption of fruits, before as well as during, pregnancy where the majority reported 
to moderately consume fruits in both states. Excess consumption was recorded for cereals 
both before as well as during pregnancy. Also the majority of the participants reported to eat 
iron rich foods (e.g. lean red meat, chicken, green leafy vegetables) on a daily basis both 
before pregnancy but percentage of pregnant women consuming more iron rich foods on a 
daily basis was significantly increased compared to pre-pregnancy. This was also consistent 
when the participants were asked about the servings of cheese, milk, yoghurt or calcium 
enriched milk they would consume every day where the percentage was increased during 
pregnancy. More than 1 litre of water / sugar free drinks were consumed by the participants 
Chapter 3  Analysis of Quest ionnaire Data  
75 
both before as well as during pregnancy. A high percentage of women reported to consume 2-
3 cups of coffee or other caffeine containing beverages before pregnancy however during 
pregnancy the majority of women reduced their daily consumption to 1 cup or fewer. Again 
the percentage of women drinking 2-3 sugary drinks on a daily basis was reduced during 
pregnancy to 1 or fewer. The majority of participants reported not to consume any alcoholic 
beverages before or during pregnancy. Lastly, the majority of the participants reported to 
change their fast food eating habits during pregnancy.  
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NUTRITION PROFILE 
  
B.P. D.P. 
Are you vegetarian? 
 
% % 
• Yes 7.8 7.8 
• No 92.2 92.2 
 
How often do you buy full-fat dairy products? 
 
% % 
• Often 63.1 N/A 
• Rarely 36.9 N/A 
 
How many meals per week would include any of the 
following:  pies, pastries, fried foods? * 
 
% % 
• None (0) 1.0 1.0 
• Light consumption (1-2) 33.0 46.1 
• Moderate consumption (3-4) 31.1 40.2 
• Excess consumption (5 or more) 35.0 12.7 
 
How many servings of vegetables/legumes do you have 
each day? 
% % 
• None (0) 3.9 2.9 
• Light consumption (1-2) 38.8 29.4 
• Moderate consumption (3-4) 52.4 60.8 
• Excess consumption (5 or more) 4.9 6.9 
 
How many servings of fruit do you have each day? 
 
% % 
• None (0) 1.9 1.0 
• Light consumption (1-2) 32.1 17.6 
• Moderate consumption (3-4) 50.5 65.7 
• Excess consumption (5 or more) 15.5 15.7 
 
How many servings of cereals do you have each day? 
 
% % 
• None (0) 2.9 2.0 
• Light consumption (1-2) 1.9 1.0 
• Moderate consumption (3-4) 33.1 32.6 
• Excess consumption (5 or more) 62.1 64.4 
 
Do you eat iron rich foods (e.g. lean red meat, chicken, 
green leafy vegetables) every day?*** 
 
% % 
• Yes 66.7 94.1 
• No 33.3 5.9 
 
Do you eat  2 or more servings of cheese, milk, yoghurt or 
calcium enriched milk every day? * 
 
% % 
• Yes 65.0 85.3 
• No 35.0 14.7 
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How much water/sugar-free drinks do you drink each 
day? 
 
 
% 
 
 
% 
 
• Less than ½ litre 5.8 3.0 
• ½ - 1 litre  8.8 4.0 
• More than 1 litre 85.4 93.0 
 
How many cups of coffee, black tea or caffeine containing 
beverages do you drink each day? *** 
 
% % 
• 4-6 1.0 0.0 
• 3-4 27.2 2.0 
• 2-3 43.6 12.7 
• 1 or fewer 28.2 85.3 
 
How much soda, sugary drinks do you normally have each 
day? *** 
 
% % 
• More than 3 36.9 2.0 
• 2-3 38.8 29.4 
• 1 or fewer 24.3 68.6 
 
How many alcoholic beverages do you consume on a 
weekly basis? *** 
 
% %  
• More than 5 0.0 0.0 
• 3-4 14.6 1.0 
• 2 or fewer 23.3 5.2 
• None 62.1 93.8 
 
How many times a week do you eat fast food? ** 
 
% % 
• Never 36.9 58.8 
• 1-2 times 42.8 35.3 
• 3-4 times 18.4 5.9 
• 5 or more times 1.9 0.0 
 
Table 3.4: Details of the nutritional profile of the participants in our study. (B.P : before pregnancy; 
DP: during pregnancy). Red stars indicate the significant responses presented further below in graph 
format, when P < 0.05 *, P < 0.001 **, P < 0.0001 ***.  
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3.2.5. Stress Profile of the participants of the study 
The last profile analysed was the stress profile of the women aiming to understand their stress 
levels as well as their attitude and feelings towards their pregnancy (Table 3.5). The majority 
of the women reported that they did not plan their pregnancy but it should be noted that the 
percentages of the planned and non-planned pregnancy were respectively very close to each 
other. The majority of the participants (65.1%) rated their stress level to vary from low to 
medium. Moreover, almost half of the participants reported to have a positive attitude 
towards their pregnancy describing it using positive words such as happy, ok and satisfied. 
Lastly, regarding the sleeping pattern of the subjects, one third reported to sleep 10 hours or 
more every night. 
STRESS PROFILE 
 
Is this a planned pregnancy? 
 
 
% 
• Yes 43.7 
• No 56.3 
 
How would you rate your current stress level? 
 
% 
• Low 27.2 
• Medium 37.9 
• High 29.1 
• Very high 5.8 
 
What word(s) describe how you feel about being pregnant? % 
• Happy - ok - satisfied 50.5 
• 
 
Tired - Sad - Stressed - Angry 
 
49.5 
 
 
How much sleep on average do you obtain each night? 
 
 
% 
 
• 10 or more hours per night 30.1 
• 9-10 hours per night 25.2 
• 7-8 hours per night 27.2 
• 5-6 hours per night 14.6 
• Less than 5 1.9 
• Not sure- do not sleep well throughout night 1.0 
 
Table 3.5: Details of the stress profile of the participants in our study.  
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3.2.6. Smoking Profile of the participants of the study 
Another important factor that was investigated in our study was the smoking habits of the 
women before, as well as, during pregnancy (Table.3.6). The majority of women reported 
that they did not smoke immediately before their pregnancy and this was maintained during 
pregnancy. Also the majority of the prospective mothers reported that someone else in their 
household was smoking both before and during their pregnancy, therefore these women were 
exposed to passive smoking.  
 
SMOKING   PROFILE 
Immediately before pregnancy did you smoke? 
 
B.P. 
% 
D.P. 
% 
• Yes 21.4 N/A 
• No 78.6 N/A 
 
Since you have been pregnant, have you smoked 
cigarettes? 
 
% % 
• Yes N/A 13.9 
• No N/A 86.1 
 
Does anyone in your household smoke? 
 
% % 
• Yes 59.2 58.8 
• No 40.8 41.2 
 
Table 3.6: Details of the smoking profile of the participants in our study.  
 
 
The following pie charts depict the overall percentages of women that smoked before (BP) 
and during (DP) pregnancy. We would like to emphasize on the importance that only a 7% of 
the women reported to have stopped smoking while pregnant where the rest of the 
participants reported to have continued this unhealthy habit. To the question if anyone in the 
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household was smoking before and if they had continued to smoke during pregnancy, a high 
percentage reported that they were exposed to passive smoking with percentage remaining 
the same irrespective of wife/partner being pregnant (Fig.3.7).  
 
 
 
Figure 3.1: Pie charts representing the smoking habits of the participants. Panel A: Indicates the 
smoking habits of the women before (BP) and during (DP) pregnancy. Panel B: indicates the smoking 
habits in the household of the women before (BP) and during (DP) pregnancy. 
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3.2.7. Statistical Analysis of questionnaire data 
As the questions were the same for the two states, before and during pregnancy, a student’s t-
test was used to evaluate the significance of the answers obtained in the different profiles of 
our questionnaires. The statistically significant data is presented beneath in graph formats. Pie 
charts were also used for each question that was significant with broke down to related sub 
categories to emphasize any variations. For comparison purposes the answers were grouped 
as before and during pregnancy and the mean values of the responses are shown in the 
representative graphs below. 
The subjects response to the question of how many portions per week would they eat pies, 
pastries or fried food, before and during pregnancy, shows from the pie chart below that there 
is a wide variation in their responses; with the prospective mothers modifying their eating 
habits during pregnancy compared to before and adopting healthier eating patterns. 
 
 
Figure 3.2: Pie charts of the answers to the question: How many meals per week would include any 
of following: pies, pastries, fried food? (DP: during pregnancy, BP: before pregnancy). Light 
consumption (1-2 portions), moderate consumption (3-4 portions) and excess consumption (5 or more 
portions). 
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When grouped according to the pregnancy state the answers indicated that the average 
number of portions that women were consuming during pregnancy (moderate consumption) 
were higher to the average portion number consumed before pregnancy (Fig. 3.3). 
 
Figure 3.3: How many meals per week would include any of following: pies, pastries, fried food? 
(DP: during pregnancy, BP: before pregnancy), P = 0.002. 
 
Pregnant women also increased their daily intake in iron rich foods such as lean red meat, 
chicken, etc., and this is depicted in the pie chart (Fig. 3.4) which is in agreement with the 
analysis performed in the grouped categories showing that the average number of iron rich 
food consumed on a daily basis was significanlty higher during pregnancy than before (Fig. 
3.5).  
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Figure 3.4: Pie charts of the answers to the question: Do you eat iron rich foods every day? (E.g. lean 
red meat, chicken, etc.) (DP: during pregnancy, BP: before pregnancy). 
 
 
Figure 3.5: Do you eat iron rich foods every day? (E.g. lean red meat, chicken, etc.) (DP: during 
pregnancy, BP: before pregnancy), P = 6.0 x 10
-7
 
 
 
The participants reported to have increased their daily consumption of dairy products such as: 
cheese, milk, yoghurt or calcium enriched milk during pregnancy. The pie charts below (Fig. 
3.6) are indicative of this increase. 
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Figure 3.6: Pie charts of the answers to the question: Do you eat 2 or more serving of cheese, milk, 
yoghurt or calcium enriched milk/day? (DP: during pregnancy, BP: before pregnancy). 
 
 
Also when the answers were examined in the grouped categories it was seen that the women 
increased significanlty their average servings of cheese, milk, yoghurt or calcium enriched 
milk/day to 2 or more during their pregnancy (Fig. 3.7). 
 
Figure 3.7: Do you eat 2 or more serving of cheese, milk, yoghurt or calcium enriched milk/day? 
(DP: during pregnancy, BP: before pregnancy), P = 0.004. 
 
Furthermore, the daily consumption of caffeine in the form of coffee, black tea or other 
beverages containing caffeine showed to be modified during pregnancy compared to the 
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drinking habits of the women before pregnancy as seen in the pie charts presented below 
(Fig.3.8). 
 
Figure 3.8: Pie charts of the answers to the question: How many cups of coffee, black tea or caffeine 
containing beverages do you drink/day? (DP: during pregnancy, BP: before pregnancy). Numbers 
indicate the number of cups.  
 
 
Also the average of the responses obtained in the two categories is in agreement with the 
observation that the prospective mothers had significantly reduced (85% reported to drink 1 
or fewer cups per day) their intake of caffeine on a daily basis (Fig. 3.9). 
 
Figure 3.9: How many cups of coffee, black tea or caffeine containing beverages do you drink/day? 
(DP: during pregnancy, BP: before pregnancy), P = 2.0 x 20
-18 
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To the question of how much soda, sugar-containing drinks do you normally have each day 
again it was evident that the women had modified their habits to meet the “guidelines” of a 
healthier approach during pregnancy as the number of responses stating to drink  1 or fewer 
during pregnancy was increased compared to before (Fig. 3.10). 
Figure 3.10: Pie charts of the answers to the question: How much soda, sugar drinks do you normally 
have each day?  (DP: during pregnancy, BP: before pregnancy). Numbers indicate the number of 
drinks.  
 
This again agrees with the two category analysis performed were a significant reduction in 
the average number of drinks consumed containing sugar that was reported during pregnancy 
in comparison  with the intake before pregnancy (Fig. 3.11). 
 
Figure 3.11: How much soda, sugar drinks do you normally have each day? (DP: during pregnancy, 
BP: before pregnancy), P = 1.4 x 10
-15
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In a similar trend, consumption of alcoholic beverages on a weekly basis showed a noticeable 
change between the two states of pregnancy and according to the numbers of beverages 
consumed (Fig. 3.12). 
Figure 3.12: Pie charts of the answers to the question: How many alcoholic beverages do you 
consume on a weekly basis? (DP: during pregnancy, BP: before pregnancy). Numbers indicate the 
number of drinks. 
 
Significanlty higher was the average consumption reported before pregancy of alcoholic 
beverages compared to  during pregancy (Fig. 3.13). 
 
Figure 3.13: How many alcoholic beverages do you consume on a weekly basis? (DP: during 
pregnancy, BP: before pregnancy), P = 9.6 x 10
-7 
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Modifiction of the consumption of fast food was also observed when sub category analysis 
was performed as seen in the pie charts below (Fig. 3.14) with the percentage of women 
reporting not to comsume any fast food at all during their pregnancies rising when compared 
to..consumption..before..pregnancy. 
 
Figure 3.14: Pie charts of the answers to the question: How many times a week do you eat fast food? 
(DP: during pregnancy, BP: before pregnancy). Numbers indicate the frequency in a week’s period. 
 
When analysis was performed in the pregnancy states, as seen below the weekly preferance 
to fast food had significanlty decreased during their pregnancy compared to before 
pregnancy. These results are depicted in Fig. 3.15. 
 
Figure 3.15: How many times a week do you eat fast food? (DP: during pregnancy, BP: before 
pregnancy), P = 0.0002 
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3.3. Discussion 
In this study we have used an extensive range of questions to obtain as much information as 
possible about the cohort of the patients we dealt with. In this chapter main emphasis was on 
exercise and nutrition of these pregnant women before and during pregnancy. It should be 
noted that maternal attitudes and foetal outcome is discussed in length in Chapter 6 of the 
thesis. A key finding of our study is that there was a significant reduction in the intake of 
alcohol, caffeine-containing and sugary drinks as well as sugary refreshments during 
pregnancy. Moreover, in our cohort 14% of women smoked during pregnancy. This is 
comparable to a recent study of Australian women that showed 14.8% of nonindegenous 
women smoking during pregnancy (Mendelsohn, 2010). Maternal smoking during pregnancy 
is a well established risk factor for perinatal mortality, miscarriage, and premature births 
(Hackshaw et al., 2011). Nicotine and carbon monoxide can cross the foeto-placental barrier 
and reach high concentrations in the foetus, reducing placental blood flow leading to foetal 
hypoxia and subsequently growth restriction (Einarson, 2009). Nicotine is a neurotoxin to the 
developing brain and causes cognitive, emotional and behavioural problems. Children born to 
mothers who smoke in pregnancy also have reduced lung function and an increased risk of 
respiratory illness. Exposure to heavy smoking in utero also increases the risk of nicotine 
dependence in adulthood (Mendelsohn, 2010). In this study another interesting finding was 
unearthed, since parental/passive smoking was not reduced in the household during 
pregnancy, staying at a high rate of 59%. This could be detrimental, as all types of passive 
smoking have been associated with a significant increase in the risk of infants developing 
lower respiratory infections in the first two years of life (Jones et al., 2011).  
In this questionnaire also incorporated seven questions relating to the immune profile of this 
cohort. We have done so, as acute infections in pregnant women are often associated with 
adverse effects such as miscarriage, pre-term labour or even stillbirth (Goldenberg et al., 
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2010; 2000).  There is also evidence from epidemiological data that infections during 
pregnancy might precipitate other pathologies like preeclampsia (Conde-Agudelo et al., 
2008). Data from this self-reported questionnaire indicated that the vast majority of 
participants do not suffer from allergies, do not have an inflammatory disease or are prone to 
cystitis. The most common infection reported was a cold and 36.5% of pregnant women 
found it hard to shift the upper respiratory infection. Interestingly, a significant inverse 
correlation has been noted between difficulty to shed an infection and number of colds and 
number of infections during pregnancy. Similar data has been obtained by a very recent study 
of Australian women, where cold was the commonest infection reported using a similar self-
reported method (Lain et al., 2011). Our study has a number of limitations, with reliance 
being one. In the study by Lain et al., only 21% of the women that reported an infection 
sought medical attention. We do not have such records for our cohort. Moreover, given that 
we have asked the patients to self-report at the end of the third trimester there might be issues 
with recall bias. We would like to acknowledge powerful conclusion from an earlier study 
using an analogous type of reporting. The authors concluded that “future studies should 
emphasise the importance of interviewing women as early as possible, as mothers tend to 
under-report infection” (Collier et al., 2009). However our data related to the immune profile 
also has certain strengths as it includes the investigation of numerous rather a single infection 
and incorporated both chronic and acute infections. These data can be of clinical importance 
as gynaecologists can use a self-reported method for infections to classify patients in a high 
or low group for predisposition towards pregnancy complications such as preeclampsia. With 
regards to caffeine effects during pregnancy, there is still some controversy in the field. 
Caffeine is readily absorbed from the mucosa of the gastrointestinal tract. It crosses the 
human placenta rapidly reaching concentration in the foetus similar to maternal plasma 
levels. Caffeine has been implicated as a cause of spontaneous abortion, intrauterine growth 
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restriction (IUGR), low birth weight (LBW) and pre-term delivery (Kuczkowski, 2009). 
However, other investigators failed to find any association between caffeine intake and poor 
pregnancy outcomes (Wen et al., 2001), whereas some studies have shown positive 
outcomes. Adeney et al., have shown that moderate caffeine consumption during pregnancy 
exerts a protective effect towards gestational diabetes mellitus (GDM) (Adeney et al., 2007). 
These mixed results may arise due to the problem of accurately assessing the caffeine intake. 
Moreover the amount of caffeine varies tremendously in different coffee chains. In a very 
recent study, analysis of 20 commercial espresso coffees using high performance liquid 
chromatography (HPLC) technology revealed differences in caffeine levels up to 6-fold 
(Crozier et al., 2011). The authors of this study concluded that single serving of high caffeine 
espresso could well place at risk individuals who are more susceptible to the effects of 
caffeine toxicity, including women who are pregnant.  In our cohort, a significant reduction 
in caffeine intake has been noted however we were not able to quantify the precise amount 
ingested. Nawrot and colleagues have suggested that women of reproductive-aged should 
consume less than 300 mg of caffeine/ day (equivalent to 4.6 mg/kg body weight per day for 
a 65-kg person; Nawrot et al., 2003). Another key finding was the significant decrease of 
sugar-containing drinks during pregnancy. In USA for example, sugar-sweetened soft drinks 
are the principal energy contributor in the diet (Block, 2004) and they appear to play a role in 
the obesity epidemic due to their high content of readily absorbed sugars (Schulze et al., 
2004). In a recent study involving 59.334 Danish pregnant women it has been shown that 
daily intake of artificially sweetened soft drinks may increase the risk of pre-term delivery 
(Halldorson et al., 2010). It appears therefore that the decreased noted in this study might 
indeed protect from preterm labour. Clearly further epidemiological studies are needed to 
confirm these effects. 
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Of interest, a wide range of responses related to the consumption of fried/fast-food during 
pregnancy were given. As mentioned previously, poor nutrition can lead to a range of health 
problems for mothers, including metabolic syndrome and cancer. Pregnancy results in a state 
of increased energy demands of  ~300 kcals/day. Moreover maternal energy metabolism is 
altered during pregnancy and varies greatly among women. The same women that had 
increased consumption of fast food had also increased intake of iron-rich and dairy products. 
However, there is no evidence to suggest that these beneficial intakes of calcium and iron 
counteract poor eating habits. Our findings are comparable to an Australian study of 409 
women where a substantial proportion of pregnant women consumed 2 meals of snacks (fast 
food/take away) per week (Wen et al., 2010). This finding might also reflect that young 
generations seem to deviate from the traditional Mediterranean dietary pattern, adopting new 
dietary trends (Baldini et al., 2009). Moreover, dietary patterns can be influenced by various 
socio-demographic characteristics. Taking these into consideration it is imperative to develop 
dietary interventions to prevent undesirable health consequences during pregnancy. Another 
factor that can affect pregnancy is exercise. Regular physical activity is associated with 
improved physiological, metabolic and psychological parameters, and with reduced risk of 
morbidity and mortality (Melzer et al., 2010). In our study (based on the Paffenbarger et al. 
1978) there was a clear shift towards a sedentary lifestyle during pregnancy. For example, 
there was an increase in overall inactivity of approximately 15% and an equal decrease of 
moderate exercise. Regular physical activity during pregnancy has been proven to be 
beneficial for the mother as well as the foetus. Maternal benefits include: better 
cardiovascular function, small weight gain during pregnancy, decreased musculoskeletal 
discomfort, and mood stability, reduction of GDM and gestational hypertension that can lead 
to preeclampsia (PE). Benefits for the foetus include: reduction of fat mass, coping better 
with stress, and advanced neurobehavioural maturation (Melzer et al., 2010). The adoption or 
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continuation of a sedentary lifestyle during pregnancy may contribute to the development of 
certain disorders such as hypertension, maternal and childhood obesity, GDM, dyspnoea, and 
PE (Melzer et al., 2010). In view of the global epidemic of sedentary life-style and obesity, 
we propose that pregnant women should increase their physical activity as prevention of 
adverse pathologies for the mother as well as the foetus. Further studies with larger sample 
sizes are needed to provide solid evidence of associations between increased physical activity 
and positive outcomes of labour and delivery. 
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CHAPTER 4  
4. EXPRESSION AND CELLULAR LOCALISATION OF mTOR 
COMPONENTS IN HUMAN PLACENTA AND PLACENTAL 
MODELS: EFFECTS OF CORTISOL ON GENE EXPRESSION 
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4.1. Introduction 
As discussed previously, the cross talk between the mother and the foetus is complex, as well 
as bidirectional. Apart from a plethora of hormonal and immunological events that take place 
during pregnancy, maternal stress is a powerful contributor to birth outcomes. Pregnancy-
related anxiety, depression or distress can be causes for maternal psychological anxiety (Zhu 
et al., 2010). Moreover, maternal stress is linked to poor foetal development in utero (Dole et 
al., 2003; Edwards et al., 1994). Since foetal growth is critically dependent on placental 
nutrient transport, placental mTOR signalling plays an important role in the regulation of 
foetal growth (Roos et al., 2009). In a hyperthermia-induced stress model, a range of changes 
were apparent regarding the mTOR pathway thus indicating that stress can affect the 
placental mTOR signalling pathway (Arroyo et al., 2009). Given that mTOR can function as 
a human placental sensor, we hypothesised that maternal stress can affect mTOR signalling at 
term and as a result influence placental growth.  In this chapter we sought to investigate the 
expression of the main  mTOR signalling components such as: mTOR, Deptor, Rictor, Raptor 
in human placental samples.  We also tested the effect of stress on mTOR signalling using 
two in vitro placental models and correlated maternal and foetal cortisol levels to maternal 
stress profiles.  
 
4.2. Results 
4.2.1. Expression of mTOR, Deptor, Rictor and Raptor in human placentas 
Quantitative RT-PCR revealed that mTOR, Deptor, Rictor and Raptor are expressed in the 
human placenta (n = 23). The expression of these genes is shown in Figure 4.1 below, where 
as seen Deptor is the primary transcript in the total cohort of patients. The ΔCt values of the 
gene expression of mTOR, Deptor, Rictor and Raptor are shown in Table 4.1 below. 
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Significantly lower levels of mTOR, Rictor and Raptor are shown upon comparison to the 
expression of Deptor. 
 
Figure 4.1: Quantitative RT-PCR analysis of mTOR, Deptor, Rictor and Raptor in human placental 
samples (P < 0.05 *) (Mparmpakas et al., 2011). 
 
 
 mTOR Deptor Rictor Raptor 
Placentas 
Samples (n=23) 
0.10 5.02 0.79 0.41 
Term (n=13) 0.09 3.93 0.78 0.33 
Preterm (n=10) 0.12 6.42 0.81 0.53 
Labour (n=18) 0.098 5.24 0.71 0.42 
Non-labour (n=5) 0.12 4.22 1.11 0.40 
 
Table 4.1: ΔCt values of the gene expression of mTOR, Deptor, Rictor, Raptor in placental tissue 
samples according to time and mode of delivery.  
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Our placental tissue bank was split according to the time of delivery into two sub-groups 
(term < 37 weeks of gestation and pre-term  > 37 weeks of gestation) and according to the 
mode of delivery (labour and non-labour). Table 4.1 above summarises the ΔCt of the 
expression of mTOR, Deptor, Rictor and Raptor in all four subgroups. When the ΔCt values 
were analysed in the term and pre-term groups, Deptor was found to be the predominant 
transcript (Fig. 4.2). There was a significant correlation between Log-transformed Deptor and 
Raptor (r = 0.729,  P < 0.005), and  Rictor with Raptor (r = 0.661, P = 0.014) only in the pre-
term placentas examined when compared to term. 
 
Figure 4.2: Expression of mTOR, Deptor, Rictor, Raptor in human term and pre-term placental 
samples. *P < 0.05 
 
 
Also the ΔCt levels (table 4.1) were analysed in the second category the labour and non-
labour. Again Deptor was shown to be the predominant transcript in both categories, the 
labour and the non-labour (Fig. 4.3). 
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Figure 4.3: Expression of mTOR, Deptor, Rictor, Raptor in human labour and non-labour placental 
samples. *P < 0.05 
 
In this cohort (i.e. in 23 patients), 52% reported high and very high levels of stress during 
pregnancy, and 48% medium and low levels. There was no correlation between maternal 
stress levels and body mass index (BMI).  Interestingly, there was a significantly lower 
LogDeptor gene expression in the high stress group (-1.34) than in the low stress group (0.07; 
t (20) = 2.41, P = 0.026). 
We then assessed whether time of delivery has an effect. In term tissues (n = 13) high stress 
inversely correlated with LogDeptor levels (r = -0.772, P = 0.002), placental weight (r =        
-0.591, P = 0.03) and foetal weight (r = -0.732, P = 0.004). In the same cohort, LogDeptor 
levels positively correlated with placenta weight (r = 0.497, P = 0.084) and foetal weight (r = 
0.616, P = 0.025). In pre-term placentas (n = 10) maternal high stress levels inversely 
correlated only with placental weight (r = -0.621, P = 0.07) and foetal weight (r = -0.695,  P 
= 0.038). Interestingly, in this group, LogDeptor levels inversely correlated with placental 
weight (r = -0.622, P = 0.055) and foetal weight (r = -0.575, P = 0.082).  
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Given the effects of timing of delivery on stress, we retested the main hypothesis. An 
ANCOVA (Analysis of Co-Variance) was used to test whether low/high stress correlates with 
Deptor, controlling for contractile status (labour/non-labour) and timing of labour (term/pre-
term) entered as covariates. Taking these confounders into consideration, we still found a 
trend towards a significant relationship between high stress and Deptor: F (1,18) = 4.12,  P = 
0.055. 
 
4.2.2. Cellular localisation of mTOR, Deptor, Rictor and Raptor in human    
placenta 
Immunofluorescent analysis of the mTOR signalling components in human placental tissue 
sections revealed the cellular localization and distribution of each of the components 
individually. Immunofluoresence staining for mTOR revealed a cytoplasmic staining in the 
syncytium layer but also in the cytoplasm of the cytotrophoblast cells (Fig. 4.4). Deptor 
staining was almost exclusively localised in the syncytium layer exhibiting a strong 
cytoplasmic localization. Staining was also visible in the cytoplasm of the cytotrophoblast 
cells beneath the syncytium layer (Fig.4.4). Rictor appeared to have a similar expression 
pattern to mTOR, showing expression in the cytoplasm of both the syncytium layer and the 
cytotrophoblast cells. The expression of Raptor was observed mainly in the syncytium layer, 
with staining observed in the cytoplasm (Fig. 4.5). 
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          mTOR       DEPTOR 
 
 
   
 
 
 
 
 
 
 
 
 
Figure 4.4: Immunofluorescence analysis in human placental tissue sections with mTOR and 
Deptor. Panels A and B are merged images of DAPI and Tetramethyl Rhodamine Isothiocyanate 
(TRITC) for mTOR and Deptor respectively. Panels C and D indicates the nuclear staining with 
DAPI for mTOR and Deptor respectively. Panels E and F indicates the specific staining of the 
antibodies (Mparmpakas et al., 2011). 
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Figure 4.5: Immunofluorescence analysis in human placental tissue sections with Rictor and Raptor. 
Panels A and B indicative of merged images of placental sections with DAPI and TRITC for Rictor 
and Raptor respectively. Panels C and D indicate the nuclear staining with DAPI for Rictor and 
Raptor respectively. Panels E and F indicate the specific staining of the antibodies of Rictor and 
Raptor respectively (Mparmpakas et al., 2011). 
 
  
   RICTOR       RAPTOR 
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Negative controls were included in the study where the primary antibody was omitted. The 
results are shown below in Fig. 4.6. 
 
                  A.            B. 
 
 
 
Figure 4.6: Negative controls where primary antibody was omitted, thus demonstrating staining 
specificity for mTOR (Panel A) and Deptor (Panel B) respectively. 
 
 
4.2.3. Measurement of Cortisol levels in maternal and foetal samples.  
ELISA assays were used to measure the plasma cortisol levels. Mothers with high stress had 
significantly (P = 0.035) elevated levels of cortisol 8.555 pg/ml ± 925 SEM compared to 
those with low stress 4.900 pg/ml  ± 1700 SEM (Fig.4.7).  The average pregnancy days for 
the high stress group were 223.2 ± 60 whereas the average gestational period for the low 
stress group was 253.7 ± 23 days. The foetal cortisol from mothers with high stress was 
measured at 7.440 pg/ml ± 1349 SEM, whereas foetal cortisol from mothers with low stress 
was measured at 7.525 pg/ml ± 1173 SEM. There was no significance amongst the two 
groups (P  > 0.4). Interestingly, a significant positive correlation between maternal and foetal 
cortisol was detected in the high but not the low stress group (r = 0.678, P = 0.022). In the 
high stress group, there was also a significant inverse correlation between foetal cortisol and 
placental weight (r = -0.638, P = 0.024) as well as foetal weight (r = -0.642,  P = 0.023). In 
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the low stress group there was a significant correlation between foetal cortisol and placental 
weight (r = 0.804, P = 0.029 as well as foetal weight (r = 0.784, P = 0.037).  
 
 
Figure 4.7: Percentage of bound cortisol in low and high stress groups of mothers and foetuses. 
 
Also there was shown to be a significant correlation between placental and foetal weight both 
in the high (r = 0.983, P < 0.0001) and low maternal stress groups (r = 0.870, P < 0.011). 
Finally, umbilical cord (foetal) cortisol samples did not vary significantly between the term 
(8.254 pg/ml ±949 SEM) and pre-term groups (6.341 pg/ml ± 1822 SEM, P > 0.1). 
Finally, taking into consideration the smoking status of the patients before and during 
pregnancy it was shown that of the 23 women, 17 did not smoke (74%) and 6 did (26%) 
before pregnancy. During pregnancy, 19 did not smoke (83%) whereas only 4 kept smoking 
(17%). Placental Deptor levels were not statistically different in the two groups during 
pregnancy. 
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4.2.4.  Expression of mTOR, Deptor, Rictor, Raptor in BeWo CT and JEG-3 
cells 
The expression of mTOR, Deptor, Rictor and Raptor genes was examined in BeWo and JEG-
3 cells. The Relative Quantity (RQ) values of BeWo cells are set at 1 as this was the 
calibrator cell line (Fig. 4.8). Significantly lower levels of Deptor, Rictor and Raptor are 
observed in JEG-3 cells when compared to BeWo cells.  
 
 
Figure 4.8: Expression of mTOR, Deptor, Rictor, Raptor in BeWo CT and JEG-3 cells. Each 
histogram represents the mean ± [2
-ΔΔSD
 (+) - 2
-ΔΔSD
 (-)] of three individual experiments (P < 0.05 *). 
 
4.2.5. Cellular localisation of mTOR and Deptor in BeWo CT and JEG-3 cells. 
Immunofluorescent analysis using a specific antibody for mTOR revealed cytoplasmic 
localisation of mTOR in both cell lines (Fig. 4.9 A & B). The staining of mTOR appeared 
granular and dispersed in nature. The cellular distribution of Deptor in the two cell lines was 
cytoplasmic. In BeWo cells Deptor localised primarily around the nucleus (Fig. 4.9 C) 
whereas in JEG-3 cells a more dispersed cytoplasmic staining was evident (Fig. 4.9 D). 
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Negative controls were included in the study where the primary antibody was omitted. The 
results are shown below in Fig. 4.9, panels E & F. 
 
 
Figure 4.9: Panel A and B: Immunofluorescence analysis of mTOR in BeWo cells (A) and JEG-3 
cells (B). Panel C and D: Immunofluorescence  analysis of Deptor in BeWo cells (C) and JEG-3 cells 
(D). Panel E and F: Negative controls of BeWo and JEG-3 respectively (Mparmpakas et al., 2010; 
Mparmpakas et al., 2011). 
 
      BeWo       JEG-3 
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4.2.6.  Effects of cortisol on the expression of Deptor in BeWo CT and JEG-3 
cells 
Given the inverse relationship of stress and Deptor in our clinical samples, we tested the 
hypothesis that cortisol might affect Deptor expression directly. BeWo and JEG-3 cells were 
treated overnight with cortisol, in an attempt to resemble a moderate and high stress 
environment in vitro. When BeWo cells were treated with 10nM, 100nM or 1000nM cortisol, 
the expression of Deptor was significantly downregulated by 50%, 41% and 39% (all P < 
0.05) respectively when compared with basal levels (Fig. 4.10). 
 
 
 
Figure 4.10: Quantitative analysis of  Deptor  levels in BeWo CT cells following 24 hours of cortisol 
treatment, significance (P < 0.05 *) (NS=no supplement) (Mparmpakas et al., 2011). 
 
 
Treatment of  JEG-3 cells with cortisol, lead to a significant decrease of Deptor expression at 
100nM (39%, P < 0.05) and at 1000nM (73%, P < 0.01) when compared with basal levels 
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(Fig. 4.11). However, cortisol treatments did not exert any significant changes in the gene 
expression of mTOR, Rictor or Raptor in both cell lines (data not shown). 
 
 
 
Figure 4.11: Quantitative analysis of Deptor levels in JEG-3 cells following 24 hours of cortisol 
treatment significance (P < 0.05
 
*) and (P < 0.01
 
**), (NS = no supplement), (Mparmpakas et al., 
2011). 
 
 
4.3. Discussion 
In this chapter of our study, 23 pregnant women self-reported their stress status ranging from 
low and medium (Low stress response) to high and very high (High stress response). The 
source of the stress was not reported. Generally, maternal stress could be due to lack of social 
support, anxiety about the pregnancy outcome, or environment-related stressful conditions 
(Douglas, 2010). Nepomnaschy and colleagues have suggested that human placentation is an 
important period for examining the relationship between maternal stress and pregnancy 
outcome (Nepomnaschy et al., 2006).  This was based on the findings of their study showing 
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that women with increased cortisol during the first 3 weeks after conception were more likely 
to result in spontaneous abortion. Indeed a major finding in our study was the significant 
inverse correlation between mRNA levels of placental Deptor and self-reported stress levels. 
None of the other mTOR components displayed any correlation with stress. It should be 
noted that the levels of self-reported stress were evaluated only at the third trimester. 
However, prenatal severe life events in the first and second but not third trimester were 
associated with an increased risk of pre-term birth (Zhu et al., 2010). Though most studies 
suggest that prenatal maternal stress predicts adverse infant outcomes (Dole et al., 2003; Rini 
et al., 1999; Edwards et al., 1994), a large scale Danish study found maternal stress to predict 
greater infant  birth weight (Tegethoff et al., 2010). The exact role of Deptor is relatively 
unknown, but emerging data suggest it plays a role in certain cells’ survival (Peterson et al., 
2009). Thus, it is possible that via reduced Deptor, stress could lead to alterations in placental 
growth that can impact on foetal development. In our study we provide evidence for a dual 
role of Deptor in term and pre-term placentas. Pre-term birth is the most important problem in 
maternal-child health. Numerous epidemiological studies suggested that maternal stress is 
associated significantly with onset of spontaneous pre-term birth (Wadhwa et al., 1993). 
Despite extensive research, the mechanisms that drive this are still poorly understood. As a 
result, the prevalence rate of pre-term birth still remains high. Several studies have 
documented an increase of the endogenous levels of cortisol with pregnancy (Rothenberger et 
al., 2011; Ruiz et al., 2005). However, due to different methodological approaches, the 
cortisol values tend to vary. For example, one group has shown that cortisol values varied 
between 13 and 46 nmol/l when sampled at 37 and 38 weeks of pregnancy. The mean cortisol 
levels were 25.3 nmol/l (de Weerth et al., 2003). However, in another study, a greater 
variation of cortisol levels in late pregnancy was noted, ranging from 3.7 to 55 nmol/l with a 
median of 11.80 nmol/l (Obel et al., 2005). Given the importance of cortisol as a stress 
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marker, we hypothesised that it might affect Deptor expression directly. We tested this in 
vitro, employing two well established choriocarcinoma cell lines (BeWo and JEG-3) that 
have been used widely to decipher placental signalling. Both cell lines were treated over 24 
hours with 10, 100 and 1000 nM of cortisol in an attempt to resemble moderate, high and 
very high stress levels. Treatment of JEG-3 cells with cortisol resulted in a dose-dependent 
downregulation of Deptor, reaching significance at 100nM and 1000nM. However, when the 
same treatments were repeated in BeWo cells, dose-dependence was not observed. This could 
be due to inherent differences that these two cell lines appear to possess. Microarray analyses 
revealed that up to 2700 genes are differentially expressed between the two cell lines 
(Burleigh et al., 2007). Interestingly, principal differences observed in various biological 
processes, including response to stress and signal transduction, were noted (Roos et al., 
2007). In our study, we demonstrate that Deptor is expressed in higher amounts in BeWo 
cells than in JEG-3 cells. It is possible that this overexpression is responsible for the partial 
resistance of downregulation of Deptor by cortisol in this cell line.  
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5. EXPRESSION AND CELLULAR LOCALISATION OF 
GLUCOCORTICOID RECEPTOR SPLICE VARIANTS AND 
GROWTH ARREST-SPECIFIC 5 IN HUMAN PLACENTA AND 
PLACENTAL MODELS 
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5.1. Introduction 
Cortisol is synthesised by the human adrenal cortex in response to CRH/ACTH and 
influences a number of responses including metabolism, immunity and is also involved in 
foetal development. In terms of pregnancy, cortisol plays a key role in foetal organ 
maturation (e.g. lung, liver and brain) and also controls synthesis of placental hormones that 
can affect the onset of labour (Johnson et al., 2008). In this study we determined the 
distribution of 4 mature GR mRNA spliced isoforms (GRα, GRβ, GRγ and GR-P) in order to 
assess labour and pregnancy-planning associated changes. We have also decided to include in 
our study the expression of Growth-Arrest-Specific Transcript-5 (GAS5) as it can act as a GR 
DNA binding decoy and compromise glucocorticoid activity. 
 
5.2. Results 
5.2.1. Glucocorticoid receptors (GRs) and the human placenta 
A total of 23 human placental tissue samples were obtained from the Department of 
Obstetrics and Gynaecology, University Hospital of University of Crete during this study. 
These samples where used to investigate the expression of GRs in the human placenta. A dot 
plot graph was constructed in order to indicate not only the average expression of these genes 
in the human placental cohort, but also to determine an expression pattern per patient. Fig. 
5.1 illustrates the relative expression of GRα, GRβ, GRγ and GR-P. An inter-patient variation 
is mainly seen in GRα whereas the expression of the other GR splice variants is more 
homogeneously expressed in our human placental samples.  
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Figure 5.1: Summary graph of the ΔCt values showing the expression of GR genes in the human 
placentas. 
 
Individual graphs of each gene were plotted illustrating each placental sample and the 
expression of the representative GR genes. As shown in the panels in Fig. 5.2, the expression 
of GRα is the higher observed in the human placenta in comparison to the ΔCt values 
obtained for the other three GR genes.  The y-axis represents the ΔCt values of the gene 
expression as it was calculated from the Q-PCR analysis.  
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Figure 5.2: Expression of GR genes in each placental sample.
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5.2.1 GAS5 and the human placenta 
Placental expression of GAS5 showed an inter patient variation and this is depicted in Fig 
5.3.  
 
 
 
Figure 5.3: Expression of GAS-5 mRNA transcript in each placental sample. 
 
 
The expression of the GR splice variants as well as the expression of GAS5, values were 
analysed according to the time of delivery (i.e. being at term or pre-term). Fig. 5.4 shows the 
results of this analysis. 
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Figure 5.4: Expression of GR genes and GAS5 in the term and pre-term category of our placental 
samples. 
 
The expression of these genes was also categorised according to the contractile status as 
performed earlier in the mTOR section. 
 
Figure 5.5: Expression of GR genes and GAS5 in the labour and non-labour category of our placental 
samples. 
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Also the expression of the GR genes, as well as the expression of GAS5 was analysed 
according to whether the pregnancy was planned or non-planned. Fig.5.6 shows the results of 
this analysis. 
 
Figure 5.6: Expression of GR genes and GAS-5 in the planned and non-planned category of our 
placental samples. 
 
 
5.2.2. Cellular distribution of GRα and GAS5 in human placentas 
Immulofluorescence analysis of the GRα protein was performed in human placenta tissue 
sections. It is evident from Fig. 5.7 that strong homogeneous staining mainly in the cytoplasm 
is detected in the syncytiotrophoblast cells on the outermost layer of the placental villi. The 
GR protein in the cytotrophoblast cells appears to be mainly dotted in staining pattern and to 
be present in the cytoplasm. 
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Figure 5.7: Immunostaining using GRα antibody in human placenta tissue sections. Panel A: Merged 
image of specific staining and nucleus staining with DAPI. Panel B: Nucleus staining. Panel C: 
Specific staining of the GRα protein. Panel D: Negative control. 
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After confirming the expression of GAS5 at gene level using Q-PCR, the RNA-FISH 
technique was used to localise the mRNA in human placenta tissue sections.  
 
 
 
Figure 5.8: RNA FISH confirmed expression of GAS5 in cytotrophoblasts cells (Panel A & B; dotted 
arrows) and syncytiotrophoblasts cells (Panel B; white arrows). 
 
 
 
 
Chapter 5   Expression of GR splice variants & GAS5 
119 
5.2.3. Correlation of the placental GR expression with stress, cortisol levels, 
pregnancy days, placental and fetal weight, and GAS5 expression at 
term. 
The data  obtained from the questionnaire regarding the maternal stress levels, the cortisol 
levels, the pregnancy days, the placental and the fetal weight, were used to further analyse 
and to correlate the expression of all GR splice variants and GAS5 transcripts with the above 
variables. The correlation values (r) along with the significance (P- values) are shown in 
tables 5.1-5.4. We have decided to analyse our clinical data in terms of duration of pregnancy 
(i.e. term or pre-term deliveries) and in terms of pregnancy planning (i.e. planned or non-
planned) according to the answers obtained from the queationnaire data. 
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Correlations TERM 
  
GRα GRβ GRγ GR-P Stress Cortisol 
Pregnancy 
Days 
Fetal Weight 
Placenta 
Weight 
GAS-5 
GRα 
Pearson Correlation 1 0.553 0.512 0.512 0.018 0.289 -0.318 0.134 0.095 0.062 
Sig. (2-tailed)  0.050 0.073 0.074 0.955 0.389 0.371 0.663 0.757 0.865 
N 13 13 13 13 13 13 13 13 13 13 
GRβ 
Pearson Correlation 0.553 1 0.580* 0.980** -0.415 0.574 0.193 0.454 0.535 0.360 
Sig. (2-tailed) 0.050  0.038 0.000 0.158 0.065 0.594 0.119 0.060 0.307 
N 13 13 13 13 13 13 13 13 13 13 
GRγ 
Pearson Correlation 0.512 0.580* 1 0.540 0.065 0.106 0.058 0.132 0.125 0.346 
Sig. (2-tailed) 0.073 0.038  0.057 0.834 0.757 0.873 0.666 0.685 0.328 
N 13 13 13 13 13 13 13 13 13 13 
GR-P 
Pearson Correlation 0.512 0.980** 0.540 1 -0.464 0.638* 0.238 0.475 0.563* 0.311 
Sig. (2-tailed) 0.074 0.000 0.057  0.110 0.035 0.507 0.101 0.045 0.381 
N 13 13 13 13 13 13 10 13 13 13 
Stress 
Pearson Correlation 0.018 -0.415 0.065 -0.464 1 -0.489 -0.486 -0.591* -0.732** -0.711* 
Sig. (2-tailed) 0.955 0.158 0.834 0.110  0.126 0.154 0.034 0.004 0.021 
N 13 13 13 13 13 13 13 13 13 13 
Cortisol 
Pearson Correlation 0.289 0.574 0.106 0.638* -0.489 1 0.747* 0.309 0.393 0.290 
Sig. (2-tailed) 0.389 0.065 0.757 0.035 0.126  0.033 0.355 0.232 0.486 
N 13 13 13 13 13 13 13 13 13 13 
Pregna. Days 
Pearson Correlation -0.318 0.193 0.058 0.238 -0.486 0.747* 1 0.279 0.410 0.017 
Sig. (2-tailed) 0.371 0.594 0.873 0.507 0.154 0.033  0.434 0.239 0.969 
N 13 13 13 13 13 13 13 13 13 13 
Foetal Weight 
Pearson Correlation 0.134 0.454 0.132 0.475 -0.591* 0.309 0.279 1 0.962** 0.444 
Sig. (2-tailed) 0.663 0.119 0.666 0.101 0.034 0.355 0.434  0.000 0.198 
N 13 13 13 13 13 13 13 13 13 13 
Placenta Weight 
Pearson Correlation 0.095 0.535 0.125 0.563* -0.732** 0.393 0.410 0.962** 1 0.517 
Sig. (2-tailed) 0.757 0.060 0.685 0.045 0.004 0.232 0.239 0.000  0.126 
N 13 13 13 13 13 13 13 13 13 13 
GAS-5 
Pearson Correlation 0.062 0.360 0.346 0.311 -0.711* 0.290 0.017 0.444 0.517 1 
Sig. (2-tailed) 0.865 0.307 0.328 0.381 0.021 0.486 0.969 0.198 0.126  
N 13 13 13 13 13 13 13 13 13 13 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
Table 5.1: Summary of correlation values (r) and significance (P-values, P < 0.05, n = 13) of the GR variants with other variables at term 
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The highest correlation observed in this cohort (i.e. term placentas) was that of GRβ with 
GR-P (r = 0.980). This correlation is depicted in Fig. 5.9 below.  
 
Figure 5.9: Correlation graph between GRβ and GR-P levels in term samples (r = 0.980, P < 0.0001, 
n = 13). 
 
Another correlation observed in the term category was between the foetal and the placental 
weight (r = 0.962, P = 0.000, n =13), this is shown in Fig. 5.10 below. 
 
Figure 5.10: Correlation graph between the placental and fetal weight in the term samples (r = 0.962, 
P = 0.000, n=13). 
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5.2.4. Correlation of the placental GR expression with stress, cortisol levels, 
pregnancy days, placental and foetal weight, and GAS5 expression at 
pre-term. 
Again the information received from the participants of this study was used in the pre-term 
category (n =10) to pursue any possible correlations between the expression of GR and GAS5 
genes with variables of the questionnaire. Table 5.2. below indicates the result of the 
correlation in this group. 
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Correlations PRE-TERM 
  
GRα GRβ GRγ GR-P Stress Cortisol 
Pregnancy 
Days 
Fetal Weight 
Placenta 
Weight 
GAS-5 
GRα 
Pearson Correlation 1 -0.291 0.314 0.710* -0.140 -0.432 0.312 0.296 0.358 -0.310 
Sig. (2-tailed)  0.415 0.376 0.021 0.719 0.568 0.381 0.407 0.310 0.417 
N 10 10 10 10 10 10 10 10 10 10 
GRβ 
Pearson Correlation -0.291 1 0.215 0.024 -0.206 -0.079 -0.106 -0.132 -0.080 0.792* 
Sig. (2-tailed) 0.415  0.551 0.947 0.595 0.921 0.771 0.717 0.827 0.011 
N 10 10 10 10 10 10 10 10 10 10 
GRγ 
Pearson Correlation 0.314 0.215 1 0.538 0.415 -0.456 0.113 0.131 0.124 0.622 
Sig. (2-tailed) 0.376 0.551  0.108 0.267 0.544 0.756 0.718 0.734 0.074 
N 10 10 10 10 10 10 10 10 10 10 
GR-P 
Pearson Correlation 0.710* 0.024 0.538 1 -0.035 0.199 0.489 0.500 0.561 0.077 
Sig. (2-tailed) 0.021 0.947 0.108  0.929 0.801 0.151 0.141 0.092 0.844 
N 10 10 10 10 10 10 10 10 10 10 
Stress 
Pearson Correlation -0.140 -0.206 0.415 -0.035 1 -0.830 -0.685* -0.621 -0.695* 0.212 
Sig. (2-tailed) 0.719 0.595 0.267 0.929  0.170 0.042 0.074 0.038 0.614 
N 10 10 10 10 10 10 10 10 10 10 
Cortisol 
Pearson Correlation -0.432 -0.079 -0.456 0.199 -0.830 1 0.764 0.746 0.746 0.203 
Sig. (2-tailed) 0.568 0.921 0.544 0.801 0.170  0.236 0.254 0.254 0.870 
N 10 10 10 10 10 10 10 10 10 10 
Pregna. Days 
Pearson Correlation 0.312 -0.106 0.113 0.489 -0.685* 0.764 1 0.986** 0.989** -0.174 
Sig. (2-tailed) 0.381 0.771 0.756 0.151 0.042 0.236  0.000 0.000 0.654 
N 10 10 10 10 10 10 10 10 10 10 
Foetal Weight 
Pearson Correlation 0.296 -0.132 0.131 0.500 -0.621 0.746 0.986** 1 0.990** -0.200 
Sig. (2-tailed) 0.407 0.717 0.718 0.141 0.074 0.254 0.000  0.000 0.606 
N 10 10 10 10 10 10 10 10 10 10 
Placenta Weight 
Pearson Correlation 0.358 -0.080 0.124 0.561 -0.695* 0.746 0.989** 0.990** 1 -0.186 
Sig. (2-tailed) 0.310 0.827 0.734 0.092 0.038 0.254 0.000 0.000  0.632 
N 10 10 10 10 10 10 10 10 10 10 
GAS-5 
Pearson Correlation -0.310 0.792* 0.622 0.077 0.212 0.203 -0.174 -0.200 -0.186 1 
Sig. (2-tailed) 0.417 0.011 0.074 0.844 0.614 0.870 0.654 0.606 0.632  
N 10 10 10 10 10 10 10 10 10 10 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
Table 5.2: Summary of correlation values (r) and significance (P -values, P < 0.05, n = 13) of the GR variants with other variables at pre-term. 
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Graphical representations of the significant correlations are presented below. From the results 
obtained it is shown that the expression of GRα is positively correlated to the expression of 
GR-P (r = 0.710, P = 0.021, n =10). Fig. 5.11 below represents this correlation. 
 
Figure 5.11: Correlation graph between GRα and GR-P in pre-term samples (r = 0.710, P = 0.021, 
n=10). 
 
The second positive correlation in the pre-term category is the expression of GRβ with GAS5 
(r = 0.792, P = 0.011, n = 10) and this is illustrated in Fig. 5.12 below. 
 
Figure 5.12: Correlation graph between GRβ and GAS5 in pre-term samples (r = 0.792, P = 0.011, 
n=10). 
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The duration of pregnancy measured in days is positively correlated in the pre-term category 
with both foetal (r = 0.986, P = 0.000, n = 10) and placental weight (r = 0.989,   P = 0.000, n 
= 10). These correlations are depicted in Figs. 5.13 & 5.14 below. 
 
Figure 5.13: Correlation graph between foetal weight and pregnancy days in pre-term samples (r = 
0.986, P = 0.000, n = 10). 
 
 
 
Figure 5.14: Correlation graph between placental weight and pregnancy days in pre-term samples (r 
= 0.989,   P = 0.000, n = 10). 
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Lastly, a positive correlation was also shown between the placental and the fetal weight (r = 
0.990, P = 0.000, n = 10) in the pre-term category. Fig. 5.15 below represents this correlation. 
 
Figure 5.15: Correlation graph between foetal weight and pregnancy days in pre-term samples (r = 
0.990, P = 0.000, n = 10). 
 
 
5.2.5. Correlation of the placental GR expression with stress, cortisol levels, 
pregnancy days, placental and foetal weight, and GAS5 expression in 
planned pregnancies. 
Following from the previous analysis in the term and pre-term categories, the clinical cohort 
was grouped and analysed based on the information in the questionnaire regarding whether 
the pregnancy was planned or non-planned. Possible correlations between the expression of 
GR and GAS-5 genes with cortisol levels, pregnancy days, foetal and placenta weight were 
analysed and the results are depicted in table 5.3 (n=11). 
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Correlations PLANNED 
  
GRα GRβ GRγ GR-P Stress Cortisol 
Pregnancy 
Days 
Fetal Weight 
Placenta 
Weight 
GAS-5 
GRα 
Pearson Correlation 1 -0.134 0.664* 0.015 0.521 -0.353 -0.158 -0.141 -0.152 0.881** 
Sig. (2-tailed)  0.695 0.026 0.965 0.100 0.438 0.643 0.679 0.655 0.001 
N 11 11 11 11 11 11 11 11 11 11 
GRβ 
Pearson Correlation -0.134 1 0.053 0.030 -0.221 -0.433 -0.183 -0.221 -.0172 0.057 
Sig. (2-tailed) 0.695  0.877 0.931 0.514 0.332 0.590 0.513 0.614 0.876 
N 11 11 11 11 11 11 11 11 11 11 
GRγ 
Pearson Correlation 0.664* 0.053 1 -0.054 0.523 -0.427 0.160 0.151 0.166 0.860** 
Sig. (2-tailed) 0.026 0.877  0.876 0.099 0.339 0.638 0.657 0.627 0.001 
N 11 11 11 11 11 11 11 11 11 11 
GR-P 
Pearson Correlation 0.015 0.030 -0.054 1 -0.363 -0.046 0.408 0.543 0.510 -0.048 
Sig. (2-tailed) 0.965 0.931 0.876  0.272 0.922 0.213 0.084 0.109 0.896 
N 11 11 11 11 11 11 11 11 11 11 
Stress 
Pearson Correlation 0.521 -0.221 0.523 -0.363 1 -0.583 -0.607* -0.544 -0.578 0.547 
Sig. (2-tailed) 0.100 0.514 0.099 0.272  0.169 0.048 0.084 0.063 0.102 
N 11 11 11 11 11 11 11 11 11 10 
Cortisol 
Pearson Correlation -0.353 -0.433 -0.427 -0.046 -0.583 1 0.404 0.200 0.230 -0.455 
Sig. (2-tailed) 0.438 0.332 0.339 0.922 0.169  0.368 0.667 0.619 0.365 
N 11 11 11 11 11 11 11 11 11 11 
Pregnancy Days 
Pearson Correlation -0.158 -0.183 0.160 0.408 -0.607* 0.404 1 0.952** 0.971** -0.412 
Sig. (2-tailed) 0.643 0.590 0.638 0.213 0.048 0.368  0.000 0.000 0.237 
N 11 11 11 11 11 11 11 11 11 11 
Fetal Weight 
Pearson Correlation -0.141 -0.221 0.151 0.543 -0.544 0.200 0.952** 1 0.996** -0.329 
Sig. (2-tailed) 0.679 0.513 0.657 0.084 0.084 0.667 0.000  0.000 0.353 
N 11 11 11 11 11 11 11 11 11 11 
Placenta Weight 
Pearson Correlation -0.152 -0.172 0.166 0.510 -0.578 0.230 0.971** 0.996** 1 -0.351 
Sig. (2-tailed) 0.655 0.614 0.627 0.109 0.063 0.619 0.000 0.000  0.320 
N 11 11 11 11 11 11 11 11 11 11 
GAS-5 
Pearson Correlation 0.881** 0.057 0.860** -0.048 0.547 -0.455 -0.412 -0.329 -0.351 1 
Sig. (2-tailed) 0.001 0.876 0.001 0.896 0.102 0.365 0.237 0.353 0.320  
N 11 11 11 11 11 11 11 11 11 11 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
Table 5.3: Summary of correlation values (r) and significance (P -values, P < 0.05, n =13) of the GR variants with other variables in planned pregnancies 
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From the results obtained the expression of GRα is positively correlated to the expression of 
GR-γ (r = 0.664, P = 0.026, n =11). Fig. 5.16 below represents this correlation. 
 
Figure 5.16: Correlation graph between GRα and GRγ in planned pregnancy samples (r = 0.664, P = 
0.026, n = 11). 
 
The duration of pregnancy showed positive correlations with both foetal (r = 0.952, P = 
0.000, n = 11) and placental weight (r = 0.996, P = 0.000, n = 11). These correlations are 
illustrated in Figs 5.17 & 5.18 below. 
 
Figure 5.17: Correlation graph between pregnancy days and foetal weight in planned pregnancy 
samples (r = 0.952, P = 0.000, n = 11). 
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Figure 5.18: Correlation graph between pregnancy days and placental weight in planned pregnancy 
samples (r = 0.996, P = 0.000, n = 11). 
 
 
The last correlation of the planned category is between the foetal and the placental weight (r 
= 0.996, P = 0.000, n = 11) .Fig. 5.19. below represents this correlation. 
 
 
Figure 5.19: Correlation graph between pregnancy days and placental weight in planned pregnancy 
samples (r = 0.996, P = 0.000, n = 11). 
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5.2.6. Correlation of the placental GR expression with stress, cortisol levels, 
pregnancy days, placental and fetal weight, and GAS5 expression in 
non planned pregnancies. 
The last category in which the information obtained from the questionnaire were used to 
determine possible correlations, was the unplanned pregnancy group (n=12). Table 5.4 below 
illustrates the results obtained. 
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Correlations NO PLANNED 
  
GRα GRβ GRγ GR-P Stress Cortisol 
Pregnancy 
Days 
Fetal Weight 
Placenta 
Weight 
GAS-5 
GRα 
Pearson Correlation 1 0.188 0.119 0.302 -0.707* 0.232 0.259 0.082 0.158 -0.114 
Sig. (2-tailed)  0.559 0.714 0.340 0.015 0.580 0.501 0.800 0.623 0.754 
N 12 12 12 12 12 12 12 12 12 12 
GRβ 
Pearson Correlation 0.188 1 0.648* 0.978** -0.646* 0.517 0.158 0.325 0.280 0.720* 
Sig. (2-tailed) 0.559  0.023 0.000 0.032 0.190 0.684 0.302 0.378 0.019 
N 12 12 12 12 12 12 12 12 12 12 
GRγ 
Pearson Correlation 0.119 0.648* 1 0.663* -0.278 0.055 0.390 0.441 0.408 0.775** 
Sig. (2-tailed) 0.714 0.023  0.019 0.409 0.896 0.300 0.152 0.188 0.008 
N 12 12 12 12 12 12 12 12 12 12 
GR-P 
Pearson Correlation 0.302 0.978** 0.663* 1 -0.645* 0.459 0.280 0.398 0.382 0.645* 
Sig. (2-tailed) 0.340 0.000 0.019  0.032 0.253 0.466 0.200 0.221 0.044 
N 12 12 12 12 12 12 12 12 12 12 
Stress 
Pearson Correlation -0.707* -0.646* -0.278 -0.645* 1 -0.423 -0.146 -0.134 -0.125 -0.322 
Sig. (2-tailed) 0.015 0.032 0.409 0.032  0.296 0.730 0.694 0.713 0.398 
N 12 12 12 12 12 12 12 12 12 12 
Cortisol 
Pearson Correlation 0.232 0.517 0.055 0.459 -0.423 1 -0.737 -0.511 -0.582 0.802 
Sig. (2-tailed) 0.580 0.190 0.896 0.253 0.296  0.155 0.195 0.130 0.055 
N 12 12 12 12 12 12 12 12 12 12 
Pregnancy 
Days 
Pearson Correlation 0.259 0.158 0.390 0.280 -0.146 -0.737 1 0.927** 0.962** -0.237 
Sig. (2-tailed) 0.501 0.684 0.300 0.466 0.730 0.155  0.000 0.000 0.572 
N 12 12 12 12 12 12 12 12 12 12 
Fetal Weight 
Pearson Correlation 0.082 0.325 0.441 0.398 -0.134 -0.511 0.927** 1 0.973** -0.082 
Sig. (2-tailed) 0.800 0.302 0.152 0.200 0.694 0.195 0.000  0.000 0.822 
N 12 12 12 12 12 12 12 12 12 12 
Placenta 
Weight 
Pearson Correlation 0.158 0.280 0.408 0.382 -0.125 -0.582 0.962** 0.973** 1 -0.176 
Sig. (2-tailed) 0.623 0.378 0.188 0.221 0.713 0.130 0.000 0.000  0.626 
N 12 12 12 12 12 12 12 12 12 12 
GAS-5 
Pearson Correlation -0.114 0.720* 0.775** 0.645* -0.322 0.802 -0.237 -0.082 -0.176 1 
Sig. (2-tailed) 0.754 0.019 0.008 0.044 0.398 0.055 0.572 0.822 0.626  
N 12 12 12 12 12 12 12 12 12 12 
*. Correlation is significant at the 0.05 level (2-tailed). 
**. Correlation is significant at the 0.01 level (2-tailed). 
Table 5.4: Summary of correlation values (r) and significance (P-values, P < 0.05, n=13) of the GR variants with other variables in non planned pregnancies. 
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The expression of GRβ revealed positive correlations with the expression of GRγ (r = 0.648,     
P = 0.023, n = 12). A graph illustrating this correlation is depicted below (Fig. 5.20). 
 
Figure 5.20: Correlation graph between GRβ and GRγ in non  planned pregnancy samples (r = 0.648,     
P = 0.023, n=12). 
 
The expression of GRγ in the non planned category shows to be positively correlated with the 
of  GAS-5 (r = 0.775, P = 0.008, n = 12). Fig. 5.21 below depicts this correlation.  
 
Figure 5.21: Correlation graph between GRγ and GAS5 in non planned pregnancy samples (r = 
0.775, P = 0.008, n = 12). 
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The expression of GR-P is  positively correlated with the expression of GAS5 in this category 
(r = 0.645, P = 0.044, n = 12) and this correlation is depicted in Fig. 5.22 below. 
 
Figure 5.22: Correlation graph between GR-P and GAS5 in non planned pregnancy samples (r = 
0.645, P = 0.044, n = 12). 
 
 
The duration of pregnancy (days) shows a positive correlation with both foetal  (r = 0.927,      
P = 0.000, n = 12) and placental weight (r = 0.962, P = 0.000, n = 12). Fig. 5.23 and 5.24 
below depict these correlations.  
 
Chapter 5   Expression of GR splice variants & GAS5 
134 
 
Figure 5.23: Correlation graph between pregnancy days and foetal weight in non planned pregnancy 
samples (r = 0.927,P = 0.000, n = 12). 
 
 
Figure 5.24: Correlation graph between pregnancy days and placental weight in non planned 
pregnancy samples (r = 0.962, P = 0.000, n=12). 
 
Finally, the last positive correlation obtained in this category  is between foetal and placental 
weight (r = 0.973, P = 0.000, n = 12). Fig. 5.25 below depicts this correlation.  
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Figure 5.25: Correlation graph between placental and foetal weight in non planned pregnancy 
samples (r = 0.973, P = 0.000, n = 12). 
 
In the term and pre-term groups the GR splice variants were examined as a ratio to the “wild-
type” GRα and key changes were noted. 
 Term (n=13) Pre-term (n=10) 
GRα / GRα 1 1 
GRα / GRβ 47 65 
GRα / GRγ 38 97 
GRα / GR-P 11 43 
GRα / GAS-5 0.8 1.5 
 
Table 5.5: Ratio of gene expression relative to GRα in term and pre-term human placental samples. 
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As it is evident there is a clear shift towards a predominance of GRα in terms of GR splicing 
in the pre-term cohort when it was compared to term placentas, including a similar change in 
the GRα/GAS-5 ratio.  
 
5.2.7. Expression of GRs and GAS-5 in BeWo cytotrophoblast (CT) and  JEG-3 
cells. 
The expression of GAS-5 was examined in BeWo CT and JEG-3 cells. The RQ values are 
presented in Fig.5.26 below. As it can be seen, significant lower levels of GAS5 were 
detected in JEG-3 cells when compared to BeWo CT under basal (unstimulated) conditions. 
 
 
 
Figure 5.26: Expression of GAS-5 in BeWo CT and JEG-3 cells (P < 0.05*). 
 
Also in these cDNA preparations of BeWo CT and JEG-3 cells the expression of GRα, GRβ, 
GRγ and GR-P was examined. Significantly higher levels are seen in the expression of GRγ 
and GR-P in the JEG-3 cells compared to the BeWo CT cells. 
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Figure 5.27: Expression of GRα, GRβ, GRγ and GR-P in BeWo CT and JEG-3 cells (P < 0.05 *). 
 
 
5.2.8. Effect of cortisol on GRs and GAS5 gene expression in BeWo CT and 
JEG-3 cells. 
The two well established choriocarcinoma cell lines (BeWo and JEG-3) that have been used 
widely to decipher placental signalling were further employed in this study. The cells were 
treated with cortisol in a dose-dependent manner (10nM, 100nM and 1000nM) for 24 hours 
in an attempt to represent a stressful environment in vitro ranging from a moderate to a very 
high stress level. The graph in Fig.5.28 depicts the results that were obtained. The expression 
of GAS-5 following the treatments with cortisol was significanlty higher compared to the non 
treated BeWo CT and JEG-3. Specifically, after treating the BeWo CT cells with 10nM, 
100nM and 1000nM, a 21.7 fold,  11.2 fold and 24.9 fold increase respectively was obtained. 
The JEG-3 cells after the same course of treatment resulted in a 28.3 fold increase, a 7.3 and 
a 13.1 increase above basal levels.  
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Figure 5.28: RQ values of the expression of GAS5 in BeWo CT and JEG-3 cells after 24 hour 
cortisol treatment with 10, 100 and 1000nM (P < 0.05 *). Each histogram represents the mean + [2
-
ΔΔSD
 (+) - 2
-ΔΔSD
 (-)] of three individual experiments, NS = non supplement. 
 
 
The levels of expression of the GR genes were analysed as previously described using RQ 
values (Y axis). The expression of GR splice variants in both cell lines following the 24 hour 
treatments were obtained and the RQ values are depicted in Fig.5.29. Even though some 
differences are seen post cortisol treatment in the expression levels of the genes, the results 
do not appear to reach significance. 
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Figure 5.29: RQ values of the expression of GRα in BeWo CT and JEG-3 cells after treating with 
cortisol. Each histogram represents the mean + [2
-ΔΔSD
 (+) - 2
-ΔΔSD
 (-)] of three individual experiments.  
 
 
 
 
 
 
 
 
 
 
Figure 5.30: RQ values of the expression of GRβ in BeWo CT and JEG-3 cells after treating with 
cortisol. Each histogram represents the mean + [2
-ΔΔSD
 (+) - 2
-ΔΔSD
 (-)] of three individual experiments. 
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Figure 5.31: RQ values of the expression of GRγ in BeWo CT and JEG-3 cells after treating with 
cortisol. Each histogram represents the mean + [2
-ΔΔSD
 (+) - 2
-ΔΔSD
 (-)] of three individual experiments.  
 
 
 
 
Figure 5.32: RQ values of the expression of GR-P in BeWo CT and JEG-3 cells after treating with 
cortisol. Each histogram represents the mean + [2
-ΔΔSD
 (+) - 2
-ΔΔSD
 (-)] of three individual experiments.  
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5.2.9. Cellular localisation and distribution of GR in the BeWo CT and   JEG-3 
cells. 
Immulofluorescence analysis of the GRα protein in BeWo CT and JEG-3 cells was 
performed. In BeWo cells this protein was localised mainly in the cytoplasm where the 
staining had a dotted appearance primarily around the nucleus (Fig. 5.33 A). In JEG-3 cells 
strong peri-nuclear staining was evident (Fig. 5.33 B). 
 
 
Figure 5.33:  Panel A and B: Immunofluorescence analysis for GRα in BeWo CT cells (A) and JEG-
3 cells (B). Panel C and D: Negative controls of BeWo and JEG-3 respectively. 
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5.3. Discussion 
The human placenta is exposed to increased levels of cortisol as pregnancy progresses 
(Johnson et al., 2008) and its effects are mediated via binding and activating GR. However, 
controversy surrounds the exact mechanisms by which these responses are regulated. GR 
alternative splicing might also influence the subsequent activation of signalling pathways by 
glucocorticoids (Johnson et al., 2008). In our study, we have shown that all known transcripts 
of GR splice variants are expressed in the human placenta with GRα being the predominant 
transcript in all categories studied. These data corroborate a previous preliminary study of 
placental GRs (Johnson et al., 2008). The qPCR data have also been grouped under plan or 
non planned pregnancies but there was no apparent difference in expression levels between 
these groups (Appendix VI).  
In addition, we demonstrate for the first time the expression of Growth-Arrest-Specific 
Transcript-5 (GAS5) in human placentas. We decided to incorporate GAS5 in the current 
study as emerging data suggests that it can act as a GR DNA binding decoy and as a result 
compromise its activity (Kino et al., 2010). Interestingly, there was equally strong expression 
of GAS5 when compared to GRα in both term and pre-term placentas. Pre-term labour is 
associated with high mortality and morbidity (Beck et al., 2010) and a recent study pointed 
towards an association between maternal stress with complications of pregnancy and 
especially with pre-term birth (Roy-Matton et al., 2011).  GRβ differs from GRα on the C-
terminus of the receptor protein. There is still controversy surrounding the exact function of 
GRβ, but it appears to exert a dominat-negative effect on GRα-induced transcriptional 
activity (Kino et al., 2010). Moreover it fails to bind hormone and subsequently activate 
transcriptional events (Sánchez-Vega et al., 2006).  GRγ is a ligand-dependent transcription 
factor with reduced transactivating activity and its function is still under investigation. In our 
clinical samples, GRγ is present at much lower levels than GRα isoform in placentas studied. 
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Similarly, controversy surrounds the role of GR-P a truncated isoform that lacks a large part 
of the ligand-binding domain, including the domains for silencing of GR in the absence of 
hormone and transcriptional activation (Sánchez-Vega et al., 2006).  Johnson et al., have 
shown that only placental GR-P mRNA levels were reduced significantly after spontaneous 
labour (Johnson et al., 2008).   
In our study, an approximate 4-fold change in the GRα / GR-P with pre-term labour was 
detected. Studies in multiple myeloma cells have shown similar changes in GRα / GR-P ratio 
in myeloma glucocorticoid resistant and parental cell lines (Sánchez-Vega et al., 2006).  
Finally, a two-fold increase in the GRα / GAS5 ratio was also noted. This is the first study 
that expression and cellular distribution of GAS5 is elucidated in the human placenta. It is 
attractive therefore to hypothesise that the change in the ratio of the splicing isoforms alters 
the responsiveness of placental GRs to cortisol. We would like to propose a model where, 
during pre-term birth GRα is the predominant receptor since there is a decrease in negative 
regulators such as GRβ, GRγ as well as the “pseudo-GRE” GAS5. This ratio changes will 
ultimately lead to an augmented response towards glucocorticoids with potential detrimental 
effects for the mother and the foetus. 
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CHAPTER 6  
6. POLYMORPHIC STUDIES OF THE GR GENE IN MATERNAL AND 
FOETAL SAMPLES: EVIDENCE FOR NATURE-NURTURE 
INTERACTIONS 
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6.1. Introduction 
Normal foetal development depends partly on the ability of the mother to adapt to changes 
taking place on physiological as well as psychosocial levels (Lobel et al., 2008).  Stress 
related to the pregnancy may be a more powerful contributor to birth outcomes such as 
preterm labour and low infant birth weight that general stress itself (DiPietro et al., 2002, 
2004; Huizink et al., 2004; Roesch et al., 2004).  Changes in the epigenetic regulation of the 
foetal GR promoter have been associated with the exposure to prenatal maternal stress 
(Lupien et al., 2009), reflecting a possible effect of maternal stress on the expression and 
function on the GR in the foetus. For example, the Bcl I polymorphism of the GR has been 
associated with increased glucocorticoid sensitivity and was over represented in pregnant 
women with pathological foeto-maternal immune adaptation (Bertalan et al., 2009). In this 
study we have examined the relationship between mothers’ stress levels and the status of four 
different GR polymorphisms, with their infants’ birth weights.  
 
6.2. Results 
6.2.1. Maternal stress, maternal attitudes towards the pregnancy and foetal 
birth weight 
Following analysis of the questionnaire responses, the maternal attitudes were classified as 
following: 35.7% positive, 16.3% neutral and 48% negative. Maternal attitudes were related 
to self-reported stress status ranging from low and medium (Low stress response) to high and 
very high (High stress response). The source of the stress was not reported. Women with 
negative attitudes towards their pregnancy showed significantly higher levels of stress during 
pregnancy (2.8) compared to women with neutral (1.6) or positive attitudes towards their 
pregnancy (1.4; t(95) = 9.8, P < 0.001). Since women with neutral and positive attitudes 
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towards the pregnancy did not differ on stress levels (t (95) = 1.0, P > 0.05), and due to the 
small number of women with neutral attitudes, both groups were merged. Women forming 
the first group with the positive and neutral attitudes were contrasted with those with negative 
attitudes. Women with negative attitudes during pregnancy gave birth to infants with 
significantly lower birth weights (2.5Kg) than those women showing a positive or neutral 
attitudes towards their pregnancy (2.9Kg; F(1,71) = 4.2, P < 0.05; Fig. 6.1), independent of 
their age and their body mass index (BMI). However, from the analysis it was shown that the 
levels of stress were unrelated to infant’s birth weights (r = -0.12, P > 0.05). 
 
Figure 6.1: Prenatal maternal attitude towards the pregnancy and foetal weight. Neutral or positive 
and negative attitudes. 
 
6.2.2. Maternal background variables, pregnancy planning and foetal birth 
weight 
We then tested whether maternal background variables predicted infant birth weight. Age, 
BMI, physical activity, alcohol and smoking during pregnancy were unrelated to infant birth 
weight (all P > 0.05). Furthermore, most immune symptoms of women (i.e., difficulty 
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overcoming an infection, number of colds or infections during pregnancy, inflammatory 
diseases, proneness to cystitis/thrush, allergies, use of antibiotics) were also unrelated to 
infant birth weight (all P > 0.05). 
 
6.2.3. Effects of maternal attitude to pregnany & pregnancy planning on infant 
birth weight 
In planned pregnancies, stress predicted infant weight, independent of age and BMI (r =         
-0.44, P = 0.01), whereas in unplanned pregnancies stress did not predict infant weight (r = -
0.19, P = 0.23). In mothers with neutral or positive attitudes towards the pregnancy, planning 
the pregnancy had no effect on infant birth weight (F(1,30) = 0.091, Not Significant). 
However, in mothers with negative attitudes towards the pregnancy, those with an unplanned 
pregnancy gave birth to infants with significantly higher weights (2681.9 gr) than those with 
planned pregnancies (1917.8 gr; F(1,36) = 7.074, P = 0.012; Fig. 6.2). 
 
 
Figure 6.2: Effects of maternal attitude to pregnancy & pregnancy planning on infant birth weight. 
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6.2.4. Maternal and infant GR polymorphisms and foetal birth weight 
Using PCR and restriction digests, we investigated four different GR polymorphisms: BclI, 
N363S, TthIII-I, and ER22/23EK and the results of this study are illustrated in Table 6.1 
below. Since the maternal attitude towards the pregnancy was a significant predictor of foetal 
birth weight, we re-examined this association as a function of the GR gene polymorphisms, 
resembling a “nature-nurture” interaction, and statistically controlling for mothers’ age, BMI, 
pregnancy planning and fast food consumption during pregnancy. 
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Restriction digest site Nucleotide 
change 
Genotype 
Mothers 
n (%) 
Foetuses 
n (%) 
Bcl  I C → G  81 87 (+ 6 twins) 
  GG 5 (6.2) 7 (8.1) 
  CC 19 (23.5) 23 (26.4) 
  GC 57 (70.4) 57 (65.5) 
N363S Asp → Lys  81 87 (+ 6 twins) 
  Wt 
a
 79 (97.5) 85 (97.7) 
  Hmz 
b
 2  (2.5) 2 (2.5) 
ThtIII 1 C → T  81 87 (+ 6 twins) 
  CC 35 (43.2) 33 (37.9) 
  TT 2  (2.5) 8  (9.2) 
  CT 44 (54.3) 46 (52.8) 
ER22/23EK Arg →Lys  81 87 (+ 6 twins) 
  Wt 78 (96.3) 84 (96.5) 
  Htz 
c
 3  (3.7) 3  (3.4) 
 
Table 6.1: GR gene polymorphic study results of Bcl I, N363S, ThtIII 1, ER/22/23EK showing the 
distribution of the genotyping in each of the four genetic polymorphism. When ( 
a 
)
 
wild type is 
inticated, ( 
b 
) homozygous carriers and ( 
c 
) heterozygous carriers. 
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6.2.5. Examining the variables of maternal background and the foetal birth 
weight.  
Some of the maternal background variables collected from the questionnaire were tested as 
possible predictors of foetal birth weight. Variables including age, BMI, physical activity, 
alcohol and smoking during pregnancy were all found to be unrelated to foetal birth weight 
(all  P > 0.05). Further to this, most immune symptoms that women reported (i.e., difficulty 
of overcoming an infection, number of colds or infections during pregnancy, inflammatory 
diseases, proneness to cystitis/thrush, allergies, use of antibiotics) were also found to be 
unrelated to foetal birth weight (all  P > 0.05).  
6.2.6. Bcl I Polymorphism 
RT-PCR analysis followed by restriction enzyme digestion revealed the distribution of Bcl I 
polymorphisms with regards to maternal samples as well as foetal samples. The distribution 
of the polymorphism in our participants can be seen in Table 6.1 In our cohort, 5 women 
were non-carriers (GG; 6.0%), 19 were homozygous carriers (CC; 22.6%) and 57 were 
heterozygous carriers (GC; 71.4%). The foetal distribution of Bcl I polymorphism was: 7 
non-carriers (6.0%), 23 homozygous carriers (28.6%) and 57 heterozygous carriers (65.4%).  
 
Figure 6.3: Results of electrophoresis following BclI restriction enzyme digestion of a 335bp 
PCR product in maternal (m) and foetal (f) samples. Lane 1 (M) shows the 1Kb DNA ladder. 
Lanes 2 (mc), 3 (fc), 4 (mc) shows the CG heterozygote as indicated by the three bands (117, 222 and 
335 bp), lanes 5 (fb), 10 (mb), 11 (fb) shows the CC homozygote as indicated by the two bands (117 
and 222 bp), lanes 6 (md),7 (fd), 8 (md), 9 (fd) shows the undigested GG homozygote with one band 
(335 bp). When ( 
b 
) homozygous carriers, ( 
c 
) heterozygous carriers and ( 
d 
) undigested GG 
homozygote carriers. 
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6.2.6.1. Examining the maternal attitude towards pregnancy, Bcl I 
polymorphism and foetal birth weight  
As the maternal attitude towards the pregnancy showed to be a significant predictor of foetal 
birth weight, this association was re-examined as a function of the GR gene Bcl I 
polymorphism. This was performed in an attempt to resemble a “nature-nurture” interaction 
and statistically were controlling for the mothers’ age and BMI planning and fast food. 
6.2.6.2. Maternal Bcl I polymorphism 
There is a partial inverse correlation between maternal attitude (“Happy”) and foetal weight, 
in Bcl I (CC) where r = -0.51, P = 0.065, while the CG group exhibited a significant yet 
moderate inverse correlation; r = - 0.27, P = 0.047.  For both (CC and GC) analyses we 
controlled for confounders mentioned previously. The GG group was not analysed as only 5 
women were genotyped with this polymorphism. 
6.2.6.3. Foetal Bcl I polymorphism 
The partial correlation between maternal attitude and foetal weight, Bcl I (CC) is r = -0.41, P 
= 0.10; while in Bcl I (GC) it is r = -0.40, P =0 .005, controlling for the same confounders. 
 
6.2.7. ThtIII 1 Polymorphism 
The next polymorphism that was analysed in our patient cohort was the ThtIII 1. RT-PCR 
analysis followed by restriction enzyme digestion revealed the distribution of this 
polymorphism as can be seen by a representative agarose gel electrophoresis result shown in 
Fig. 6.4. The distribution of this polymorphism in our subjects is shown in Table 6.1 where it 
is evident that our subjects carried all three types of the ThtIII 1 genetic polymorphism  
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Figure 6.4: Results of electrophoresis following ThtIII1 polymorphism genotyping in maternal 
(m) and foetal (f) samples. Lane 1 (M) shows the 1Kb DNA ladder. Lanes 2 (ma), 3 (fa), 4 (ma), 5 
(fa), 10 (ma) shows the CC genotype as indicated by the one band (167 bp), lane 6 (mb) shows the TT 
genotype as indicated by the one band (337 bp), lanes 7 (fc), 8 (mc), 9 (fc), 11 (fc) shows the CT 
genotype as indicated by the two bands (167 and 337 bp). When ( 
a 
)
 
wild type is inticated, ( 
b 
) 
homozygous carriers and ( 
c 
) heterozygous carriers. 
 
 
6.2.7.1. Maternal ThtIII 1 Polymorphism 
Statistical analysis of the maternal ThtIII 1 polymorphism has shown an inverse correlation 
between maternal attitudes and in ThtIII 1 CC (r=-0.41) P = 0.030. In ThtIII 1 CT, no 
significant correlations were noted;  r = -0.16, P = 0.31 (NS), controlling for age, BMI, 
pregnancy planning, and fast food DP.  
These data are also suggestive of a nature - nurture interaction since only in CC, maternal 
stress attitude predictes foetal weight-reduction, but not in CT, independent of confounders. 
Hence, the effects of maternal stress on foetal weight depend on the mother's polymorphism 
of GR gene. 
6.2.7.2. Foetal ThtIII1 Polymorphism 
Correlation between maternal attitude and foetal weight in each group of foetal CC r = -0.43, 
P = 0.030, in CC; r = -0.29, P = 0.08 in CT, controlling for age, BMI, planning, and fast food 
during pregnancy. 
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6.2.8. ER22/23EK Polymorphism  
As seen in the table 6.1 where the distributions are shown, our subjects carried both types of 
this genetic polymorphism with the wild type being the predominant type in both mothers and 
foetus. Below in Fig. 6.5 a representative image is shown after restriction enzyme digestion 
indicating the differences at molecular level. As only six ER22/23EK heterozygote subjects 
were identified in total, these subjects were not statistically analyzed due to the small subject 
number. 
 
 
Figure 6.5:  Results of electrophoresis following ER22/23EK polymorphism genotyping in 
maternal (m) and foetal (f) samples. Lane 1 (M) shows the 1Kb DNA ladder. Lanes 2 (mc), 3 (fc), 
shows the heterozygous samples as indicated by the two bands (163 and 184 bp), lanes 3-11 show the 
wild-type samples as indicated by the two bands (149 and 163 bp). When ( 
a 
)
 
wild type is inticated, 
and ( 
c 
) heterozygous carriers. 
 
 
6.2.9. N363S Polymorphism 
The next polymorphism that was analysed in our patient cohort was the N363S. Again the 
distribution is shown in Table.6.1. Both types of this genetic polymorphism were shown to be 
carried by our subjects but as only four N363S homozygotes were identified in total again 
these subjects were not statistically analyzed due to the small subject number. 
Chapter 6   Polymorphic s tudies  of the GR gene  
154 
 
 
Figure 6.6:  Results of electrophoresis following N363S polymorphism genotyping in maternal 
(m) and foetal (f) samples. Lane 1 (M) shows the Low Molecular Weight DNA ladder. Lanes 2-8 
and 10-11 show the heterozygous samples as indicated by the two bands (113 and 95 bp), lane 9 
shows the homozygous sample as indicated by the two bands (122 and 95 bp). When ( 
a 
)
 
wild type is 
inticated and ( 
b 
) homozygous carriers. 
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6.3. Discussion 
The present study extends previous findings and provides evidence for the first time how 
environment (i.e. stress/pregnancy planning) and genetics (i.e. polymorphisms of the GR 
gene) can possibly affect foetal outcome. Maternal stress during gestation period affects 
placental as well as embryonic/foetal development and can lead to critical complications 
(Gheorghe et al., 2010). Prenatal maternal stress has been shown to have long-term effects on 
the psychological as well as behavioural development of the offspring (Mulder et al., 2002). 
One of the key findings in our study is that pregnancy planning and maternal attitudes 
towards pregnancy appear to affect foetal weight. Worldwide approximately 87 million 
unplanned pregnancies occur every year (Adetunji, 1998). Unplanned pregnancy has been 
reported to affect both mothers and children. Emerging studies link negative experiences of 
pregnant women of unplanned pregnancies before and after labour. For example two studies 
have linked unplanned pregnancies with poor relationships with their spouses, experienced 
financial and educational difficulties and problems with their professional careers (Coleman 
et al., 2005; Robbins et al., 2005).  Recently a study of 314 women from Turkey revealed that 
unplanned pregnancy discouraged women to develop positive attitudes during their 
pregnancies as well as compromised performance of prenatal care (Karacam et al., 2009). 
Interestingly, babies born to the women with unplanned pregnancies were shorter in stature 
(Karacam et al., 2010). Data from our study suggest that there is no mother-foetal coherence 
in the group of unplanned pregnancies. An interesting finding are the effects of maternal 
attitude to pregnancy and pregnancy planning on infant birth weight. A potential 
interpretation would be that holding a positive or neutral (accepting) attitude towards the 
pregnancy buffers or protects against any potential negative effects of planning/not planning 
the pregnancy on fetal weight. However, in women with negative attitudes towards the 
pregnancy, those who planned the baby may be in conflict and hence, chronic stress and 
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possibly adversely affects the foetal development and weight more than those with negative 
attitude and an unplanned pregnancy. 
In terms of the polymorphisms analyses, only the maternal ThtIII 1 polymorphism was 
suggestive of a gene-environment interaction since only in ThtIII 1 (CC), maternal stress 
attitude predicts foetal weight-reduction, but not in ThtIII 1 (GC) independent of 
confounders. These effects were independent of women’s age and BMI, and were not 
explained by gestational age. Additionally, multiple other immune symptoms and 
demographic variables tested were also not predictive of foetal weight. Hence, the effects of 
maternal stress on foetal weight depend on the mother's polymorphism of the GR gene. 
Similar gene-environment interactions were found in a study related to ER22/23EK 
polymorphism and risk for depression, which occurred only if people were additionally 
exposed to childhood stress (Bet et al., 2009).  
It should be noted that apart from the well established polymorphisms that can be detected by 
the use of restriction digest enzymes, novel GR polymorphisms have also been reported in 
the literature. For example, in children with sporadic nephrotic syndrome except the known 
GR (NR3C1) polymorphisms, six novel polymorphisms have been documented (1206C > T, 
1374A > G, 2382C > T, 2193T > G, IVS7-68_-63delAAAAAA, and IVS8-9C > G). 
Moreover, they have also identified one known NR3C1 haplotype, [198G > A; 200G > A], 
and two novel NR3C1 haplotypes (H1, [1374A > G; IVS7-68_-63delAAAAAA; IVS8-
9C > G; 2382C > T] and H2, [1896C > T; 2166C > T; 2430T > C]) (Ye et al., 2006). This 
was done by denaturing and renaturing PCR products to form heteroduplexes, followed by 
processing on a DHPLC apparatus. Another study using DNA sequencing showed a T to C 
substitution at codon 766 (position 2430) of the GR gene that is associated with systemic 
lupus erythematosus (Lee et al., 2004)”. 
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This study posed some limitations. Firstly, our sample included small numbers in certain 
categories of polymorphic groups. Nevertheless, the statistically significant effect and the 
size of differences observed between mothers with negative versus positive and neutral 
attitudes in the ThtIII 1 polymorphism group suggest that this effect may be robust. Secondly, 
the distribution of Bcl I polymorphism seen in this sample may be unique, since there are 
important geographical/ethnic differences in the prevalence of these polymorphisms. It 
should be emphasized that in the present study, we included a homogeneous cohort of 
Mediterranean patients from Crete. Despite these limitations, this is the first study to 
demonstrate a gene-maternal environment synergism in relation to infant birth weight, using 
a very brief assessment of maternal attitudes to pregnancy. Should these finding be replicated 
in a much wider cohort, given the simplicity in assessing such attitudes and the feasibility to 
identify the homozygous group of women early on in pregnancy, these findings may have 
significant implications for public health and prevention.  
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7.1. Introduction 
Here we have used forskolin (a syncytialisation agent) in order to fuse and differentiate 
BeWo cells into syncytiotrophoblasts. Previous in house studies have verified the 
differentiation process. We have used a cell membrane marker, pan-Cadherin to examine the 
levels of the cadherin protein in forskolin-treated and untreated cells to determine whether a 
decrease in total plasma membrane was achieved following treatment using 
immunofluorescence and western blotting. The cell viability/death was assessed using an 
MTT as well as a trypan blue assay. Finally, the amount of syncytin-2 (a syncytialisation 
marker) was assessed in the same cells using qPCR. This is in contrast with the 
undifferentiated state, as well, as the JEG-3 cells that resemble a cellular milieu of a first 
trimester placenta. Therefore the effect of forskolin, the inducer of syncytialisation on the 
expression of the mTOR main components as well as the GRs and GAS5 was assessed using 
quantitative PCR. Moreover, the cellular distribution of mTOR, Deptor, Rictor and Raptor 
was elucidated in syncytialised cells. 
 
7.2. Results 
7.2.1. BeWo and JEG-3 cell line as placental models: effect of syncytialisation 
on gene expression. 
In this experimental model, syncytialisation was achieved using forskolin. The 
syncytialisation model on BeWo cells has been evaluated in detail in our laboratory, prior to 
elucidating the expression of mTOR signalling components in the differentiated state 
(syncytiotrophoblasts) of BeWo cells. The expression of PCNA was investigated using RT-
PCR (Fig. 7.1). BeWo cells treated with forskolin (50 and 100 μM) for 48 hrs revealed down-
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regulation of expression of PCNA at the mRNA level (Fig. 7.2). These data suggest that 
BeWo cells cease to proliferate, indicative of differentiation events taking place.  
 
 
Figure 7.1: RT-PCR gel demonstrating the expression of PCNA and β-actin housekeeping gene in 
treated and untreated BeWo cells. Lane 1: DNA ladder; lane 2: cDNA from untreated BeWo cells (48 
hours); lane 3: cDNA from stimulated BeWo cells (50 μM forskolin, 48 hours); lane 4: cDNA from 
untreated BeWo cells (48 hours); lane 5: cDNA from stimulated BeWo cells (100 μM forskolin, 48 
hours) (Mparmpakas et al., 2010). 
 
 
 
Figure 7.2: Densitometric analysis of PCNA in forskolin treated and untreated BeWo cells. 
Expression of PCNA was normalised against the expression of β-actin housekeeping gene. Each 
histogram represents the mean ± SEM of three individual experiments. Blue lines indicate 
significance, P < 0.0001***. 
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7.2.2. Effect of BeWo cell syncytialisation on mTOR signalling components.  
Q-PCR analysis revealed that in syncytialised BeWo cells (ST) all transcripts were expressed 
(Fig.7.1). No significance changes were seen in the expression of mTOR, Rictor and Raptor 
when their expression was compared to that observed in BeWo cytotrophoblast cells (CT). 
However, significant down regulation in the expression of Deptor was evident in BeWo ST 
cells when compared to BeWo CT (P < 0.05*). 
 
 
Figure 7.3: RQ values of the expression of mTOR, Deptor, Rictor, Raptor in BeWo CT and BeWo 
ST. Each histogram represents the mean + [2
-ΔΔSD
 (+) - 2
-ΔΔSD
 (-)] of three individual experiments (P < 
0.05 *).  
 
7.2.3. Cellular distribution of mTOR, Deptor, Rictor and Raptor in BeWo ST 
cells 
The protein expression of mTOR and each component was assessed in syncytialised BeWo 
cells, using immunofluorescent analysis. Similar intense cytoplasmic staining was detected in 
unstimulated BeWo cells as previously described (Fig. 7.4).  
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Figure 7.4: Cellular distribution of mTOR (A), Deptor (B), Rictor (C) and Raptor (D) proteins in 
forskolin (50μM) treated BeWo cells for 48 hrs. Also representative images are shown of the negative 
controls included in the study (E & F) (Mparmpakas et al., 2010; Panel A & E). 
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7.2.4. Glucocorticoid Receptor expression in syncytialised BeWo cells 
Further, the expression of the GR splice variants was examined in  syncytialised BeWo cells. 
The graph in Fig.7.4 depicts the results of the GR expression in BeWo CT and BeWo ST. 
The expression of GRβ, GRγ and GR-P splice variants as seen below are significantly higher 
in BeWo ST when compared to BeWo CT. The individual RQ values of all the splice variants 
for both cell types are shown in brackets in the figure legend 7.5.  
 
 
Figure 7.5: RQ values of the expression of GRα (3.43), GRβ (380.52), GRγ (10.92), and GR-P 
(98.25) in BeWo ST and BeWo CT (all RQ values were standardized at 1). Each histogram represents 
the mean + [2
-ΔΔSD
 (+) - 2
-ΔΔSD
 (-)] of three individual experiments, P < 0.05*, P < 0.001**, P < 
0.0001***).   
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7.2.5. Expression of GAS5 in BeWo ST and BeWo CT  
The expression of GAS5 has been examined by Q-PCR in three different states: 
undifferentiated BeWo CT, differentiated BeWo ST as well as in the JEG-3 cell line. The 
results are depicted in Fig.7.6 where significantly lower levels (5.5 fold) of GAS5 were seen 
in BeWo CT cells when compared to the untreated BeWo ST cells. Upon comparison of 
BeWo CT with JEG-3 cells the expression of GAS5 in JEG-3 cells was significantly lower 
(3.7 fold) than that shown in BeWo CT.  
 
 
Figure 7.6: RQ values of the expression of GAS5 in BeWo ST and BeWo CT. Each histogram 
represents the mean + [2
-ΔΔSD
 (+) - 2
-ΔΔSD
 (-)] of three individual experiments, (P < 0.05*). 
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7.3. Discussion 
The two cell lines studied are widely used as in vitro models to investigate placental 
physiology and function. These cell lines have distinct fusigenic capacities. The JEG-3 cell 
line, despite being of a choriocarcinoma origin, is unable to morphologically differentiate and 
therefore it resembles the undifferentiated and hormonally inactive cytotrophoblast cells, 
making it an appropriate in vitro model to investigate first trimester placental events 
(Ntrivalas et al., 2006). BeWo cells are fusigenic and when they are fully differentiated (i.e. 
syncytialised) they resemble a third trimester placental model. At this stage the predominant 
feature of the human placenta is the hormonally active syncytiotrophoblast layer. The 
multinucleated syncytiotrophoblasts cover the external surface of the placental villous and are 
in direct interface with maternal blood (Das et al., 2004). Undifferentiated BeWo cells are 
similar in morphology to primary trophoblast cultures, with a monolayer and microvillar 
projections on the apical side. The capability of BeWo cells to differentiate has established 
these cells as an in vitro model to study immune, endocrine and developmental aspects 
(Heaton et al., 2008; Neelima & Rao, 2008; Ellinger et al., 1999), as well as placental 
transport mechanisms (Manley et al., 2005). More specifically, BeWo and JEG-3 cells were 
used extensively as placental models to study a variety of placental-based pathologies and 
cellular functions. These include: preeclampsia (Jain et al., 2012), hypoxia (Liao et al., 2012), 
specific maternal serum markers (Orendi et al., 2010), preterm labour (Lim et al., 2012), 
chorioamnionitis (Ikoma et al., 2003), trophoblast invasion (Arimoto-Ishidat et al., 2009), 
implantation events (Benaitreau et al., 2009) and gestational diabetes (Ma et al., 2010). 
In this chapter we provide evidence of how the process of syncytialisation affects the 
expression of mTOR, Deptor, Rictor, Raptor, GR splice variants and GAS5 in BeWo cells. In 
our study, nuclear expression of mTOR and Deptor under basal conditions in undifferentiated 
BeWo was not observed. Even after forskolin induced syncytialisation, no apparent 
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translocation of mTOR was noted in BeWo cells at either 48 or 72 hrs. Similarly, Deptor, 
Rictor, Raptor also demonstrated an intense cytoplasmic staining, with Rictor demonstrating 
some plasma membrane localisation in a few cells. This could be due to changes in the total 
membrane content during the process of syncytialisation rather a true representation of where 
Rictor is localised. 
In our experimental model, treatment with forskolin (48 h) induced a significant decrease in 
the gene expression of Deptor and GAS5 in BeWo CT cells, whereas a significant 
upregulation of GRβ was noted when compared to BeWo ST. Due to lack of commercially 
available antibodies of GR splice variants, we have only determined the expression of GRα in 
BeWo ST cells. Intense perinuclear staining was evident, with some nuclear translocation-in 
agreement with its role as a nuclear steroid receptor. These results support a recent study 
showing that forskolin altered the expression of several genes during differentiation of BeWo 
cells. For example, mRNA expression of SLPI, ELF-1·-1, prolyl 4-hydroxylase-ß and gastric 
associated differentially expressed protein was up-regulated after forskolin induced 
differentiation. In contrast, LMO-4 and Rab-5 interacting protein transcripts were down-
regulated during cytotrophoblast differentiation (Neelima & Rao, 2008).  
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8.1. General Discussion and Concluding Remarks 
8.1.1. Why is this study so important? 
The key hypothesis of our study was that for a successful pregnancy outcome, there are 
tightly linked events at psychosocial, biochemical, genetic and molecular levels. Despite a 
plethora of studies identifying a number of potential risk factors for the mother, or the foetus, 
there has not been a comprehensive analysis of these factors from matched mothers and 
foetuses. Here we have studied the relative contribution of each factor for a successful 
pregnancy and allowed a model of their inter-relationships to be developed. As a result we 
have adopted a more holistic approach, investigating how stress, exercise, nutrition, 
immunity, placental genes, glucocorticoid receptor polymorphisms and serum levels of 
cortisol will influence pregnancy outcome. 
8.1.2. What can we conclude from the questionnaire data? 
We have used a wide repertoire of questions in order to acquire as many information as 
possible about the cohort of the patients we dealt with. With regards to the nutritional profile, 
a major finding was the significant reduction in the intake of alcohol, caffeine-containing and 
sugar-containing refreshments. The importance of nutrition during pregnancy with regard to 
pregnancy outcome has long been acknowledged. This importance has only been further 
emphasized by the recent changes in food quality and availability, lifestyle changes, and a 
new understanding of foetal programming on adult outcomes (Shapira, 2009). The 
Mediterranean dietary pattern (MDP) has been shown to exert certain beneficial effects, since 
it has appeared to be associated with the reduction in the risk of the offspring’s affected by 
spina bifida (Vujkovic et al., 2009), and with children been less wheezy or asthmatic (de 
Batlle et al., 2008). A recent study proposed a diet quality index for pregnancy based on 
MDP evaluating the diet of a group of pregnant women by applying the Mediterranean Diet 
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Score (MDS) and evaluating their intake of micronutrients required in optimal amounts 
during pregnancy (Mariscal-Arcas et al., 2009). Of interest, the nature of fat in north Europe 
is primarily from dairy fat and lard whereas in Crete the main source was pure olive oil 
(Willet, 2006). It should be noted therefore, that different populations can have distinctive 
nutritional needs according to their age, lifestyle or specific physiologic situations or medical 
history. As a result analysis of our data cannot provide universally applicable results.  
Another major finding of this part of the study was the effects of maternal stress on foetal 
weight and how pregnancy planning was implicated in this complex relation. Pregnancy is 
associated with major physiological and future psychosocial changes and maternal adaptation 
to these changes is crucial for normal foetal development. Psychological stress in pregnancy 
predicts earlier birth and lower birth weight. Perceived life-event stress, as well as depression 
and anxiety, predicted lower birth weight, decreased Apgar scores and small for gestational 
age babies as a recent study has shown (Marcus, 2009). It appears therefore that pregnancy-
specific stress may be a more powerful contributor to birth outcomes than general stress 
(Lobel et al., 2008). In our cohort, women with negative attitudes during pregnancy gave 
birth to infants with significantly lower birth weights (2.5Kg) than those women showing 
positive or neutral attitudes towards their pregnancy (2.9Kg). However, in mothers with 
negative attitudes towards the pregnancy, those with an unplanned pregnancy gave birth to 
infants with significantly higher weights (2.7 Kg) than those with planned pregnancies. It has 
also been reported that women that had unplanned pregnancies had more psychological 
problems throughout their pregnancies when compared with those that planned their 
pregnancy (Karacam &Ancel, 2009). These novel findings suggest an important role of 
pregnancy planning with relation to foetal outcomes. This is of increasing importance since it 
is estimated that around 87 million pregnancies occur every year worldwide, out of which 41 
million result in labour (Adetunji, 1998).  So what can be done? Collectively, data from our 
Chapter 8  General Discussion  
170 
study suggest that there is no mother-foetal coherence in the group of unplanned pregnancies. 
Therefore, raising awareness of the impact of unplanned/unintended pregnancy is of key 
importance. This can be done by educating the public about social and health issues related to 
unintended pregnancy. Unintended pregnancy affects not only the individuals, but their 
families and communities as well. By communicating this problem to the public, increasing 
the understanding of the community and the individuals about prevention and improving 
access to necessary services, the society can ensure more positive outcomes for both mother 
and foetus. 
8.1.3. Why is so important the pre-term labour sub-classification of clinical 
samples? 
To this date, pre-term labour is still the leading cause of perinatal morbidity and mortality in 
the developed world. Despite the advances in diagnosis and molecular basis of disease, 
efforts to prevent pre-term birth have been compromised by a poor understanding of the 
underlying pathophysiology and not fully effective therapeutic interventions. The 
aetiopathology varies: certain clinical studies indicate that genito-urinary tract infections play 
a critical role in the pathogenesis of pre-term birth, or gene-environment interactions may 
play a key role in the onset of pre-term birth (Holst & Garnier, 2008). This is of increasing 
importance in our study since previous studies have pointed towards a link between maternal 
stress (i.e. pregnancy-related anxiety, distress or depression) and higher risk of pre-term birth 
or low birth weight in general (Orr et al., 2007; Copper et al., 1996). However, a number of 
older studies have questioned this link. For example, in a study of 1860 white women it was 
concluded that “in the general population of pregnant women, anxiety and depression during 
pregnancy, while undesirable in themselves, are of little importance in the evolution of 
obstetric complications” (Perkin et al., 1993). Similarly, Peacock and her colleagues have 
shown that no evidence of any association between psychosocial factors and pre-term 
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delivery exist (Peacock et al., 1995).  Interestingly, in our cohort we did not observe any 
significant correlation between stress and gestational period. This might have to do with the 
fact that we have measured maternal stress only in the third trimester and might have missed 
the gestational time window when exposure to high stress levels can act as a “hard-wiring” 
process and affect the timing of birth. For example, in a recent study of 1800 Chinese women 
concluded that “prenatal severe life events, especially in the first trimester, may play an 
important role in increasing the risk of preterm birth and low birth weight” (Zhu et al., 2010). 
There is also evidence that diet might also influence the timing of birth. In a large cohort of 
35.500 Danish women, it has been suggested that a shift towards a Mediterranean-type diet 
during pregnancy may reduce the risk of pre-term birth (Mikkelsen et al., 2008).  We would 
like to propose that combining better nutritional habits and managing psychological stress 
through coping will lead to better management of pregnancy and reduce the chances of 
delivering prematurely. 
8.1.4. What is the potential role of GAS5 in the human placenta? 
In our study we have demonstrated for the first time the expression and cellular distribution 
of GAS5 (growth arrest-specific transcript 5) in the human placenta and 2 placental cell lines. 
As already mentioned, GAS5 encodes a single strand noncoding RNA (ncRNA) and hence its 
name as it can accumulate in growth-arrested cells (Schneider & King, 1988). In a recent 
study by Kino and colleagues it was demonstrated that GAS5 ncRNA may be a repressor for 
the GR by acting as a decoy “glucocorticoid response element (GRE)”, thus, competing with 
DNA GREs for binding to the GR. The net effect is the inhibition of the association of GRs 
with their DNA recognition sequence (Kino et al., 2010). 
In this study we provide further information about the regulation of this transcript by cortisol 
using two in vitro models. We demonstrate using Q-PCR that the GAS5 transcript is 
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upregulated by cortisol dose independently. This finding provides further evidence of 
regulation of GAS5 by stress and corroborates initial in vivo data in mice (Mayer et al., 
2010). In a study using, C57BL/6 male mice, stress induced GAS5 RNA levels in the 
hippocampus and this increase was accompanied by a rise of corticosterone levels (Mayer et 
al., 2010). These two in vitro  and in vivo observations are highly suggestive of a functional 
link between stress and this ncRNA. 
We have also shown that GAS5 is expressed at levels as high as GRα in the human placenta, 
suggesting a higher order of complexity in the regulation of glucocorticoid signalling during 
pregnancy. Moreover, when we performed RNA FISH the GAS5 transcript was localised 
almost exclusively in the syncytiotrophoblast layer of the human placenta both at cytoplasmic 
and nuclear level. Interestingly, we have also demonstrated that GRα is also localised in the 
cytoplasm of syncytiotrophoblasts. In view of previous data in Hela cells where GAS5 
translocates from the cytoplasm into the nucleus with GR in response to dexamethasone 
(Kino et al., 2010), this co-localisation is highly suggestive of a potential cross-talk at 
placental level. Indeed, we have shown that there is an increase in the ratio of GRα / GAS5 in 
pre-term labour when compared with term placental samples. This shift might affect how 
GRα responds to cortisol, and subsequently impact on GR-mediated signalling at placental 
level. 
8.1.5.  Is there a gene-environment interaction? Evidence from GR 
polymorphism studies. 
As stated earlier the GR is crucial for the effects of glucocorticoids (GCs). Indeed there are 
several clinical features associated with GR polymorphisms. Our study provides a novel 
insight into the involvement of GR polymorphisms in pregnancy outcome. We have 
demonstrated that only the maternal ThtIII 1 polymorphism was suggestive of a nature-
nurture interaction since only in ThtIII 1 (CC), maternal stress attitude predicts foetal weight-
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reduction, but not in ThtIII 1 (GC) independent of confounders such as BMI, pregnancy 
planning or fast food eating during pregnancy. Moreover, a partial correlation between 
maternal attitude (“Happy”) and foetal weight, in Bcl I (CC) polymorphism was also noted. 
This is the first time that a gene-environment interaction between a common GR 
polymorphism and foetal weight was noted. In a study conducted a similar nature-nurture 
interaction was noted between the ER22/23EK polymorphism and the effect of childhood 
adversity on depression. In addition, patients carrying the ER22/23EK had decreased in Free 
Cortisol Index, whereas heterozygotes for the Bcl I polymorphism, were less vulnerable for 
depression in conjunction with childhood adversity, than Bcl I homozygotes and wild-type 
(Bet et al., 2008). In our study, no correlation between circulating plasma cortisol levels and 
any of the polymorphisms was detected (data not shown). 
To this date, there is still controversy surrounding the potential role of these polymorphisms 
in terms of mediating maternal stress responses during pregnancy. It was recently shown that  
GR gene polymorphisms were not associated with birth weight or early postnatal weight and 
no associations were noted with length and head circumference. Moreover, neither were these 
polymorphisms associated with the risks of low birth weight or growth acceleration from 
birth to 24 months of age (Geelhoed et al., 2010). However, Bertalan and his colleagues have 
shown that the Bcl I polymorphism of the foetal GR gene is significantly associated with 
higher gestational age-adjusted birth weight in preterm neonates (Bertalan et al., 2008). The 
same group has later demonstrated that there was an overrepresentation of Bcl I 
polymorphism of the GR gene in pregnant women with HELLP (hemolysis, elevated liver 
enzymes and low platelet counts) syndrome compared to healthy pregnant women. Moreover, 
there were no significant differences in carrier and allelic frequencies of the N363S and 
ER22/23EK polymorphisms between healthy pregnant women and those with severe 
preeclampsia (Bertalan et al., 2009). As mentioned previously, Bcl I polymorphism 
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denominates a SNP in intron 2, located 647 bp inside the intron at the 3’ side of exon 2. The 
exact mechanism via which Bcl I polymorphism can alter signalling is not known given that 
the mutation resides within an intron and therefore its location does not involve a coding, 
regulatory or splicing part of the GR gene. It has been suggested that this polymorphism 
might be in linkage with other variations, e.g., in the promoter region, or linked to other 
functionally important polymorphisms (Manenschijn et al., 2009). It is also possible that this 
SNP results in an intron-mediated RNA interference (Ying & Lin, 2009). Of interest, the 
intron 2 of the GR gene is quite large in size and a mutation on its 5’-end might affect the 
splicing machinery.  
In our cohort, Bcl I polymorphism deviated from the Hardy Weinberg equilibrium (that states 
that both allele and genotype frequencies in a population remain constant). However this 
deviation is not uncommon in genetic studies. Violations of the Hardy Weinberg equilibrium 
can be due to numerous causes such as: inbreeding (leads to an increase in homozygosity for 
all genes), mutation (can exert a subtle effect on allele frequencies), or small population size 
(can cause a random change in allele frequencies; genetic drift). We feel that is important to 
incorporate these data as they do provide a novel insight into the role of GR polymorphisms. 
Indeed this appears to be the general consensus. For example, in a study of 42 gene-disease 
associations assessed in meta-analyses of 591 studies revealed that exclusion of studies 
violating the equilibrium resulted in loss of statistical significance of the overall meta-
analysis in three studies and changed the formal significance of the estimated between-study 
heterogeneity in three instances (Trikalinos et al., 2006). Should our findings be replicated in 
larger cohort, given the simplicity in assessing such attitudes and the feasibility to identify the 
polymorphic group of women early on in pregnancy, these findings will have significant 
implications for public health and prevention.  
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8.1.6. How is mTOR and GR signalling implicated in pre-term labour and 
maternal stress responses?  
One of the most important findings of our study came from the preclinical studies using 
placental tissues. Quantitative PCR revealed that the major transcripts in the human placenta 
are GRα, GAS5 and Deptor. The key finding is that there are marked differences in the 
relative mRNA abundance of these components between term and pre-term labour. For 
example, when we assessed these levels as a function of a ratio of GRα over the remaining 
GRs there is a clear shift towards GRα, rendering it the main receptor during preterm labour. 
This coincides with a two-fold increase in the GRα/GAS5 ratio. This is of increasing 
importance since GR activity is known to be repressed by GAS5 that folds into a soluble 
glucocorticoid response element-like sequence and serves as a decoy for GR DNA binding. 
In this cohort of patients, maternal high stress levels inversely correlated with placental and 
fetal weights, and there is a strong correlation between GRα and GR-P as well as GRβ and 
GAS5, indicating possible tissue/pathology-specific splicing phenomena. Interestingly, in this 
preterm cohort, Deptor levels inversely correlated with placenta weight. Moreover there is an 
1.6 fold increase in the expression of Deptor in the preterm samples and a notable 83% 
decrease of the GRα / Deptor ratio when compared to term placentas. Collectively these data 
point towards a convergence of mTOR and GR signalling. This is not surprising as emerging 
studies points towards a cross talk between these two components. In skeletal muscle “mTOR 
activation inhibits GR transcription function and efficiently counteracts the catabolic 
processes provoked by glucocorticoids” as shown by a recent study (Shimizu et al., 2011). 
Glucocorticoid resistance is caused by increased activity of mTOR (Sionov, 2008). This is of 
increasing importance in terms of signalling as glucocorticoid resistance is associated with 
weak increase in GR transcriptional activity, and no increase in GR protein levels (Miller et 
al., 2007), followed by secondary resistance driving downregulation of GRs due to prolonged 
exposure to glucocorticoids (Sionov, 2008).  As expected, treatment with rapamycin (an 
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mTOR inhibitor) can resensitise the lymphoblastic leukaemia cells to glucocorticoids (Gu et 
al., 2010). An unexpected twist in this story was that inhibition of human T-cell proliferation 
by mTOR antagonists (e.g. rapamycin) requires GAS5 (Mourtada-Maarabouni et al., 2010). 
In view of these exciting data we would like to propose the following model for cross-talk in 
pre-term placenta: GRα is the predominant receptor due to a change in the ratio with the other 
splice variants GRβ, GRγ that act as repressors as well as the decoy GRE GAS5. This 
coincides with a rise in the expression of Deptor (an mTOR inhibitor). The end effect will be 
a sensitisation of glucocorticoid signalling and subsequent increase of GR transcriptional 
activity with a potential negative impact in stress conditions during pregnancy. 
8.1.7. What do in silico analyses tell us about GR function? 
In order to dissect complex cellular/tissue phenotypes, it is imperative to elucidate functional 
partnership amongst the proteins of interest and subsequently the potential networks formed 
by these interacting proteins. As we have already discussed, the exact role of GR splice 
variant is not fully elucidated. For this reason, we have used an in silico approach employing 
the database and web-tool STRING (Search Tool for the Retrieval of Interacting Genes-
Proteins) in order to identify any potential novel interactions at protein level. STRING is a 
metaresource that collects the available data on protein–protein associations and predicts 
interactions. Over the past 11 years, STRING has grown into the most comprehensive 
resource of its type (Jensen et al., 2009). Analysis using the latest version STRING 8 has 
produced the following interactions (Appendix III): 
GRα potentially interacts with: HSP90AA1 (heat shock protein 90kDa alpha (cytosolic), 
class A member 1), NCOA1 (nuclear receptor coactivator 1), SMARCA4 (matrix associated, 
actin dependent regulator of chromatin, subfamily a), NFKB1 (nuclear factor of kappa light 
polypeptide gene enhancer in B-cells 1), RELA (v-rel reticuloendotheliosis viral oncogene 
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homolog A), BAG1 (BCL2-associated athanogene), TAT (tyrosine aminotransferase), JUN 
(jun oncogene), NRIP1 (nuclear receptor interacting protein 1),  GRIP1 (glutamate receptor 
interacting protein 1). 
GRβ: Similar associations with GRα were noted. However, another 10 predicted interactions 
were provided with FKBP4 (FK506 binding protein 4), STAT5A (signal transducer and 
activator of transcription 5A), NCOA2 (nuclear receptor coactivator 2), CEBPB 
(CCAAT/enhancer binding protein (C/EBP)), POU2F1 (POU class 2 homeobox 1), CREB1 
(cAMP responsive element binding protein 1), NCOA3 (nuclear receptor coactivator 3), 
CALR (calreticulin), POMC (proopiomelanocortin), DAP3 (death associated protein 3). 
GRγ: Very similar interactions with GRβ were predicted. However, STRING 8 has proposed 
that certain associations of this gene result in an inhibitory phenotype, something that was not 
predicted for GRβ. For example, due ot its interactions with TAT it appears to inhibit 
CREB1. Similarly, NCOA3 exerts an inhibitory effect on JUN, as GRγ does in a directly. 
Finally, there is an inhibitory interplay between CEBP and RELA.  
GR-P: GR-P appears to also interact with very similar proteins as GRα. 
These findings provide potential scaffolds for modelling interactions of the GR splice 
variants. However, caution should be exercised as these are predicted interactions based on 
automatic data-mining searches, and computerised “scoring”. Future studies using co-
immunoprecipitation or other complex techniques such as FRET would allow us to gain a 
better insight of how “real” these interactions are, and how they can modify glucocorticoid 
pharmacology. 
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8.1.8. What are the limitations of this study? 
We would also like to acknowledge that our study has a number of limitations. The placental 
samples, blood and plasma come from a fairly homogeneous population from the island of 
Crete in Greece. However, the uniformity of our cohort could also have certain advantages - 
we do not need to control for the effects of other variables such as lifestyle and ethnicity, as 
these have been quite similar among the participants of this study (all samples obtained from 
the same University Hospital, in the capital city Heraklion). In terms of the questionnaire, the 
source of the stress was not reported. It is accepted that individual differences may contribute 
to how the emotion is perceived and subsequently experienced. People with more negative 
personality characteristics report higher levels of emotional distress and negative emotions 
when faced with stressful events (Winter & Kuiper, 1997). 
With regards to the polymorphic study, this could have been benefited by a larger number of 
participants from other European countries. Reproducibility of phenotyping for GRs has been 
shown to be affected by the number of individuals studied and racial heterogeneity (van 
Rossum et al., 2005). In a very recent study, generalized GC resistance accompanied with an 
adrenocortical adenoma was caused by a novel point mutation of the GR gene. A C to T 
substitution at nucleotide position of 1667 (exon 5) in GRα gene was detected in this patient 
by sequencing analysis (Zhu et al., 2011). Sequencing of the full length gene will provide a 
better insight into novel mutations and how might be associated with certain reproductive 
pathologies. 
Another restriction we were faced with was the lack of access to clinical samples of the first 
and second trimester, due to ethical restrictions. A larger cohort of placental samples from the 
first, second and third trimester might have alleviated inter-patient variation as well as 
provided a more detailed map of these key components throughout pregnancy.  When we 
Chapter 8  General Discussion  
179 
have used a placental synsytialisation model to represent the third trimester, certain changes 
in the expression of mTOR and GRs were noted.  
Our in vitro studies provided an interesting perspective of the regulation of Deptor by 
cortisol. However, no direct conclusions can be drawn unless these studies are repeated in 
primary placental trophoblasts or using organotypic placental cultures and the effects of 
cortisol on mTOR and GR signalling components warrant further evaluation. Finally, the 
changes detected in the placental samples using QPCR should be confirmed at protein level 
using semi-quantitative western blotting. A drawback for this analysis is the lack of 
commercially available antibodies for GR splice variants and the fact that GAS5 does not 
translate into a protein. 
 
8.1.9. What are the future directions? 
8.1.9.1. Study further modifications of GRs.  
It should be emphasised that GR function can also be affected epigenetically (i.e. DNA 
methylation) which can affect directly GR function (Claes, 2010). The GR gene has a number 
of alternative promoters that can be methylated. Therefore, methylation status of the GR 
promoters can be examined by bisulfite sequencing. It will also be of interest to determine 
using QPCR the use of different promoters of GR in relation to term or pre-term delivery as 
well as maternal stress levels. 
In addition, it is documented that mutations in the human GR gene can impair the molecular 
mechanisms of GRα action and subsequently modifies tissue sensitivity to glucocorticoids 
(Charmandari et al., 2007). Therefore, apart from the polymorphism analyses, it will be of 
great interest to sequence the whole GR gene using sets of primers designed at the 
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exon/intron junction sequences as previously described (Charmandari et al., 2007). The 
identification of natural-occuring mutations in mothers' GR gene will improve our 
understanding of the molecular mechanisms underlying glucocorticoid action in the human 
placenta, with main emphasis to certain pathologies. 
8.1.9.2. Elucidate further the activity of mTORC-1/mTORC-2 complexes 
The activity of mTORC complexes can also be modulated post-translationally. It is important 
therefore to assess the phosphorylation status of the following key components: mTOR 
(Ser2481, Ser2448), Akt (Ser473, Thr308), S6K (Thr389, Ser371), 4E-BP1 (Thr37/46), 
PRAS40 (Thr246), Raptor (Ser792) and Rictor (Thr1135). Currently there are no 
commercially available antibodies for Deptor. The phosphorylation changes should be 
measured not only in placental samples but also in the cells lines treated with cortisol. 
8.1.9.3. Define where in the placental cells mTOR complexes are located. 
We have provided evidence of localisation of mTOR, Deptor, Rictor and Raptor in the 
cytoplasm of BeWo and JEG-3 cells as well as in the syncytiotrophoblasts of the human 
placentas. Further work is clearly required to determine where exactly mTORC-1 and 
mTORC-2 complexes reside, since there is evidence for localisation of mTORC-1 in 
mitochondria, endoplasmic reticulum, Golgi, and nucleus. The trafficking of mTOR 
signalling should also be investigated upon treatment of the two cell models with cortisol. It 
will also be of interest to determine whether placental mTOR signalling components change 
their trafficking/distribution with relation to the length of gestation or in conditions involving 
nutrient restriction such as intrauterine growth restriction. 
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8.1.9.4. Assess the stoichiometry of Deptor with mTORC-1/mTORC-2 at 
placental level.   
As mentioned previously, little is known about how Deptor modulates mTOR activity. It is 
therefore crucial to understand the molecular proximity of Deptor with mTORC-1 and 
mTORC-2 complexes. The stoichiometry of mTOR complexes with Deptor in placental 
tissues can be measured using: a) co-immunoprecipitation studies and b) transmission 
electron microscopy (TEM). Moreover, we can also assess the impact of Deptor depletion 
and overexpression in mTORC-1 and mTORC-2 stoichiometry in vitro. The two placental 
cell lines can be used to study the hetero-dimerisation of Deptor with components of 
mTORC1 and mTORC2 complexes using Fluorescence Resonance Energy Transfer (FRET).  
8.1.9.5. Investigate the involvement of mTOR/GR/GAS5 signalling in 
pathologies. 
 Given the involvement of these pathways in mediating stress; it will be of interest to provide 
a detailed map of these components in placentas from cohorts of patients diagnosed with pre-
eclampsia, intrauterine growth restriction and gestational diabetes mellitus. Apart from QPCR 
analyses, semi-quantitative western blotting should be employed to dissect any changes in the 
expression at protein level at least for mTOR, Deptor, Rictor, Raptor, and GRα using a larger 
cohort of clinical tissues.  
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BeWo CELL LINE 
 
Obtained Health Protection Agency Culture Collections 
(www.hpacultures.co.uk)  
Catalogue No. 86082803 
Description The first human, trophoblastic endocrine cell type to be 
maintained in continuous culture. It was initiated from a malignant 
gestational choriocarcinoma of the foetal placenta.  
Species Human (Choriocarcinoma) 
Tissue Endocrine 
Morphology Epithelial 
Growth Mode Adherent 
Subculture Routine Split cultures at 70-80% confluence 1:3 i.e. seeding at 4x10.000 
cells/cm
2
 using 0.25% trypsin/EDTA, 5% CO2; 37C. 
Vacuolisation will occur at confluence. 
Culture Medium HAM’s F-12K + 2mM Glutamine + 10% Foetal Bovine Serum 
(FBS) 
Karyotype 2n = 46 
Products Gonadotrophin, lactogen and steroid hormones 
Country USA 
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JEG-3 CELL LINE 
 
Obtained Health Protection Agency Culture Collections 
(www.hpacultures.co.uk)  
Catalogue No. 92120308 
Description One of 6 clones derived from cells implanted into a hampster 
cheek pouch, and then propagated on irradiated feeder layers of 
human fibroblasts.  
Species Human (Choriocarcinoma) 
Tissue Unknown 
Morphology Epithelial 
Growth Mode Adherent 
Subculture 
Routine 
Split cultures at 70-80% confluence 1:3 to 1:6 i.e. seeding at 1-
3x10,000 cells/cm
2
 using 0.25% trypsin, 5% CO2; 37C. 
Vacuolisation will occur at confluence. 
Culture Medium EMEM (EBSS) + 2mM Glutamine + 1% Non-Essential Amino 
Acids (NEAA) + 1mM Sodium Pyruvate (NaP) + 10% Foetal 
Bovine Serum (FBS) 
Karyotype 2n = 46 
Products HcCJ and somatomammotrophin 
Country UK 
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SOURCES OF QUESTIONNAIRE 
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APPENDIX IV 
  A.     STANDARD CURVE FOR CORTISOL ASSAY 
 B.      MAP OF RESTRICTION DIGEST ENZYMES 
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a) Typical standard curve used for cortisol measurements 
 
 
b) Summary of restriction digest enzymes used for the polymorphic studies 
 
 
Polymorphism 
 
Restriction Enzyme 
 
Restriction Site 
 
Bcl I 
 
Bcl I 
 
 
 
N363S 
 
Tsp509I 
 
 
 
ThtIII 1 
 
TthIII 1 
 
 
 
ER22/23EK 
 
MnI I 
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APPENDIX V 
SUMMARY OF SIGNIFICANT CORRELATION FROM: 
TERM /  PRE-TERM  &  PLAN  /  NO PLAN  CLINICAL DATA 
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Summary of  correlation values and significance of the GR with other variables. 
 
 
Correlations TERM  
(n = 13) 
 
 ( r ) P values 
 
GRβ / GRγ 
 
 
0.580* 
 
 
0.038 
 
 
GRβ / GR-P 
 
 
  0.980** 
 
 
0.000 
 
 
GR-P / Cortisol 
 
 
0.638* 
 
 
0.035 
 
 
Stress / Fetal weight 
 
 
 - 0.591* 
 
 
0.034 
 
 
Stress / Placenta weight 
 
 
  - 0.732** 
 
 
0.004 
 
 
Stress / GAS5 
 
 
 - 0.711* 
 
 
0.021 
 
 
Cortisol / Pregn. days 
 
 
0.747* 
 
 
0.033 
 
 
Fetal weight / Placenta weight 
 
 
  0,962** 
 
 
0.000 
 
 
 
 
Correlations PRE-TERM           
(n = 10) 
 
 ( r ) P values 
 
GRα / GR-P 
 
 
 0.710* 
 
 
0.021 
 
 
GRβ / GAS5 
 
 
 0.792* 
 
 
0.011 
 
 
Stress / Pregnancy days 
 
 
- 0.685* 
 
 
0.042 
 
 
Stress / Placenta weight 
 
 
 - 0.695* 
 
 
0.038 
 
 
Pregn. days / Fetal weight 
 
 
   0.986** 
 
 
0.000 
 
 
Pregn. days / Placenta weight 
 
 
   0.989** 
 
 
0.000 
 
 
Fetal weight / Placenta weight 
 
 
   0.990** 
 
 
0.000 
 
 
*.  Correlation is significant at the 0.05 level (2-tailed) 
**.  Correlation is significant at the 0.01 level (2-tailed) 
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 Correlations PLAN  
(n = 11) 
 
 ( r ) P values 
 
GRα / GRγ 
 
 
 0.664* 
 
 
0.026 
 
 
GRα / GAS5 
 
 
 0.881* 
 
 
0.001 
 
 
GRγ / GAS5 
 
 
   0.860** 
 
 
0.001 
 
 
Stress / Pregn. days 
 
 
 - 0.607* 
 
 
0.048 
 
 
Pregn. days / Fetal weight 
 
 
   0.952** 
 
 
0.000 
 
 
Pregn. days / Placenta weight 
 
 
   0.971** 
 
 
0.000 
 
 
Fetal weight / Placenta weight 
 
 
   0.996** 
 
 
0.000 
 
 
 Correlations NO PLAN  
(n = 12) 
 
 ( r ) P values 
 
GRα / Stress 
 
 
 0.707* 
 
 
0.015 
 
 
GRβ / GRγ 
 
 
 0.648* 
 
 
0.023 
 
 
GRβ / GR-P 
 
 
   0.978** 
 
 
0.000 
 
 
GRβ / Stress 
 
 
-0.646* 
 
 
0.032 
 
 
GRβ / GAS5 
 
 
  0.720* 
 
 
0.019 
 
 
GRγ / GR-P 
 
 
  0.663* 
 
 
0.019 
 
 
GRγ / GAS5 
 
 
   0.775** 
 
 
0.008 
 
 
GR-P / Stress 
 
 
- 0.645* 
 
 
  0.0032 
 
 
GR-P / GAS5 
 
 
- 0.645 
 
 
0.044 
 
 
Pregn. days / Fetal weight 
 
 
   0.927** 
 
 
0.000 
 
 
Pregn. days / Placenta weight 
 
 
   0.962** 
 
 
0.000 
 
 
Fetal weight / Placenta weight 
 
 
   0.973** 
 
 
0.000 
 
 
*.  Correlation is significant at the 0.05 level (2-tailed) 
**.  Correlation is significant at the 0.01 level (2-tailed) 
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EXPRESSION OF  mTOR  SIGNALLING  COMPONENTS  IN  
PLAN  /  NO PLAN   PREGANCY  
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Expression  of  mTOR  signalling  components 
 
 
 
   mTOR-  
Plan  
mTOR-  
No Plan  
Deptor-  
Plan  
Deptor-  
No Plan  
Rictor-  
Plan  
Rictor-  
No Plan  
Raptor-  
Plan  
Raptor-  
No Plan  
Minimum 0.0344 0.0228 0.0033 0.0017 0.1966 0.0743 0.0339 0.0145 
25% Percentile 0.0575 0.03268 0.0122 0.0047 0.2279 0.1950 0.2178 0.0615 
Median 0.0857 0.07890 0.9235 0.01945 0.3784 0.4521 0.4406 0.1285 
75% Percentile 0.1535 0.1468 6.793 0.2028 0.9459 1.283 0.7361 0.4043 
Maximum 0.1844 0.4142 8.339 2.480 2.933 2.724 1.959 1.017 
         
Mean 0.09801 0.1096 2.821 0.3277 0.8222 0.7784 0.5596 0.2814 
Std. Deviation 0.04883 0.1129 3.523 0.7828 0.9901 0.8264 0.5339 0.3403 
Std. Error 0.01472 0.03259 1.174 0.2475 0.2985 0.2385 0.1610 0.09824 
         
Lower 95% CI 
of mean 0.06521 0.03785 0.1131 -0.2323 0.1570 0.2534 0.2009 0.06512 
Upper 95% CI 
of mean 0.1308 0.1813 5.529 0.8877 1.487 1.303 0.9182 0.4976 
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String  for  GRα 
 
HSP90AA1: Heat shock protein 90kDa alpha (cytosolic), class A member 1; 
NCOA1: Nuclear receptor coactivator 1 
SMARCA4: SWI/SNF related matrix associated, actin dependent regulator of chromatin, subf.  A 
NFKB1: Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 
RELA: v-rel reticuloendotheliosis viral ongogene homolog A 
BAG1: BCL2-associated athanogene; 
TAT: Tyrosine aminotransferase 
JUN: Jun ongogene;  
NRIP1: Nuclear receptor interacting protein 1; 
GRIP1: Glutamate receptor interacting protein1; 
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String  for  GRβ 
 
HSP90AA1: Heat shock protein 90kDa alpha (cytosolic), class A member 1; 
NCOA1: Nuclear receptor coactivator 1 
SMARCA4: SWI/SNF related matrix associated, actin dependent regulator of chromatin, subf. A 
NFKB1: Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 
RELA: v-rel reticuloendotheliosis viral ongogene homolog A 
BAG1: BCL2-associated athanogene; 
TAT: Tyrosine aminotransferase 
JUN: Jun ongogene;  
NRIP1: Nuclear receptor interacting protein 1; 
GRIP1: Glutamate receptor interacting protein1; 
FKBP4: FK506 binding protein 4; 
STAT5A: Singnal transducer and activator of transcription5A 
NCOA2: Nuclear receptor coactivator 2. 
CEBPB: CCAAT/enhancer binding protein(C/EBP) beta 
POU2F1: POU class 2 homeobox 1. 
CREB1: cAMP responsive element binding protein 1. 
NCOA3: Nuclear receptor coactivator 3. 
CALR: Calreticulin. 
DAP3: Death associated protein 3. 
POMC: Proopiomelanocortin. 
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String  for  GRγ 
 
HSP90AA1: Heat shock protein 90kDa alpha (cytosolic), class A member 1; 
NCOA1: Nuclear receptor coactivator 1 
SMARCA4: SWI/SNF related matrix associated, actin dependent regulator of chromatin, subf. A 
NFKB1: Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 
RELA: v-rel reticuloendotheliosis viral ongogene homolog A 
BAG1: BCL2-associated athanogene; 
TAT: Tyrosine aminotransferase 
JUN: Jun ongogene;  
NRIP1: Nuclear receptor interacting protein 1; 
GRIP1: Glutamate receptor interacting protein1; 
FKBP4: FK506 binding protein 4; 
STAT5A: Singnal transducer and activator of transcription5A 
NCOA2: Nuclear receptor coactivator 2. 
CEBPB: CCAAT/enhancer binding protein(C/EBP) beta 
POU2F1: POU class 2 homeobox 1. 
CREB1: cAMP responsive element binding protein 1. 
NCOA3: Nuclear receptor coactivator 3. 
CALR: Calreticulin. 
DAP3: Death associated protein 3. 
POMC: Proopiomelanocortin. 
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String  for  GR-P 
 
 
 
 
HSP90AA1: Heat shock protein 90kDa alpha (cytosolic), class A member 1; 
NCOA1: Nuclear receptor coactivator 1 
SMARCA4: SWI/SNF related matrix associated, actin dependent regulator of chromatin, subf. A 
NFKB1: Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 
RELA: v-rel reticuloendotheliosis viral ongogene homolog A 
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